Cover
Cover | 6 Months Ended |
Jun. 30, 2022 | |
Cover [Abstract] | |
Document Type | 6-K |
Entity Registrant Name | Barclays PLC |
Amendment Flag | false |
Document Fiscal Year Focus | 2022 |
Document Fiscal Period Focus | Q2 |
Document Period End Date | Jun. 30, 2022 |
Entity Central Index Key | 0000312069 |
Current Fiscal Year End Date | --12-31 |
Condensed consolidated income s
Condensed consolidated income statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Profit or loss [abstract] | |||
Interest and similar income | £ 7,134 | £ 5,279 | [1] |
Interest and similar expense | (2,371) | (1,376) | [1] |
Net interest income | 4,763 | 3,903 | [1] |
Fee and commission income | 4,726 | 4,682 | [1] |
Fee and commission expense | (1,302) | (976) | [1] |
Net fee and commission income | 3,424 | 3,706 | [1] |
Net trading income | 5,013 | 3,482 | [1] |
Net investment income | (116) | 152 | [1] |
Other income | 120 | 72 | [1] |
Total income | 13,204 | 11,315 | [1] |
Credit impairment (charges)/releases | (341) | 742 | [1] |
Net operating income | 12,863 | 12,057 | [1] |
Staff costs | (4,583) | (4,334) | [1] |
Infrastructure, administration and general expenses | (2,687) | (2,798) | [1] |
Litigation and conduct | (1,857) | (176) | [1] |
Total operating expenses | (9,127) | (7,308) | [1] |
Share of post-tax results of associates and joint ventures | (3) | 154 | [1] |
Profit on disposal of subsidiaries, associates and joint ventures | 0 | (1) | [1] |
Profit before tax | 3,733 | 4,902 | [2] |
Tax charge | (823) | (742) | [1] |
Profit after tax | 2,910 | 4,160 | [3] |
Attributable to: | |||
Profit attributable to ordinary equity holders of the parent | 2,475 | 3,752 | [1] |
Other equity instrument holders | 414 | 389 | [1] |
Total equity holders of the parent | 2,889 | 4,141 | [1] |
Non-controlling interests | 21 | 19 | [1] |
Profit after tax | £ 2,910 | £ 4,160 | [3] |
Earnings per share | |||
Basic earnings per ordinary share (in GBP per share) | £ 0.148 | £ 0.219 | [1] |
Diluted earnings per ordinary share (in GBP per share) | £ 0.145 | £ 0.213 | [1] |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 73 |
Condensed consolidated statemen
Condensed consolidated statement of comprehensive income (unaudited) - GBP (£) £ in Millions | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | |||
Statement of comprehensive income [abstract] | ||||
Profit after tax | £ 2,910 | £ 4,160 | [1] | |
Other comprehensive income/(loss) that may be recycled to profit or loss:3 | ||||
Currency translation reserve | [2] | 1,703 | (495) | [3] |
Fair value through other comprehensive income reserve | [2] | (913) | (365) | [3] |
Cash flow hedging reserve | [2] | (3,818) | (911) | [3] |
Other comprehensive loss that may be recycled to profit | [2] | (3,028) | (1,771) | [3] |
Other comprehensive income/(loss) not recycled to profit or loss:3 | ||||
Retirement benefit remeasurements | [2] | 1,090 | 103 | [3] |
Fair value through other comprehensive income reserve | [2] | 154 | 115 | [3] |
Own credit | [2] | 855 | (47) | [1] |
Other comprehensive income not recycled to profit | [2] | 2,099 | 171 | [3] |
Other comprehensive loss for the period | (929) | (1,600) | [3] | |
Total comprehensive income for the period | 1,981 | 2,560 | [1] | |
Attributable to: | ||||
Equity holders of the parent | 1,960 | 2,541 | [3] | |
Non-controlling interests | 21 | 19 | [3] | |
Total comprehensive income for the period | £ 1,981 | £ 2,560 | [1] | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Condensed consolidated balance
Condensed consolidated balance sheet (unaudited) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | [1] |
Assets | |||
Cash and balances at central banks | £ 283,136 | £ 238,574 | |
Cash collateral and settlement balances | 132,623 | 92,542 | |
Loans and advances at amortised cost | 395,824 | 361,451 | |
Reverse repurchase agreements and other similar secured lending | 1,639 | 3,227 | |
Trading portfolio assets | 127,004 | 147,035 | |
Financial assets at fair value through the income statement | 212,723 | 191,972 | |
Derivative financial instruments | 344,855 | 262,572 | |
Financial assets at fair value through other comprehensive income | 63,194 | 61,753 | |
Investments in associates and joint ventures | 911 | 999 | |
Goodwill and intangible assets | 8,245 | 8,061 | |
Property, plant and equipment | 3,582 | 3,555 | |
Current tax assets | 551 | 261 | |
Deferred tax assets | 5,044 | 4,619 | |
Retirement benefit assets | 5,233 | 3,879 | |
Other assets | 4,666 | 3,785 | |
Total assets | 1,589,230 | 1,384,285 | |
Liabilities | |||
Deposits at amortised cost | 568,670 | 519,433 | |
Cash collateral and settlement balances | 124,724 | 79,371 | |
Repurchase agreements and other similar secured borrowing | 28,566 | 28,352 | |
Debt securities in issue | 115,906 | 98,867 | |
Subordinated Liabilities | 11,871 | 12,759 | |
Trading portfolio liabilities | 76,638 | 54,169 | |
Financial liabilities designated at fair value | 255,136 | 250,960 | |
Derivative financial instruments | 321,396 | 256,883 | |
Current tax liabilities | 449 | 689 | |
Deferred tax liabilities | 5 | 37 | |
Retirement benefit liabilities | 309 | 311 | |
Other liabilities | 11,538 | 10,505 | |
Provisions | 3,426 | 1,908 | |
Total liabilities | 1,518,634 | 1,314,244 | |
Equity | |||
Called up share capital and share premium | 4,508 | 4,536 | |
Other reserves | (218) | 1,770 | |
Retained earnings | 52,980 | 50,487 | |
Shareholders' equity attributable to ordinary shareholders of the parent | 57,270 | 56,793 | |
Other equity instruments | 12,357 | 12,259 | |
Total equity excluding non-controlling interests | 69,627 | 69,052 | |
Non-controlling interests | 969 | 989 | |
Total equity | 70,596 | 70,041 | |
Total liabilities and equity | £ 1,589,230 | £ 1,384,285 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Condensed consolidated statem_2
Condensed consolidated statement of changes in equity (unaudited) - GBP (£) | Total | Total | Total share capital and share premium | Other equity instruments | Other reserves | Retained earnings | Non-controlling interests | |||||||
Beginning Balance, equity at Dec. 31, 2020 | £ 66,882,000,000 | [1] | £ 65,797,000,000 | [1] | £ 4,637,000,000 | [2] | £ 11,172,000,000 | [2] | £ 4,461,000,000 | [2] | £ 45,527,000,000 | [1] | £ 1,085,000,000 | [3] |
Profit after tax | 4,160,000,000 | [1] | 4,141,000,000 | [1] | 389,000,000 | [2] | 3,752,000,000 | [1] | 19,000,000 | [3] | ||||
Currency translation movements | (495,000,000) | [4],[5] | (495,000,000) | [1] | (495,000,000) | [2] | ||||||||
Fair value through other comprehensive income reserve | (250,000,000) | [1] | (250,000,000) | [1] | (250,000,000) | [2] | ||||||||
Cash flow hedges | (911,000,000) | [4],[5] | (911,000,000) | [1] | (911,000,000) | [2] | ||||||||
Retirement benefit remeasurements | 103,000,000 | [4],[5] | 103,000,000 | [1] | 103,000,000 | [1] | ||||||||
Own credit | (47,000,000) | [1],[5] | (47,000,000) | [1] | (47,000,000) | [2] | ||||||||
Total comprehensive income for the period | 2,560,000,000 | [1] | 2,541,000,000 | [1] | 389,000,000 | [2] | (1,703,000,000) | [2] | 3,855,000,000 | [1] | 19,000,000 | [3] | ||
Employee share schemes and hedging thereof | 314,000,000 | [1] | 314,000,000 | [1] | 25,000,000 | [2] | 289,000,000 | [1] | ||||||
Other equity instruments coupon paid | (389,000,000) | [1] | (389,000,000) | [1] | (389,000,000) | [2] | ||||||||
Vesting of employee share schemes | (393,000,000) | [1] | (393,000,000) | [1] | 4,000,000 | [2] | (397,000,000) | [1] | ||||||
Dividends paid | (189,000,000) | [1] | (173,000,000) | [1] | (173,000,000) | [1] | (16,000,000) | [3] | ||||||
Repurchase of shares | (700,000,000) | [1] | (700,000,000) | [1] | (94,000,000) | [2] | 94,000,000 | [2] | (700,000,000) | [1] | ||||
Other movements | (29,000,000) | [1] | (5,000,000) | [1] | (5,000,000) | [2] | (24,000,000) | [3] | ||||||
Ending Balance, equity at Jun. 30, 2021 | 68,056,000,000 | [1] | 66,992,000,000 | [1] | 4,568,000,000 | [2],[6] | 11,167,000,000 | [2],[6] | 2,856,000,000 | [2],[6] | 48,401,000,000 | [1] | 1,064,000,000 | [7] |
Beginning Balance, equity at Dec. 31, 2020 | 66,882,000,000 | [1] | 65,797,000,000 | [1] | 4,637,000,000 | [2] | 11,172,000,000 | [2] | 4,461,000,000 | [2] | 45,527,000,000 | [1] | 1,085,000,000 | [3] |
Profit after tax | 7,056,000,000 | |||||||||||||
Total comprehensive income for the period | 4,838,000,000 | |||||||||||||
Other movements | 9,000,000 | |||||||||||||
Ending Balance, equity at Dec. 31, 2021 | 70,041,000,000 | [8] | 69,052,000,000 | 4,536,000,000 | [6] | 12,259,000,000 | [6] | 1,770,000,000 | [6] | 50,487,000,000 | 989,000,000 | [7] | ||
Beginning Balance, equity at Jun. 30, 2021 | 68,056,000,000 | [1] | 66,992,000,000 | [1] | 4,568,000,000 | [2],[6] | 11,167,000,000 | [2],[6] | 2,856,000,000 | [2],[6] | 48,401,000,000 | [1] | 1,064,000,000 | [7] |
Profit after tax | 2,896,000,000 | 2,868,000,000 | 415,000,000 | [6] | 2,453,000,000 | 28,000,000 | [7] | |||||||
Currency translation movements | 364,000,000 | 364,000,000 | 364,000,000 | [6] | ||||||||||
Fair value through other comprehensive income reserve | (38,000,000) | (38,000,000) | (38,000,000) | [6] | ||||||||||
Cash flow hedges | (1,517,000,000) | (1,517,000,000) | (1,517,000,000) | [6] | ||||||||||
Retirement benefit remeasurements | 540,000,000 | 540,000,000 | 540,000,000 | |||||||||||
Own credit | 33,000,000 | 33,000,000 | 33,000,000 | [6] | ||||||||||
Total comprehensive income for the period | 2,278,000,000 | 2,250,000,000 | 415,000,000 | [6] | (1,158,000,000) | [6] | 2,993,000,000 | 28,000,000 | [7] | |||||
Employee share schemes and hedging thereof | (19,000,000) | (19,000,000) | 35,000,000 | [6] | (54,000,000) | |||||||||
Issue and redemption of other equity instruments | 1,009,000,000 | 1,084,000,000 | 1,078,000,000 | [6] | 6,000,000 | (75,000,000) | [7] | |||||||
Other equity instruments coupon paid | (415,000,000) | (415,000,000) | (415,000,000) | [6] | ||||||||||
Vesting of employee share schemes | (16,000,000) | (16,000,000) | (3,000,000) | [6] | (13,000,000) | |||||||||
Dividends paid | (367,000,000) | (339,000,000) | (339,000,000) | (28,000,000) | [7] | |||||||||
Repurchase of shares | (500,000,000) | (500,000,000) | (67,000,000) | [6] | 67,000,000 | [6] | (500,000,000) | |||||||
Other movements | 15,000,000 | 15,000,000 | 14,000,000 | [6] | 8,000,000 | [6] | (7,000,000) | |||||||
Ending Balance, equity at Dec. 31, 2021 | 70,041,000,000 | [8] | 69,052,000,000 | 4,536,000,000 | [6] | 12,259,000,000 | [6] | 1,770,000,000 | [6] | 50,487,000,000 | 989,000,000 | [7] | ||
Profit after tax | 2,910,000,000 | 2,889,000,000 | 414,000,000 | [6] | 2,475,000,000 | 21,000,000 | [7] | |||||||
Currency translation movements | 1,703,000,000 | [5] | 1,703,000,000 | 1,703,000,000 | [6] | |||||||||
Fair value through other comprehensive income reserve | (759,000,000) | (759,000,000) | (759,000,000) | [6] | ||||||||||
Cash flow hedges | (3,818,000,000) | [5] | (3,818,000,000) | (3,818,000,000) | [6] | |||||||||
Retirement benefit remeasurements | 1,090,000,000 | [5] | 1,090,000,000 | 1,090,000,000 | ||||||||||
Own credit | 855,000,000 | [5] | 855,000,000 | 855,000,000 | [6] | |||||||||
Total comprehensive income for the period | 1,981,000,000 | 1,960,000,000 | 414,000,000 | [6] | (2,019,000,000) | [6] | 3,565,000,000 | 21,000,000 | [7] | |||||
Employee share schemes and hedging thereof | 450,000,000 | 450,000,000 | 33,000,000 | [6] | 417,000,000 | |||||||||
Issue and redemption of other equity instruments | 120,000,000 | 140,000,000 | 115,000,000 | [6] | 25,000,000 | (20,000,000) | [7] | |||||||
Other equity instruments coupon paid | (414,000,000) | (414,000,000) | (414,000,000) | [6] | ||||||||||
Partial disposal of ABSA holding | 0 | 0 | (39,000,000) | [6] | 39,000,000 | |||||||||
Vesting of employee share schemes | (457,000,000) | (457,000,000) | 7,000,000 | [6] | (464,000,000) | |||||||||
Dividends paid | (685,000,000) | (664,000,000) | (664,000,000) | (21,000,000) | [7] | |||||||||
Repurchase of shares | (432,000,000) | (432,000,000) | (61,000,000) | [6] | 61,000,000 | [6] | (432,000,000) | |||||||
Other movements | (8,000,000) | (8,000,000) | (17,000,000) | [6] | 2,000,000 | [6] | 7,000,000 | |||||||
Ending Balance, equity at Jun. 30, 2022 | £ 70,596,000,000 | £ 69,627,000,000 | £ 4,508,000,000 | [6] | £ 12,357,000,000 | [6] | £ (218,000,000) | [6] | £ 52,980,000,000 | £ 969,000,000 | [7] | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 89 91 78 73 89 90 78 73 |
Condensed consolidated cash flo
Condensed consolidated cash flow statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | [1] | Dec. 31, 2021 | ||
Reconciliation of profit before tax to net cash flows from operating activities: | |||||
Profit before tax | £ 3,733 | £ 4,902 | £ 8,194 | ||
Adjustment for non-cash items | (7,115) | 6,977 | |||
Net (increase)/decrease in loans and advances at amortised cost | (17,667) | 432 | |||
Net increase in deposits at amortised cost | 49,237 | 19,859 | |||
Net increase in debt securities in issue | 19,748 | 13,041 | |||
Changes in other operating assets and liabilities | 14,719 | (5,559) | |||
Corporate income tax paid | (401) | (712) | |||
Net cash from operating activities | 62,254 | 38,940 | |||
Net cash from investing activities | (14,939) | (3,389) | |||
Net cash from financing activities | (5,500) | (2,562) | |||
Effect of exchange rates on cash and cash equivalents | 7,047 | (5,535) | |||
Net increase in cash and cash equivalents | 48,862 | 27,454 | |||
Cash and cash equivalents at beginning of the period | 259,206 | 210,142 | 210,142 | [1] | |
Cash and cash equivalents at end of period | £ 308,068 | £ 237,596 | £ 259,206 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Basis of preparation
Basis of preparation | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of initial application of standards or interpretations [abstract] | |
Basis of preparation | Basis of preparation These condensed consolidated interim financial statements ("the financial statements") for the six months ended 30 June 2022 have been prepared in accordance with the Disclosure Guidance and Transparency Rules (DTR) of the UK’s Financial Conduct Authority (FCA) and IAS 34, Interim Financial Reporting, as published by the International Accounting Standards Board (IASB) and adopted by the UK. The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2021. The annual financial statements for the year ended 31 December 2021 were prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 and in accordance with International Financial Reporting Standards (IFRS) and interpretations (IFRICs) as issued by the IASB and adopted by the UK. The accounting policies and methods of computation used in these condensed consolidated interim financial statements are the same as those used in the Barclays PLC Annual Report on Form 20-F for the financial year ended 31 December 2021, as amended (the Annual Report 2021). 1. Going concern The financial statements are prepared on a going concern basis, as the Directors are satisfied that the Group and parent company have the resources to continue in business for a period of at least 12 months from approval of the interim financial statements. In making this assessment, the Directors have considered a wide range of information relating to present and future conditions and includes a review of a working capital report (WCR). The WCR is used by the Directors to assess the future performance of the business and that it has the resources in place that are required to meet its ongoing regulatory requirements. The WCR also includes an assessment of the impact of internally generated stress testing scenarios on the liquidity and capital requirement forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Group could experience. The WCR indicated that the Group had sufficient capital in place to support its future business requirements and remained above its regulatory minimum requirements in the internal stress scenarios. 2. Other disclosures The Credit risk disclosures on pages 31 52 Restatement of financial statements The comparatives in these condensed consolidated interim financial statements for the six months ended 30 June 2022 (the financial statements) have been restated to reflect both a provision and contingent liability disclosure in respect of the impact of an over-issuance of securities (the Over-issuance of Securities) in excess of the maximum aggregate offering price registered under Barclays Bank PLC’s shelf registration statement on Form F-3, as declared effective by the SEC in August 2019 (2019 F-3) and Barclays Bank PLC’s predecessor shelf registration statement on Form F-3 filed in 2018 (Predecessor Shelf). Due to a historic SEC settlement order, at the time the 2019 F-3 was filed and the Predecessor Shelf was amended, Barclays Bank PLC had ceased to be a “well-known seasoned issuer” (or WKSI) and had become an “ineligible issuer”, as defined in Rule 405 under the Securities Act of 1933, as amended (Securities Act), thus being required to register upfront a certain amount of securities with the SEC. In March 2022, Barclays Bank PLC became aware that it had issued securities in the US materially in excess of the amount it had registered with the SEC under the 2019 F-3 and subsequently became aware that securities had also been issued in excess of the amount it had registered with the SEC under the Predecessor Shelf. The securities that were issued in this period comprise structured notes and exchange traded notes (ETNs). As such, certain offers and sales of these securities were not made in compliance with the Securities Act, giving rise to rights of rescission for certain purchasers of the securities. Under Section 12(a)(1) of the Securities Act, certain purchasers of unregistered securities have a right to recover, upon the tender of such security, the consideration paid for such security with interest, less the amount of any income received, or damages if the purchaser no longer owns the security (the Rescission Price). As a result, Barclays Bank PLC has elected to make a rescission offer to eligible purchasers of the relevant affected securities at the Rescission Price (the Rescission Offer). A proportion of the expected costs associated with the rights of rescission of certain investors are attributable to Barclays PLC’s financial statements for the year ended 31 December 2021. Accordingly, the comparatives in these financial statements have been restated. The restatement impacts the consolidated income statement, the consolidated statement of comprehensive income, the consolidated balance sheet, the consolidated statement of changes in equity, and the consolidated cash flow statement for the year ended 31 December 2021, as well as quarterly and half yearly financial information that is presented within this document. There was no material effect on Barclays PLC’s previously reported financial statements for the year ended 31 December 2020 and 2019. The table below reflects each of the consolidated financial statement line items that were affected by the restatement: Impact on the consolidated income statement As reported Restatement As restated Half year ended 30.06.21 £m £m £m Litigation and conduct (99) (77) (176) Operating expenses (7,231) (77) (7,308) Profit before tax 4,979 (77) 4,902 Taxation (759) 17 (742) Profit after tax 4,220 (60) 4,160 Year ended 31.12.21 £m £m £m Litigation and conduct (177) (220) (397) Operating expenses (14,439) (220) (14,659) Profit before tax 8,414 (220) 8,194 Taxation (1,188) 50 (1,138) Profit after tax 7,226 (170) 7,056 Impact on the consolidated statement of comprehensive income Half year ended 30.06.21 £m £m £m Profit after tax 4,220 (60) 4,160 Total comprehensive income for the period 2,620 (60) 2,560 Year ended 31.12.21 £m £m £m Profit after tax 7,226 (170) 7,056 Total comprehensive income for the period 5,008 (170) 4,838 Impact on the cash flow statement Half year ended 30.06.21 £m £m £m Profit before tax 4,979 (77) 4,902 Adjustment for non-cash items 6,900 77 6,977 Impact on the consolidated balance sheet As at 31.12.21 £m £m £m Current tax liabilities 739 (50) 689 Provisions 1,688 220 1,908 Total liabilities 1,314,074 170 1,314,244 Retained earnings 50,657 (170) 50,487 Total equity 70,211 (170) 70,041 |
Segmental reporting
Segmental reporting | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of operating segments [abstract] | |
Segmental reporting | Segmental reporting Analysis of results by business Barclays Barclays Head Barclays Half year ended 30.06.22 £m £m £m £m Total income 3,373 9,940 (109) 13,204 Credit impairment (charges)/releases (48) (310) 17 (341) Net operating income/(expenses) 3,325 9,630 (92) 12,863 Operating costs (2,083) (5,042) (145) (7,270) Litigation and conduct (25) (1,832) — (1,857) Total operating expenses (2,108) (6,874) (145) (9,127) Other net income/(expenses) 1 — 13 (16) (3) Profit/(loss) before tax 1,217 2,769 (253) 3,733 As at 30.06.22 £bn £bn £bn £bn Total assets 318.8 1,250.6 19.8 1,589.2 Restated 2 Restated 2 Barclays Barclays Head Barclays Half year ended 30.06.21 £m £m £m £m Total income 3,199 8,218 (102) 11,315 Credit impairment releases 443 293 6 742 Net operating income/(expenses) 3,642 8,511 (96) 12,057 Operating costs (2,114) (4,606) (412) (7,132) Litigation and conduct (22) (161) 7 (176) Total operating expenses (2,136) (4,767) (405) (7,308) Other net income 1 — 22 131 153 Profit/(loss) before tax 1,506 3,766 (370) 4,902 As at 31.12.21 £bn £bn £bn £bn Total assets 321.2 1,044.1 19.0 1,384.3 1 Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures and gains on acquisitions. 2 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 Split of income by geographic region 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m United Kingdom 7,972 5,895 Europe 1,311 1,222 Americas 3,200 3,608 Africa and Middle East 31 20 Asia 690 570 Total 13,204 11,315 1 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income
Net fee and commission income | 6 Months Ended |
Jun. 30, 2022 | |
Fee and commission income (expense) [abstract] | |
Net fee and commission income | Net fee and commission income Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Barclays UK Barclays International Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 1 515 1,448 — 1,963 Advisory 83 511 — 594 Brokerage and execution 125 762 — 887 Underwriting and syndication — 1,102 — 1,102 Other 29 80 2 111 Total revenue from contracts with customers 752 3,903 2 4,657 Other non-contract fee income — 69 — 69 Fee and commission income 1 752 3,972 2 4,726 Fee and commission expense (147) (1,153) (2) (1,302) Net fee and commission income 605 2,819 — 3,424 Barclays UK Barclays International Head Office Total Half year ended 30.06.21 £m £m £m £m Fee type Transactional 408 1,181 — 1,589 Advisory 83 459 1 543 Brokerage and execution 109 553 — 662 Underwriting and syndication — 1,715 — 1,715 Other 35 73 3 111 Total revenue from contracts with customers 635 3,981 4 4,620 Other non-contract fee income — 62 — 62 Fee and commission income 635 4,043 4 4,682 Fee and commission expense 1 (108) (861) (7) (976) Net fee and commission income 527 3,182 (3) 3,706 1 Barclays has corrected the presentation of the scheme fees incurred when Barclays acts as an “acquirer” as part of the payment transaction cycle. From 2022 onwards, the scheme fees reported under "Barclays International" are presented within fees and commission income under "Transactional" fee type, which had previously been recognised in fees and commission expense. The reclassification into Fee and Commission income is a reduction of £103m for H122. The comparatives have not been restated as the effect is not considered material although the effect would have been a reduction of H121: £88m with no impact on Net fee and commission income. There is no impact on Net assets or Cash flows reported. Transactional fees are service charges on deposit accounts, cash management services and transactional processing fees. These include interchange and merchant fee income generated from credit and bank card usage. Advisory fees are generated from wealth management services and investment banking advisory services related to mergers, acquisitions and financial restructurings. Brokerage and execution fees are earned for executing client transactions with various exchanges and over-the-counter markets and assisting clients in clearing transactions. Underwriting and syndication fees are earned for the distribution of client equity or debt securities and the arrangement and administration of a loan syndication. These include commitment fees to provide loan financing. |
Staff costs
Staff costs | 6 Months Ended |
Jun. 30, 2022 | |
Classes of employee benefits expense [abstract] | |
Staff costs | Staff costs Half year ended 30.06.22 Half year ended 30.06.21 Compensation costs £m £m Upfront bonus charge 705 824 Deferred bonus charge 280 262 Other incentives 44 6 Performance costs 1,029 1,092 Salaries 2,278 2,117 Social security costs 377 336 Post-retirement benefits 282 275 Other compensation costs 241 223 Total compensation costs 4,207 4,043 Other resourcing costs Outsourcing 268 171 Redundancy and restructuring (15) 23 Temporary staff costs 53 55 Other 70 42 Total other resourcing costs 376 291 Total staff costs 4,583 4,334 Barclays Group compensation costs as a % of total income 31.9% 35.7% No material awards have yet been granted in relation to the 2022 bonus pool as decisions regarding incentive awards are not taken by the Remuneration Committee until the performance for the full year can be assessed. The current year bonus charge for the first six months represents an accrual for estimated costs in accordance with accounting requirements. One of the primary considerations when evaluating the accrual is Group and business level returns, aligning colleague and shareholder interests. The Group has entered into physically settled forward contracts to hedge the settlement of certain share-based payment schemes. The present value of the fixed forward price to be paid under these outstanding contracts is £287m and has been recorded in retained earnings. |
Infrastructure, administration
Infrastructure, administration and general expenses | 6 Months Ended |
Jun. 30, 2022 | |
Expenses by nature [abstract] | |
Infrastructure, administration and general expenses | Infrastructure, administration and general expenses Half year ended 30.06.22 Half year ended 30.06.21 Infrastructure costs £m £m Property and equipment 744 709 Depreciation and amortisation 863 832 Lease payments 14 20 Impairment of property, equipment and intangible assets 21 304 Total infrastructure costs 1,642 1,865 Administration and general expenses Consultancy, legal and professional fees 288 262 Marketing and advertising 206 163 Other administration and general expenses 551 508 Total administration and general expenses 1,045 933 Total infrastructure, administration and general expenses 2,687 2,798 |
Tax
Tax | 6 Months Ended |
Jun. 30, 2022 | |
Major components of tax expense (income) [abstract] | |
Tax | Tax The tax charge for H122 was £823m (restated1 H121: £742m), representing an effective tax rate (ETR) of 22.0% (restated 1 H121: 15.1%). The ETR for H122 includes a charge recognised for the re-measurement of the Group’s UK deferred tax assets (DTAs) due to the enactment of legislation in Q122 which will result in the UK banking surcharge rate being reduced from 8% to 3% effective from 1 April 2023. The ETR excluding the impact of this downward re-measurement of UK DTAs was 12.8%, which includes a 5.8% benefit relating to adjustments in respect of prior years. Included in the H122 tax charge is a credit of £110m (H121: £104m) in respect of payments made on AT1 instruments that are classified as equity for accounting purposes. The H121 ETR included a benefit recognised for the re-measurement of the Group’s UK DTAs as a result of the enactment of legislation to increase the UK corporation tax rate to 25% effective from 1 April 2023. The re-measurement of UK DTAs has resulted in the Group's DTAs decreasing by £318m with a tax charge in the income statement of £346m and a tax credit within other comprehensive income of £28m. In October 2021, the OECD and G20 Inclusive Framework on Base Erosion and Profit Shifting announced plans to introduce a global minimum tax rate of 15%. The model rules were released by the OECD in December 2021 with further guidance published in March 2022. Draft legislation published by the UK government on 20 July 2022 to implement the global minimum tax regime is expected to apply for accounting periods beginning on or after 31 December 2023. The Group is reviewing the published OECD model rules and guidance and will review further guidance as well as new legislation to be released by governments implementing this new tax regime as it is published to assess the potential impact of new legislation. In the USA, the proposed Build Back Better Act was passed by the House of Representatives in 2021 but it was not passed by the Senate and it is uncertain whether various proposals contained in the Act will progress further. The Act included proposals to implement material changes to international tax provisions, including amendments to the Base Erosion and Anti-Abuse Tax and the imposition of an alternative minimum tax based on accounting profits. It is unclear at this time whether any of these proposals could have a significant impact on the Group if enacted. The Group will continue to monitor developments and assess the potential impact of any future legislative changes ultimately enacted. 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 As at 30.06.22 As at 31.12.21 Deferred tax assets and liabilities £m £m UK 3,046 2,183 USA 1,530 2,006 Other territories 468 430 Deferred tax assets 5,044 4,619 Deferred tax liabilities (5) (37) Analysis of deferred tax assets Temporary differences 3,871 3,399 Tax losses 1,173 1,220 Deferred tax assets 5,044 4,619 |
Non-controlling interests
Non-controlling interests | 6 Months Ended |
Jun. 30, 2022 | |
Non-controlling interests [Abstract] | |
Non-controlling interests | Non-controlling interests Profit attributable to Equity attributable to Half year ended 30.06.22 Half year ended 30.06.21 As at 30.06.22 As at 31.12.21 £m £m £m £m Barclays Bank PLC issued: - Preference shares 15 13 529 529 - Upper T2 instruments 6 3 438 458 Other non-controlling interests — 3 2 2 Total 21 19 969 989 |
Earnings per share
Earnings per share | 6 Months Ended |
Jun. 30, 2022 | |
Earnings per share [abstract] | |
Earnings per share | Earnings per share Restated 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m Profit attributable to ordinary equity holders of the parent 2,475 3,752 m m Basic weighted average number of shares in issue 16,684 17,140 Number of potential ordinary shares 428 467 Diluted weighted average number of shares 17,112 17,607 p p Basic earnings per ordinary share 14.8 21.9 Diluted earnings per ordinary share 14.5 21.3 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Dividends on ordinary shares
Dividends on ordinary shares | 6 Months Ended |
Jun. 30, 2022 | |
Dividends on ordinary shares [Abstract] | |
Dividends on ordinary shares | Dividends on ordinary shares A half year dividend for 2022 of 2.25p (H121: 2p) per ordinary share will be paid on 16 September 2022 to shareholders on the register on 12 August 2022. Half year ended 30.06.22 Half year ended 30.06.21 Per share Total Per share Total Dividends paid during the period p £m p £m Full year dividend paid during period 4.0 664 1.0 173 For qualifying American Depositary Receipt (ADR) holders, the half year dividend of 2.25p per ordinary share becomes 9.0p per American Depositary Share (representing 4 shares). The depositary bank will post the half year dividend on 16 September 2022 to ADR holders on the record at close of business on 12 August 2022. The Directors have confirmed their intention to initiate a share buyback of up to £500m after the balance sheet date. The share buyback is expected to commence in the third quarter of 2022. The financial statements for the six months ended 30 June 2022 do not reflect the impact of the proposed share buyback, which will be accounted for as and when shares are repurchased by the Company. |
Derivative financial instrument
Derivative financial instruments | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Derivative financial instruments | Derivative financial instruments Contract notional amount Fair value Assets Liabilities As at 30.06.22 £m £m £m Foreign exchange derivatives 6,732,093 135,207 (123,662) Interest rate derivatives 44,275,712 130,628 (116,541) Credit derivatives 1,640,043 8,128 (8,228) Equity and stock index and commodity derivatives 2,510,981 70,066 (71,830) Derivative assets/(liabilities) held for trading 55,158,829 344,029 (320,261) Derivatives in hedge accounting relationships Derivatives designated as cash flow hedges 139,040 701 (21) Derivatives designated as fair value hedges 107,809 106 (1,054) Derivatives designated as hedges of net investments 4,097 19 (60) Derivative assets/(liabilities) designated in hedge accounting relationships 250,946 826 (1,135) Total recognised derivative assets/(liabilities) 55,409,775 344,855 (321,396) As at 31.12.21 Foreign exchange derivatives 5,824,856 76,140 (74,437) Interest rate derivatives 38,816,432 125,846 (114,803) Credit derivatives 1,272,104 5,682 (6,561) Equity and stock index and commodity derivatives 1,899,382 54,010 (59,946) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) Derivatives in hedge accounting relationships Derivatives designated as cash flow hedges 114,313 798 (3) Derivatives designated as fair value hedges 102,815 59 (1,129) Derivatives designated as hedges of net investments 2,423 37 (4) Derivative assets/(liabilities) designated in hedge accounting relationships 219,551 894 (1,136) Total recognised derivative assets/(liabilities) 48,032,325 262,572 (256,883) The IFRS netting posted against derivative assets was £55bn including £12bn of cash collateral netted (December 2021: £24bn including £4bn cash collateral netted) and £55bn for liabilities including £12bn of cash collateral netted (December 2021: £24bn including £4bn of cash collateral netted). Derivative asset exposures would be £306bn (December 2021: £237bn) lower than reported under IFRS if netting were permitted for assets and liabilities with the same counterparty or for which the Group holds cash collateral of £40bn (December 2021: £35bn). Similarly, derivative liabilities would be £293bn (December 2021: £235bn) lower reflecting counterparty netting and cash collateral placed of £26bn (December 2021: £32bn). In addition, non-cash collateral of £13bn (December 2021: £6bn) was held in respect of derivative assets and £3bn (December 2021: £2bn) was placed in respect of derivative liabilities. Collateral amounts are limited to net on balance sheet exposure so as to not include over-collateralisation. |
Fair value of financial instrum
Fair value of financial instruments | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of fair value measurement of assets [abstract] | |
Fair value of financial instruments | Fair value of financial instruments This section should be read in conjunction with Note 17, Fair value of financial instruments of the Barclays PLC Annual Report 2021 which provides more detail about accounting policies adopted, valuation methodologies used in calculating fair value and the valuation control framework which governs oversight of valuations. There have been no changes in the accounting policies adopted or the valuation methodologies used. Valuation The following table shows the Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.22 £m £m £m £m Trading portfolio assets 58,419 64,329 4,256 127,004 Financial assets at fair value through the income statement 1,115 202,026 9,582 212,723 Derivative financial instruments 11,653 329,329 3,873 344,855 Financial assets at fair value through other comprehensive income 22,455 40,696 43 63,194 Investment property — — 5 5 Total assets 93,642 636,380 17,759 747,781 Trading portfolio liabilities (47,870) (28,686) (82) (76,638) Financial liabilities designated at fair value (193) (254,496) (447) (255,136) Derivative financial instruments (12,674) (304,343) (4,379) (321,396) Total liabilities (60,737) (587,525) (4,908) (653,170) As at 31.12.21 Trading portfolio assets 80,926 63,828 2,281 147,035 Financial assets at fair value through the income statement 5,093 177,167 9,712 191,972 Derivative financial instruments 6,150 252,412 4,010 262,572 Financial assets at fair value through other comprehensive income 22,009 39,706 38 61,753 Investment property — — 7 7 Total assets 114,178 533,113 16,048 663,339 Trading portfolio liabilities (27,529) (26,613) (27) (54,169) Financial liabilities designated at fair value (174) (250,376) (410) (250,960) Derivative financial instruments (6,571) (244,253) (6,059) (256,883) Total liabilities (34,274) (521,242) (6,496) (562,012) The following table shows the Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.22 As at 31.12.21 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,573 (1,849) 1,091 (1,351) Foreign exchange derivatives 786 (560) 376 (374) Credit derivatives 234 (615) 323 (709) Equity derivatives 1,280 (1,355) 2,220 (3,625) Corporate debt 1,171 (13) 1,205 (21) Reverse repurchase and repurchase agreements 178 (188) 13 (172) Non-asset backed loans 8,660 — 6,405 — Asset backed securities 291 — 558 — Equity cash products 422 (3) 393 — Private equity investments 1,297 (8) 1,095 (6) Other 1 1,867 (317) 2,369 (238) Total 17,759 (4,908) 16,048 (6,496) 1 Other includes commercial real estate loans, funds and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. Assets and liabilities reclassified between Level 1 and Level 2 During the period, there were no material transfers between Level 1 and Level 2 (period ended 31 December 2021: no material transfers between Level 1 and Level 2). Level 3 movement analysis The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 01.01.22 Purchases Sales Issues Settle-ments Trading income Other income In Out As at 30.06.22 £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Asset backed securities 454 72 (80) — (297) (20) — — 100 (66) 163 Equity cash products 303 21 (56) — — 24 — — 52 (17) 327 Other 377 326 (42) — (5) 56 — — 39 (84) 667 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Non-asset backed loans 5,647 1,847 (757) — (484) (334) — — 52 (9) 5,962 Equity cash products 90 — — — — 3 2 — — — 95 Private equity investments 1,095 99 (16) — (1) 84 (26) — 59 (4) 1,290 Other 2,880 4,817 (5,579) — (156) 11 182 — 99 (19) 2,235 Financial assets at fair value through the income statement 9,712 6,763 (6,352) — (641) (236) 158 — 210 (32) 9,582 Private equity investments — — — — — — — 1 6 — 7 Asset backed securities 38 — — — — — — (2) — — 36 Assets at fair value through other comprehensive income 38 — — — — — — (1) 6 — 43 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (410) (5) — (13) 47 (22) — — (81) 37 (447) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 171 980 (1) — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 218 849 (10) — 217 358 (506) Total 9,552 9,586 (7,126) (13) (695) 687 147 (1) 636 78 12,851 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. Level 3 movement analysis As at 01.01.21 Purchases Sales Issues Settle- Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.21 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 305 (87) — — 25 — — 40 (11) 423 Non-asset backed loans 709 620 (131) — (84) 13 — — 124 (106) 1,145 Asset backed securities 686 112 (294) — — (10) — — 43 (48) 489 Equity cash products 214 13 (17) — — 32 — — 29 (9) 262 Other 103 21 — — (51) (1) — — 162 (1) 233 Trading portfolio assets 1,863 1,071 (529) — (135) 59 — — 398 (175) 2,552 Non-asset backed loans 5,580 698 (299) — (687) (119) — — 69 (48) 5,194 Equity cash products 326 160 (194) — — (171) 18 — 1 — 140 Private equity investments 874 106 (9) — (8) (5) 92 — — (71) 979 Other 1,726 2,291 (2,389) — (162) (19) 1 — 16 — 1,464 Financial assets at fair value through the income statement 8,506 3,255 (2,891) — (857) (314) 111 — 86 (119) 7,777 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 4 — — (5) — — 2 — — 48 Assets at fair value through other comprehensive income 153 4 — — (5) — — 2 — (106) 48 Investment property 10 — (2) — — — — — — — 8 Trading portfolio liabilities (28) (3) 14 — — (7) — — — 7 (17) Financial liabilities designated at fair value (355) — — — 98 7 (2) — (78) 18 (312) Interest rate derivatives (2) 9 — — 33 (121) 4 — 21 (297) (353) Foreign exchange derivatives 1 — — — 58 (6) — — 3 (34) 22 Credit derivatives (155) (117) 2 — (5) 12 (1) — 1 (1) (264) Equity derivatives (1,614) (315) (1) — (32) (221) (1) — 28 808 (1,348) Net derivative financial instruments 1 (1,770) (423) 1 — 54 (336) 2 — 53 476 (1,943) Total 8,379 3,904 (3,407) — (845) (591) 111 2 459 101 8,113 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,657m and derivative financial liabilities were £5,600m. Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.22 Half year ended 30.06.21 Income statement Other compre hensive income Total Income statement Other compre hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets 121 — — 121 35 — — 35 Financial assets at fair value through the income statement (165) (22) — (187) (201) 114 — (87) Financial assets at fair value through other comprehensive income — — (1) (1) — — — — Investment properties — (1) — (1) — — — — Trading portfolio liabilities (35) — — (35) (6) — — (6) Financial liabilities designated at fair value (14) — — (14) 7 — — 7 Net derivative financial instruments 862 (1) — 861 (367) — — (367) Total 769 (24) (1) 744 (532) 114 — (418) Valuation techniques and sensitivity analysis Sensitivity analysis is performed on products with significant unobservable inputs (Level 3) to generate a range of reasonably possible alternative valuations. The sensitivity methodologies applied take account of the nature of valuation techniques used, as well as the availability and reliability of observable proxy and historical data and the impact of using alternative models. Current year valuation and sensitivity methodologies are consistent with those described within Note 17, Fair value of financial instruments in the Barclays PLC Annual Report 2021. Sensitivity analysis of valuations using unobservable inputs As at 30.06.22 As at 31.12.21 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 75 — (108) — 51 — (79) — Foreign exchange derivatives 15 — (22) — 20 — (28) — Credit derivatives 111 — (115) — 111 — (103) — Equity derivatives 107 — (112) — 187 — (195) — Corporate debt 36 — (35) — 38 — (28) — Non-asset backed loans 298 — (334) — 165 — (256) — Equity cash products 73 — (129) — 42 — (61) — Private equity investments 272 1 (286) (1) 246 — (236) — Other 1 27 — (36) — 20 — (19) — Total 1,014 1 (1,177) (1) 880 — (1,005) — 1 Other includes commercial real estate loans, funds and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. The effect of stressing unobservable inputs to a range of reasonably possible alternatives, alongside considering the impact of using alternative models, would be to increase fair values by up to £1,015m (December 2021: £880m) or to decrease fair values by up to £1,178m (December 2021: £1,005m) with substantially all the potential effect impacting profit and loss rather than reserves. Significant unobservable inputs The valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 are consistent with Note 17, Fair value of financial instruments in the Barclays PLC Annual Report 2021. Fair value adjustments Key balance sheet valuation adjustments are quantified below: As at 30.06.22 As at 31.12.21 £m £m Exit price adjustments derived from market bid-offer spreads (539) (506) Uncollateralised derivative funding (82) (127) Derivative credit valuation adjustments (388) (212) Derivative debit valuation adjustments 208 91 • Exit price adjustments derived from market bid-offer spreads increased by £33m to £539m as a result of movements in market bid offer spreads. • Uncollateralised derivative funding decreased by £45m to £82m as a result of reduction in uncollateralised funding exposure due to increases in interest rates which offset impact of wider funding spreads. • Derivative credit valuation adjustments increased by £176m to £388m as a result of widening input counterparty credit spreads • Derivative debit valuation adjustments increased by £117m to £208m as a result of widening input own credit spreads Portfolio exemption The Group uses the portfolio exemption in IFRS 13, Fair Value Measurement to measure the fair value of groups of financial assets and liabilities. Instruments are measured using the price that would be received to sell a net long position (i.e. an asset) for a particular risk exposure or to transfer a net short position (i.e. a liability) for a particular risk exposure in an orderly transaction between market participants at the balance sheet date under current market conditions. Accordingly, the Group measures the fair value of the group of financial assets and liabilities consistently with how market participants would price the net risk exposure at the measurement date. Unrecognised gains as a result of the use of valuation models using unobservable inputs The amount that has yet to be recognised in income that relates to the difference between the transaction price (the fair value at initial recognition) and the amount that would have arisen had valuation models using unobservable inputs been used on initial recognition, less amounts subsequently recognised, is £117m (December 2021: £133m) for financial instruments measured at fair value and £221m (December 2021: £230m) for financial instruments carried at amortised cost. There are additions and FX gains of £19m (December 2021: £59m) and amortisation and releases of £35m (December 2021: £42m) for financial instruments measured at fair value and additions of £nil (December 2021: £nil) and amortisation and releases of £9m (December 2021: £17m) for financial instruments carried at amortised cost. Third party credit enhancements Structured and brokered certificates of deposit issued by the Group are insured up to $250,000 per depositor by the Federal Deposit Insurance Corporation (FDIC) in the United States. The FDIC is funded by premiums that Barclays and other banks pay for deposit insurance coverage. The carrying value of these issued certificates of deposit that are designated under the IFRS 9 fair value option includes this third party credit enhancement. The on balance sheet value of these brokered certificates of deposit amounted to £3,065m (December 2021: £790m). Comparison of carrying amounts and fair values for assets and liabilities not held at fair value Valuation methodologies employed in calculating the fair value of financial assets and liabilities measured at amortised cost are consistent with those described within Note 17, Fair value of financial instruments in the Barclays PLC Annual Report 2021. The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Group’s balance sheet. As at 30.06.22 As at 31.12.21 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Loans and advances at amortised cost 395,824 396,475 361,451 362,424 Reverse repurchase agreements and other similar secured lending 1,639 1,639 3,227 3,227 Financial liabilities Deposits at amortised cost (568,670) (568,715) (519,433) (519,436) Repurchase agreements and other similar secured borrowing (28,566) (28,569) (28,352) (28,358) Debt securities in issue (115,906) (115,777) (98,867) (100,657) Subordinated liabilities (11,871) (11,799) (12,759) (13,334) |
Loans and advances and deposits
Loans and advances and deposits at amortised cost | 6 Months Ended |
Jun. 30, 2022 | |
Loans and advances and deposits at amortised cost [Abstract] | |
Loans and advances and deposits at amortised cost | Loans and advances and deposits at amortised cost As at 30.06.22 As at 31.12.21 £m £m Loans and advances at amortised cost to banks 12,532 9,698 Loans and advances at amortised cost to customers 337,220 319,922 Debt securities at amortised cost 46,072 31,831 Total loans and advances at amortised cost 395,824 361,451 Deposits at amortised cost from banks 29,891 17,819 Deposits at amortised cost from customers 538,779 501,614 Total deposits at amortised cost 568,670 519,433 |
Goodwill and intangible assets
Goodwill and intangible assets | 6 Months Ended |
Jun. 30, 2022 | |
Intangible assets and goodwill [abstract] | |
Goodwill and intangible assets | Goodwill and intangible assets Goodwill and intangible assets are allocated to business operations according to business segments as follows: As at 30.06.22 As at 31.12.21 Goodwill Intangibles Total Goodwill Intangibles Total £m £m £m £m £m £m Barclays UK 3,560 1,247 4,807 3,560 1,233 4,793 Barclays International 308 3,079 3,387 291 2,930 3,221 Head Office 44 7 51 42 5 47 Total 3,912 4,333 8,245 3,893 4,168 8,061 |
Subordinated liabilities
Subordinated liabilities | 6 Months Ended |
Jun. 30, 2022 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Subordinated liabilities Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance as at 1 January 12,759 16,341 Issuances 259 1,890 Redemptions (1,180) (4,807) Other 33 (665) Closing balance 11,871 12,759 Issuances of £259m comprise £128m USD Floating Rate Notes, £89m ZAR Floating Rate Notes and £42m EUR Floating Rate Notes issued externally by Barclays subsidiaries. Redemptions of £1,180m comprise £1,039m notes issued externally by Barclays Bank PLC, £74m USD Floating Rate Notes issued externally by a Barclays subsidiary and £67m GBP Undated Subordinated Loan Notes (secured) issued externally by a Barclays securitisation special purpose vehicle (SPV). £1,039m notes issued externally by Barclays Bank PLC comprise £838m EUR 6.625% Fixed Rate Subordinated Notes, £147m USD 6.86% Callable Perpetual Core Tier One Notes, £42m EUR Subordinated Floating Rate Notes and £12m GBP 6% Callable Perpetual Core Tier One Notes. |
Provisions
Provisions | 6 Months Ended |
Jun. 30, 2022 | |
Provisions [abstract] | |
Provisions | Provisions Restated 1 As at 30.06.22 As at 31.12.21 £m £m Customer redress 1,985 530 Legal, competition and regulatory matters 418 226 Redundancy and restructuring 216 326 Undrawn contractually committed facilities and guarantees 526 542 Onerous contracts — 5 Sundry provisions 281 279 Total 3,426 1,908 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 Over-issuance of securities As at 30 June 2022, Barclays PLC has recognised a balance sheet provision of £1,757m (December 2021: £220m) in relation to the Over-issuance of Securities (see Basis of preparation on page 73 The amount of the provision in relation to the rescission rights of investors in over-issued structured notes is determined by (among other things) the market value of the structured notes subject to the Rescission Offer, participation rates in such Rescission Offer, prevailing interest rates, and movements in foreign exchange rates. The majority of the structured notes subject to the Rescission Offer provide an equity linked return to investors. As such, the value of these notes is highly sensitive to movements in the price of individual securities and a range of indices. The increase in the provision of £1,372m predominantly reflects a reduction in the market value of the structured notes and additional accrued interest that would be payable to investors on rescission. The US equity markets have been volatile during the first half of 2022, with significant reductions in the value of US equity indices such as the S&P 500 from the year end 2021 levels, which has led to a reduction in the market value of the structured notes, and increased the size of the provision. The provision does not include the impact of market hedges that have been entered into subsequent to the year-end and were initiated from the end of the first quarter of 2022 to reduce the net volatility to the income statement. When determining these market hedges, consideration was given to changes in the rescission costs which would arise from volatility in the market along with the positioning of the Markets business. The structured notes also accrue interest on a monthly basis (at current prevailing interest rates and participation rate assumptions this is c£34m a month) until the Rescission Price has been paid. The provision also assumes that not all structured note investors whose securities are out of the money will accept the Rescission Offer. If all investors were to accept the Rescission Offer, the provision would increase by c£60m. The remaining increase in the provision of £165m results from Barclays PLC’s estimate of the potential SEC resolution. |
Retirement benefits
Retirement benefits | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of defined benefit plans [abstract] | |
Disclosure of retirement benefits | Retirement benefits As at 30 June 2022, the Group’s IAS 19 net pension surplus across all schemes was £4.9bn (December 2021: £3.6bn). The UK Retirement Fund (UKRF), which is the Group’s main scheme, had an IAS 19 net pension surplus of £5.2bn (December 2021: £3.8bn). The movement for the UKRF was driven by an overall increase in AA corporate bond yields (used for discounting future liabilities), a reduction in long-term expected price inflation assumption and the payment of deficit reduction contributions. These movements were partially offset by the fall in the value of UKRF's assets and the impact of high recent inflation on the liabilities. UKRF funding valuations The latest annual update as at 30 September 2021 showed the funding position had improved to a surplus of £0.6bn from a deficit of £0.9bn shown at 30 September 2020. The improvement was mainly due to £0.7bn of deficit reduction contributions and favourable asset returns, partially offset by higher expected long term price inflation. The deficit recovery plan agreed at the last triennial valuation requires deficit reduction contributions from Barclays Bank PLC of £294m in 2022 and £286m in 2023. The deficit reduction contributions are in addition to the regular contributions to meet the Group’s share of the cost of benefits accruing over each year. £147m of the 2022 deficit reduction contributions were paid in April, with the remaining £147m due in September. The next triennial actuarial valuation of the UKRF is due to be completed in 2023 with an effective date of 30 September 2022. |
Called up share capital
Called up share capital | 6 Months Ended |
Jun. 30, 2022 | |
Equity [abstract] | |
Called up share capital | Called up share capital Ordinary share capital Share premium Total share capital and share premium Half year ended 30.06.22 £m £m £m Opening balance as at 1 January 4,188 348 4,536 Issue of shares under employee share schemes 6 27 33 Repurchase of shares (61) — (61) Closing balance 4,133 375 4,508 Called up share capital comprises 16,531m (December 2021: 16,752m) ordinary shares of 25p each. The decrease is mainly due to the repurchase of 244m shares as part of the £1.0bn share buyback announced in the FY21 results, partially offset by an increase due to the issuance of shares under employee share schemes. |
Other equity instruments
Other equity instruments | 6 Months Ended |
Jun. 30, 2022 | |
Miscellaneous components of equity [abstract] | |
Other equity instruments | Other equity instruments Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance as at 1 January 12,259 11,172 Issuances 1,247 1,078 Redemptions (1,132) — Securities held by the Group (17) 9 Closing balance 12,357 12,259 Other equity instruments of £12,357m (December 2021: £12,259m) comprise AT1 securities issued by Barclays PLC. There was one issuance and one redemption in the six months to 30 June 2022. The AT1 securities are perpetual securities with no fixed maturity and are structured to qualify as AT1 instruments under prevailing capital rules applicable as at the relevant issue date. AT1 securities are undated and are redeemable, at the option of Barclays PLC, in whole on (i) the initial call date, or on any fifth anniversary after the initial call date or (ii) any day falling in a named period ending on the initial reset date, or on any fifth anniversary after the initial reset date. In addition, the AT1 securities are redeemable, at the option of Barclays PLC, in whole in the event of certain changes in the tax or regulatory treatment of the securities. Any redemptions require the prior consent of the PRA. |
Other reserves
Other reserves | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | Other reserves As at 30.06.22 As at 31.12.21 £m £m Currency translation reserve 4,443 2,740 Fair value through other comprehensive income reserve (1,081) (283) Cash flow hedging reserve (4,671) (853) Own credit reserve (103) (960) Other reserves and treasury shares 1,194 1,126 Total (218) 1,770 Currency translation reserve The currency translation reserve represents the cumulative gains and losses on the retranslation of the Group’s net investment in foreign operations, net of the effects of hedging. As at 30 June 2022, there was a credit balance of £4,443m (December 2021: £2,740m credit) in the currency translation reserve. The £1,703m credit movement principally reflects the weakening of GBP against USD during the period. Fair value through other comprehensive income reserve The fair value through other comprehensive income reserve represents the changes in the fair value of fair value through other comprehensive income investments since initial recognition. As at 30 June 2022, there was a debit balance of £1,081m (December 2021: £283m debit) in the fair value through other comprehensive income reserve. The loss of £798m is principally driven by a loss of £1,237m from the decrease in fair value of bonds due to increasing bond yields, £5m of net gains transferred to the income statement and £39m of gains transferred to retained earnings on sale of 7.45% equity stake in Absa Group Limited. This is partially offset by a gain of £153m due to an increase in the Absa Group Limited share price and a tax credit of £326m. Cash flow hedging reserve The cash flow hedging reserve represents the cumulative gains and losses on effective cash flow hedging instruments that will be recycled to the income statement when the hedged transactions affect profit or loss. As at 30 June 2022, there was a debit balance of £4,671m (December 2021: £853m debit) in the cash flow hedging reserve. The decrease of £3,818m principally reflects a £4,747m decrease in the fair value of interest rate swaps held for hedging purposes as major interest rate forward curves increased and £429m of gains transferred to the income statement. This is partially offset by a tax credit of £1,358m. Own credit reserve The own credit reserve reflects the cumulative own credit gains and losses on financial liabilities at fair value. Amounts in the own credit reserve are not recycled to profit or loss in future periods. As at 30 June 2022, there was a debit balance of £103m (December 2021: £960m debit) in the own credit reserve. The movement of £857m principally reflects a £1,258m gain from the widening of Barclays’ funding spreads partially offset by a tax charge of £403m. Other reserves and treasury shares Other reserves relate to redeemed ordinary and preference shares issued by the Group. Treasury shares relate to Barclays PLC shares held principally in relation to the Group’s various share schemes. As at 30 June 2022, there was a credit balance of £1,194m (December 2021: £1,126m credit) in other reserves and treasury shares. This is driven by an increase of £61m due to the repurchase of 244m shares as part of the £1.0bn share buyback and a £7m increase in the treasury shares balance held in relation to employee share schemes. |
Contingent liabilities and comm
Contingent liabilities and commitments | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | Contingent liabilities and commitments As at 30.06.22 As at 31.12.21 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 16,463 15,549 Performance guarantees, acceptances and endorsements 5,877 5,797 Total 22,340 21,346 Commitments Documentary credits and other short-term trade related transactions 1,888 1,584 Standby facilities, credit lines and other commitments 396,038 344,127 Total 397,926 345,711 Further details on contingent liabilities, where it is not practicable to disclose an estimate of the potential financial effect on Barclays relating to legal and competition and regulatory matters can be found in Note 21. |
Legal, competition and regulato
Legal, competition and regulatory matters | 6 Months Ended |
Jun. 30, 2022 | |
Legal, competition and regulatory matters [Abstract] | |
Legal, competition and regulatory matters | Legal, competition and regulatory matters The Group faces legal, competition and regulatory challenges, many of which are beyond our control. The extent of the impact of these matters cannot always be predicted but may materially impact our operations, financial results, condition and prospects. Matters arising from a set of similar circumstances can give rise to either a contingent liability or a provision, or both, depending on the relevant facts and circumstances. The recognition of provisions in relation to such matters involves critical accounting estimates and judgments in accordance with the relevant accounting policies applicable to Note 15, Provisions. We have not disclosed an estimate of the potential financial impact or effect on the Group of contingent liabilities where it is not currently practicable to do so. Various matters detailed in this note seek damages of an unspecified amount. While certain matters specify the damages claimed, such claimed amounts do not necessarily reflect the Group’s potential financial exposure in respect of those matters. Matters are ordered under headings corresponding to the financial statements in which they are disclosed. 1. Barclays PLC and Barclays Bank PLC Investigations into certain advisory services agreements FCA proceedings In 2008, Barclays Bank PLC and Qatar Holdings LLC entered into two advisory service agreements (the Agreements). The Financial Conduct Authority (FCA) conducted an investigation into whether the Agreements may have related to Barclays PLC’s capital raisings in June and November 2008 (the Capital Raisings) and therefore should have been disclosed in the announcements or public documents relating to the Capital Raisings. In 2013, the FCA issued warning notices (the Notices) finding that Barclays PLC and Barclays Bank PLC acted recklessly and in breach of certain disclosure-related listing rules, and that Barclays PLC was also in breach of Listing Principle 3. The financial penalty provided in the Notices is £50m. Barclays PLC and Barclays Bank PLC continue to contest the findings. Following the conclusion of the Serious Fraud Office (SFO) proceedings against certain former Barclays executives resulting in their acquittals, the FCA proceedings, which were stayed, have resumed. A hearing took place before the Regulatory Decisions Committee in the first quarter of 2022 and a decision is expected in the second half of 2022. Investigations into LIBOR and other benchmarks and related civil actions Regulators and law enforcement agencies, including certain competition authorities, from a number of governments have conducted investigations relating to Barclays Bank PLC’s involvement in allegedly manipulating certain financial benchmarks, such as LIBOR. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Group and other banks in relation to the alleged manipulation of LIBOR and/or other benchmarks. USD LIBOR civil actions The majority of the USD LIBOR cases, which have been filed in various US jurisdictions, have been consolidated for pre-trial purposes in the US District Court in the Southern District of New York (SDNY). The complaints are substantially similar and allege, among other things, that Barclays PLC, Barclays Bank PLC, Barclays Capital Inc. (BCI) and other financial institutions individually and collectively violated provisions of the US Sherman Antitrust Act (Antitrust Act), the US Commodity Exchange Act (CEA), the US Racketeer Influenced and Corrupt Organizations Act (RICO), the Securities Exchange Act of 1934 and various state laws by manipulating USD LIBOR rates. Putative class actions and individual actions seek unspecified damages with the exception of one lawsuit, in which the plaintiffs are seeking no less than $100m in actual damages and additional punitive damages against all defendants, including Barclays Bank PLC. Some of the lawsuits also seek trebling of damages under the Antitrust Act and RICO. Barclays Bank PLC has previously settled certain claims. Two class action settlements, where Barclays Bank PLC has respectively paid $7.1m and $20m, have received final court approval. Barclays Bank PLC also settled two further matters for $7.5m, and $1.95m respectively. Sterling LIBOR civil actions In 2016, two putative class actions filed in the SDNY against Barclays Bank PLC, BCI and other Sterling LIBOR panel banks alleging, among other things, that the defendants manipulated the Sterling LIBOR rate in violation of the Antitrust Act, CEA and RICO, were consolidated. The defendants’ motion to dismiss the claims was granted in 2018. The plaintiffs have appealed the dismissal. Japanese Yen LIBOR civil actions In 2012, a putative class action was filed in the SDNY against Barclays Bank PLC and other Japanese Yen LIBOR panel banks by a lead plaintiff involved in exchange-traded derivatives and members of the Japanese Bankers Association’s Euroyen Tokyo Interbank Offered Rate (Euroyen TIBOR) panel. The complaint alleges, among other things, manipulation of the Euroyen TIBOR and Yen LIBOR rates and breaches of the CEA and the Antitrust Act. In 2014, the court dismissed the plaintiff’s antitrust claims, and, in 2020, the court dismissed the plaintiff’s remaining CEA claims. The plaintiff has appealed the lower court’s dismissal of such claims. In 2015, a second putative class action, making similar allegations to the above class action, was filed in the SDNY against Barclays PLC, Barclays Bank PLC and BCI. Barclays and the plaintiffs have reached a settlement of $17.75m for both actions, which is subject to court approval. SIBOR/SOR civil action In 2016, a putative class action was filed in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants, alleging manipulation of the Singapore Interbank Offered Rate (SIBOR) and Singapore Swap Offer Rate (SOR). The plaintiffs and remaining defendants (which includes Barclays Bank PLC) have reached a joint settlement to resolve this matter for $91m, which has received preliminary court approval. A final court approval hearing has been scheduled for November 2022. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Group’s operating results, cash flows or financial position. ICE LIBOR civil actions In 2019, several putative class actions were filed in the SDNY against a panel of banks, including Barclays PLC, Barclays Bank PLC, BCI, other financial institution defendants and Intercontinental Exchange Inc. and certain of its affiliates (ICE), asserting antitrust claims that defendants manipulated USD LIBOR through defendants’ submissions to ICE. These actions have been consolidated. The defendants’ motion to dismiss was granted in 2020 and the plaintiffs appealed. In February 2022, the dismissal was affirmed on appeal. The plaintiffs have not sought U.S. Supreme Court review. This matter is now concluded. In August 2020, an ICE LIBOR-related action was filed by a group of individual plaintiffs in the US District Court for the Northern District of California on behalf of individual borrowers and consumers of loans and credit cards with variable interest rates linked to USD ICE LIBOR. The plaintiffs' motion seeking, among other things, preliminary and permanent injunctions to enjoin the defendants from continuing to set LIBOR or enforce any financial instrument that relies in whole or in part on USD LIBOR was denied. The defendants have moved to dismiss the case. Non-US benchmarks civil actions There remains one claim, issued in 2017, against Barclays Bank PLC and other banks in the UK in connection with alleged manipulation of LIBOR. Proceedings have also been brought in a number of other jurisdictions in Europe, Argentina and Israel relating to alleged manipulation of LIBOR and EURIBOR. Additional proceedings in other jurisdictions may be brought in the future. Credit Default Swap civil action A putative antitrust class action is pending in New Mexico federal court against Barclays Bank PLC, BCI and various other financial institutions. The plaintiffs, the New Mexico State Investment Council and certain New Mexico pension funds, allege that the defendants conspired to manipulate the benchmark price used to value Credit Default Swap (CDS) contracts at settlement (i.e. the CDS final auction price). The plaintiffs allege violations of US antitrust laws and the CEA, and unjust enrichment under state law. The defendants have moved to dismiss the case. Foreign Exchange investigations and related civil actions In 2015, the Group reached settlements totalling approximately $2.38bn with various US federal and state authorities and the FCA in relation to investigations into certain sales and trading practices in the Foreign Exchange market. The European Commission announced two settlements in May 2019 and the Group paid penalties totalling approximately €210m. In June 2019, the Swiss Competition Commission announced two settlements and the Group paid penalties totalling approximately CHF27m. In December 2021, the European Commission announced a final settlement which required the Group to pay penalties totalling approximately €54m, which amount has been provided for in previous periods. The financial impact of any ongoing investigations is not expected to be material to the Group’s operating results, cash flows or financial position. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Group and other banks in relation to alleged manipulation of Foreign Exchange markets. FX opt out civil action In 2018, Barclays Bank PLC and BCI settled a consolidated action filed in the SDNY, alleging manipulation of Foreign Exchange markets (Consolidated FX Action), for a total amount of $384m. Also in 2018, a group of plaintiffs who opted out of the Consolidated FX Action filed a complaint in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants. Some of the plaintiffs' claims were dismissed in 2020. Retail basis civil action In 2015, a putative class action was filed against several international banks, including Barclays PLC and BCI, on behalf of a proposed class of individuals who exchanged currencies on a retail basis at bank branches (Retail Basis Claims). The SDNY has ruled that the Retail Basis Claims are not covered by the settlement agreement in the Consolidated FX Action. The Court subsequently dismissed all Retail Basis Claims against the Group and all other defendants. The plaintiffs have filed an amended complaint. Non-US FX civil actions Legal proceedings have been brought or are threatened against Barclays PLC, Barclays Bank PLC, BCI and Barclays Execution Services Limited (BX) in connection with alleged manipulation of Foreign Exchange in the UK, a number of other jurisdictions in Europe, Israel, Brazil and Australia. Additional proceedings may be brought in the future. The above-mentioned proceedings include two purported class actions filed against Barclays PLC, Barclays Bank PLC, BX, BCI and other financial institutions in the UK Competition Appeal Tribunal (CAT) in 2019 following the settlements with the European Commission described above. The CAT refused to certify these claims in the first quarter of 2022 although the claimants are seeking permission to appeal. Also in 2019, a separate claim was filed in the UK in the High Court of Justice (High Court), and subsequently transferred to the CAT, by various banks and asset management firms against Barclays Bank PLC and other financial institutions alleging breaches of European and UK competition laws related to FX trading. Metals related civil actions A number of US civil complaints, each on behalf of a proposed class of plaintiffs, have been consolidated and transferred to the SDNY. The complaints allege that Barclays Bank PLC and other members of The London Gold Market Fixing Ltd. manipulated the prices of gold and gold derivative contracts in violation of the Antitrust Act and other federal laws. The parties have reached a joint settlement to resolve this matter for $50m, which has received preliminary court approval, with the final court approval hearing scheduled for August 2022. The financial impact of Barclays’ share of the joint settlement is not expected to be material to the Group’s operating results, cash flows or financial position. A separate US civil complaint by a proposed class of plaintiffs against a number of banks, including Barclays Bank PLC, BCI and BX, alleging manipulation of the price of silver in violation of the CEA, the Antitrust Act and state antitrust and consumer protection laws, has been dismissed as against the Barclays entities. The plaintiffs have the option to seek the court’s permission to appeal. Civil actions have also been filed in Canadian courts against Barclays PLC, Barclays Bank PLC, Barclays Capital Canada Inc. and BCI on behalf of proposed classes of plaintiffs alleging manipulation of gold and silver prices. US residential mortgage related civil actions There are two pending US Residential Mortgage-Backed Securities (RMBS) related civil actions arising from unresolved repurchase requests submitted by Trustees for certain RMBS, alleging breaches of various loan-level representations and warranties (R&Ws) made by Barclays Bank PLC and/or a subsidiary acquired in 2007. In one action, the Barclays defendants’ motion for summary judgment was granted in June 2022 and the plaintiffs’ R&W breach claim was dismissed. The plaintiffs may appeal. The other repurchase action is pending. Barclays Bank PLC has reached settlements to resolve two other repurchase actions, which have received final court approval. Payment of the settlement amount of one of those repurchase actions was completed in the first quarter of 2022, and the other will be completed in the third quarter of 2022. The financial impact of the settlements is not expected to be material to the Group’s operating results, cash flows or financial position. In 2020, a civil litigation claim was filed in the New Mexico First Judicial District Court by the State of New Mexico against six banks, including BCI, on behalf of two New Mexico state pension funds and the New Mexico State Investment Council relating to legacy RMBS purchases. As to BCI, the complaint alleges that the funds purchased approximately $22m in RMBS underwritten by BCI. The parties have reached a joint settlement to resolve this matter for $32.5m. The settlement was paid in April 2022. The financial impact of BCI’s share of the joint settlement is not material to the Group’s operating results, cash flows or financial position. Government and agency securities civil actions Treasury auction securities civil actions Consolidated putative class action complaints filed in US federal court against Barclays Bank PLC, BCI and other financial institutions under the Antitrust Act and state common law allege that the defendants (i) conspired to manipulate the US Treasury securities market and/or (ii) conspired to prevent the creation of certain platforms by boycotting or threatening to boycott such trading platforms. The court dismissed the consolidated action in March 2021. The plaintiffs filed an amended complaint. The defendants’ motion to dismiss the amended complaint was granted in March 2022. The plaintiffs are appealing this decision. In addition, certain plaintiffs have filed a related, direct action against BCI and certain other financial institutions, alleging that defendants conspired to fix and manipulate the US Treasury securities market in violation of the Antitrust Act, the CEA and state common law. Supranational, Sovereign and Agency bonds civil actions Civil antitrust actions have been filed in the SDNY and Federal Court of Canada in Toronto against Barclays Bank PLC, BCI, BX, Barclays Capital Securities Limited and, with respect to the civil action filed in Canada only, Barclays Capital Canada, Inc. and other financial institutions alleging that the defendants conspired to fix prices and restrain competition in the market for US dollar-denominated Supranational, Sovereign and Agency bonds. In one of the actions filed in the SDNY, the court granted the defendants’ motion to dismiss the plaintiffs’ complaint. The dismissal was affirmed on appeal; however, the district court subsequently informed the parties of a potential conflict. The motion to dismiss were assigned to a new district court judge and the plaintiffs have moved to vacate the dismissal order. The plaintiffs have voluntarily dismissed the other SDNY action. In the Federal Court of Canada action, the plaintiffs reached settlements with a small number of banks in 2020 (not including Barclays Capital Canada, Inc.). The plaintiffs have commenced the class certification process. There is no court scheduled deadline and the action remains at an early stage. Variable Rate Demand Obligations civil actions Civil actions have been filed against Barclays Bank PLC and BCI and other financial institutions alleging the defendants conspired or colluded to artificially inflate interest rates set for Variable Rate Demand Obligations (VRDOs). VRDOs are municipal bonds with interest rates that reset on a periodic basis, most commonly weekly. Two actions in state court have been filed by private plaintiffs on behalf of the states of Illinois and California. Three putative class action complaints have been consolidated in the SDNY. In the consolidated SDNY class action, certain of the plaintiffs’ claims were dismissed in November 2020 and defendants’ motion for partial dismissal of the amended consolidated complaint was granted in part and denied in part in June 2022. In the California action, the plaintiffs’ claims were dismissed in June 2021. The plaintiffs have appealed the dismissal. Odd-lot corporate bonds antitrust class action In 2020, BCI, together with other financial institutions, were named as defendants in a putative class action. The complaint alleges a conspiracy to boycott developing electronic trading platforms for odd-lots and price fixing. The plaintiffs demand unspecified money damages. The defendants’ motion to dismiss was granted in 2021 and the plaintiffs have appealed the dismissal. The district court subsequently informed the parties of a potential conflict and the case was reassigned to a new district court judge. The plaintiffs have filed a motion seeking a ruling that would vacate the dismissal and allow the plaintiffs to file an amended complaint if the appeals court remands the case for further proceedings. Interest rate swap and credit default swap US civil actions Barclays PLC, Barclays Bank PLC and BCI, together with other financial institutions that act as market makers for interest rate swaps (IRS) are named as defendants in several antitrust class actions which were consolidated in the SDNY in 2016. The complaints allege the defendants conspired to prevent the development of exchanges for IRS and demand unspecified money damages. In 2018, trueEX LLC filed an antitrust class action in the SDNY against a number of financial institutions including Barclays PLC, Barclays Bank PLC and BCI based on similar allegations with respect to trueEX LLC’s development of an IRS platform. In 2017, Tera Group Inc. filed a separate civil antitrust action in the SDNY claiming that certain conduct alleged in the IRS cases also caused the plaintiff to suffer harm with respect to the Credit Default Swaps market. In 2018 and 2019, respectively, the court dismissed certain claims in both cases for unjust enrichment and tortious interference but denied motions to dismiss the federal and state antitrust claims, which remain pending. BDC Finance L.L.C. In 2008, BDC Finance L.L.C. (BDC) filed a complaint in the Supreme Court of the State of New York (NY Supreme Court), demanding damages of $298m, alleging that Barclays Bank PLC had breached a contract in connection with a portfolio of total return swaps governed by an ISDA Master Agreement (the Master Agreement). Following a trial, the court ruled in 2018 that Barclays Bank PLC was not a defaulting party, which was affirmed on appeal. In April 2021, the trial court entered judgement in favour of Barclays Bank PLC for $3.3m and as yet to be determined legal fees and costs. BDC appealed. In January 2022, the appellate court reversed the trial court’s summary judgment decision in favour of Barclays Bank PLC and remanded the case to the lower court for further proceedings, with the trial scheduled to commence in the fourth quarter of 2022. In 2011, BDC’s investment advisor, BDCM Fund Adviser, L.L.C. and its parent company, Black Diamond Capital Holdings, L.L.C. also sued Barclays Bank PLC and BCI in Connecticut State Court for unspecified damages allegedly resulting from Barclays Bank PLC’s conduct relating to the Master Agreement, asserting claims for violation of the Connecticut Unfair Trade Practices Act and tortious interference with business and prospective business relations. This case is currently stayed. Civil actions in respect of the US Anti-Terrorism Act There are a number of civil actions, on behalf of more than 4,000 plaintiffs, filed in US federal courts in the US District Court in the Eastern District of New York (EDNY) and SDNY against Barclays Bank PLC and a number of other banks. The complaints generally allege that Barclays Bank PLC and those banks engaged in a conspiracy to facilitate US dollar-denominated transactions for the Iranian Government and various Iranian banks, which in turn funded acts of terrorism that injured or killed the plaintiffs or the plaintiffs’ family members. The plaintiffs seek to recover damages for pain, suffering and mental anguish under the provisions of the US Anti-Terrorism Act, which allow for the trebling of any proven damages. The court granted the defendants’ motions to dismiss three out of the six actions in the EDNY. The plaintiffs have appealed in one action. The remaining actions are stayed pending a decision on the appeal. Out of the two actions in the SDNY, the court also granted the defendants’ motion to dismiss the first action, which is stayed pending a decision on the EDNY appeal. The second SDNY action is stayed, pending any appeal on the dismissal of the first. Shareholder derivative action In November 2020, a purported Barclays shareholder filed a putative derivative action in New York state court against BCI and a number of current and former members of the Board of Directors of Barclays PLC and senior executives or employees of the Group. The shareholder filed the claim on behalf of nominal defendant Barclays PLC, alleging that the individual defendants harmed the company through breaches of their duties, including under the Companies Act 2006. The plaintiff seeks damages on behalf of Barclays PLC for the losses that Barclays PLC allegedly suffered as a result of these alleged breaches. An amended complaint was filed in April 2021, which BCI and certain other defendants moved to dismiss. The motion to dismiss was granted in April 2022. The plaintiffs are appealing the decision. Derivative transactions civil action In 2021, Vestia (a Dutch housing association) brought a claim against Barclays Bank PLC in the UK in the High Court in relation to a series of derivative transactions entered into with Barclays Bank PLC between 2008 and 2011, seeking damages of £329m. Barclays Bank PLC is defending the claim and has made a counterclaim. Timeshare loans, skilled person review, and associated matters In August 2020, the FCA granted an application by Clydesdale Financial Services Limited (CFS), which trades as Barclays Partner Finance and houses Barclays’ point-of-sale finance business, for a validation order with respect to certain loans to customers brokered between April 2014 and April 2016 by Azure Services Limited (ASL), a timeshare operator, which did not, at the point of sale, hold the necessary broker licence. As a condition to the validation order, the FCA required CFS to undertake a skilled person review of the assessment of affordability processes for the loans brokered by ASL (ASL Loans) as well as CFS’ policies and procedures for assessing affordability and oversight of brokers more generally, and dictated a remediation methodology in the event that ASL Loans did not pass the affordability test. CFS voluntarily agreed to remediate the ASL Loans, in accordance with the FCA’s methodology and the remediation exercise is substantively complete. The remaining scope of the skilled person review is also complete. The skilled person made a number of observations, some of which were adverse, about both current and historic affordability practices as well as current oversight practices. CFS is not required to conduct a full back book review but, following a review of certain cohorts of loans to determine historic affordability and/or broker oversight practices that may have caused customer harm, where harm is identified, CFS’ intention is to remediate. To date CFS has identified a number of areas for remediation but the scoping exercise is ongoing. Separately, and notwithstanding this, CFS decided in March 2022 to extend the proactive remediation of ASL Loans beyond those brokered between April 2014 to April 2016 to include the full portfolio of ASL Loans brokered between 2006 and 2018. In the first quarter of 2022, a customer remediation provision of £181m has been recognised in relation to the remediation of the ASL Loans originated outside the April 2014 to April 2016 period. This provision represents the best estimate as at 30 June 2022. CFS continues to review complaints about other legacy partner finance loans, however, it is not currently possible to predict the outcome of this review or the financial impact on the Group. Over-issuance of securities in the US Barclays Bank PLC maintains a US shelf registration statement with the Securities and Exchange Commission (SEC) in order to issue securities to US investors. In May 2017, Barclays Bank PLC was the subject of an SEC settlement order as a result of which it lost its status as a “well-known seasoned issuer” (or WKSI) and was required to register a specified amount of securities to be issued under any US shelf registration statements filed with the SEC. On 10 March 2022, executive management became aware that Barclays Bank PLC had issued securities materially in excess of the set amount under its 2019 US shelf registration statement (2019 F-3) and subsequently became aware that securities had also been issued in excess of the set amount under the predecessor US shelf registration statement (the Predecessor Shelf). The securities that have been over-issued comprise structured notes and exchange traded notes (ETNs). Securities issued in excess of the amount registered are considered to be “unregistered securities” for the purposes of US securities laws, with certain purchasers of those securities having a right to recover, upon the tender of such security to Barclays Bank PLC, the consideration paid for such security with interest, less the amount of any income received, or to recover damages from Barclays Bank PLC if the purchaser no longer owns the security and had sold the security at a loss (the Rescission Price). Barclays Bank PLC is expected to launch a rescission offer on 1 August 2022, by which Barclays Bank PLC will offer to repurchase the relevant affected securities for the rescission price (the Rescission Offer). Although the Rescission Offer is expected to reduce liability with respect to potential private civil claims, it will not necessarily prevent such claims from being asserted against Barclays Bank PLC and/or its affiliates, including claims under applicable US federal securities laws. Further, the Rescission Offer does not bar the SEC and other regulators from pursuing enforcement actions against Barclays Bank PLC and its affiliates, which are expected to result in fines, penalties and/or other sanctions. The Group is engaged with, and responding to inquiries and requests for information from, various regulators, including the SEC. The SEC’s investigation into this matter is at an advanced stage and the Group has had preliminary discussions with the staff of the SEC's Division of Enforcement about resolving this matter. As at 30 June 2022, Barclays PLC has recognised a balance sheet provision of £1,757m (December 2021: £220m) in relation to this matter, out of which £1,592m (December 2021: £220m) relates to the over-issuance of structured notes and £165m (December 2021: nil) relates to liabilities that could be incurred arising out of ongoing discussions in respect of a potential SEC resolution. A contingent liability exists in relation to the over-issuance of ETNs due to evidentiary challenges and the high level of trading in the securities. A contingent liability also exists in relation to any potential civil claims or enforcement actions taken against Barclays Bank PLC and/or its affiliates, but Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of such claims or actions. Any liabilities, claims or actions in connection with the over-issuance of securities under its 2019 F-3 and the Predecessor Shelf could have an adverse effect on Barclays Bank PLC’s and the Group’s business, financial condition, results of operations and reputation as a frequent issuer in the securities markets. Investigation into the use of unapproved communications platforms In July 2022, Barclays Bank PLC and BCI reached an agreement in principle with the staff of the SEC's Division of Enforcement and the staff of the Commodity Futures Trading Commission (CFTC) in connection with investigations by the SEC and the CFTC of Barclays Bank PLC, BCI and other financial institutions as part of a financial industry sweep regarding compliance with record-keeping obligations in connection with business-related communications sent over unapproved electronic messaging platforms. The SEC and the CFTC found that Barclays Bank PLC and BCI failed to comply with their respective record keeping rules, where such communications were sent or received by employees over electronic messaging channels that had not been approved by the bank for business use by employees. The proposed resolution with the SEC and the CFTC, will include Barclays Bank PLC and BCI paying a combined $125m civil monetary penalty to the SEC and a $75m civil monetary penalty to the CFTC. There will also be non-financial components to the settlements which have yet to be finalised and agreed with the SEC and CFTC. Subject to final agreement of the terms of the settlements and related documentation, as well as the SEC's and CFTC's approval, the civil monetary penalties are expected to be paid during the third quarter of 2022. 2. Barclays PLC, Barclays Bank PLC and Barclays Bank UK PLC HM Revenue & Customs (HMRC) assessments concerning UK Value Added Tax In 2018, HMRC issued notices that have the effect of removing certain overseas subsidiaries that have operations in the UK from Barclays’ UK VAT group, in which group supplies between members are generally free from VAT. The notices have retrospective effect and correspond to assessments of £181m (inclusive of interest), of which Barclays would expect to attribute an amount of approximately £128m to Barclays Bank UK PLC and £53m to Barclays Bank PLC. HMRC’s decision has been appealed to the First Tier Tribunal (Tax Chamber). Local authority civil actions concerning LIBOR Following settlement by Barclays Bank PLC of various governmental investigations concerning certain benchmark interest rate submissions referred to above in ‘Investigations into LIBOR and other benchmarks and related civil actions’, in the UK, certain local authorities brought claims in 2018 against Barclays Bank PLC and Barclays Bank UK PLC asserting that they entered into loans between 2006 and 2008 in reliance on misrepresentations made by Barclays Bank PLC in respect of its conduct in relation to LIBOR. Barclays Bank PLC and Barclays Bank UK PLC were successful in their applications to strike out the claims. The claims have been settled on terms such that the parties have agreed not to pursue these claims further and to bear their own costs. The financial impact of the settlements is not material to the Group’s operating results, cash flows or financial position. 3. Barclays PLC Alternative trading systems In 2020, a claim was brought against Barclays PLC in the UK in the High Court by various shareholders regarding Barclays PLC’s share price based on the allegations contained within a co |
Related party transactions
Related party transactions | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of transactions between related parties [abstract] | |
Related party transactions | Related party transactionsRelated party transactions in the half year ended 30 June 2022 were similar in nature to those disclosed in the Barclays PLC Annual Report 2021. No related party transactions that have taken place in the half year ended 30 June 2022 have materially affected the financial position or the performance of the Group during this period. |
Interest rate benchmark reform
Interest rate benchmark reform | 6 Months Ended |
Jun. 30, 2022 | |
Interest rate benchmark reform [Abstract] | |
Interest rate benchmark reform | Interest rate benchmark reform Following the financial crisis, the reform and replacement of benchmark interest rates such as LIBOR became a priority for global regulators. The FCA and other global regulators instructed market participants to prepare for the cessation of GBP, EUR, CHF, JPY LIBOR and the 1-week and 2-month USD settings of LIBOR after the end of 2021, The remaining USD LIBOR settings are scheduled to cease immediately after 30 June 2023. How the Group is managing the transition to alternative benchmark rates Barclays established a Group-wide LIBOR Transition Programme, further detail on the transition programme is available in the Barclays PLC Annual Report 2021. This Programme oversaw transition for GBP, EUR, CHF and JPY LIBOR exposures and continues to work to transition the remaining residual of unremediated exposures off of synthetic rates, in addition to overseeing USD LIBOR transition in preparation for the 30 June 2023 cessation. The majority of GBP, EUR, CHF and JPY exposures have now transitioned off of LIBOR and good progress has been made with the unremediated exposures reported at year-end 2021. A small residual population of GBP, EUR and JPY contracts remain unremediated at the end of H1 2022. The majority of these have now reset onto GBP and JPY Synthetic LIBOR rates. We continue to work with clients to bilaterally transition these trades and have raised potential risks regarding note holder consent for securitised products and Local Authority consent for Public Finance Initiative (PFI) loan deals with our regulators. The Barclays Group-wide LIBOR Transition Programme has also commenced focus on the transition of USD LIBOR exposures impacted by the 30 June 2023 cessation timeline. As with GBP, EUR, CHF and JPY LIBOR, USD LIBOR transition approaches will vary by product and nature of counterparty. H122 saw focused efforts to transition uncommitted lending exposure with further wide scale client engagement for other products due to commence in H222. Both active conversion of exposures and inclusion of fallback provisions will be leveraged for bilateral derivative and non-derivatives products. For cleared derivatives, Barclays is working with central clearing counterparties (CCPs) on transition which is expected to follow a market wide, standardised approach to reform similar to the CCP-led conversions in 2021. The Group met the Q121 Federal Reserve Bank of New York milestone to cease new use of US dollar LIBOR, with limited exceptions. The Group has put in place controls so that any exceptions or exemptions are approved. |
Barclays PLC parent company bal
Barclays PLC parent company balance sheet | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of subsidiaries [abstract] | |
Barclays PLC parent company balance sheet | Barclays PLC parent company balance sheet As at 30.06.22 As at 31.12.21 Assets £m £m Investment in subsidiaries 63,633 62,528 Loans and advances to subsidiaries 20,369 22,072 Financial assets at fair value through the income statement 24,052 25,091 Derivative financial instruments 5 4 Other assets 235 68 Total assets 108,294 109,763 Liabilities Deposits at amortised cost 545 488 Debt securities in issue 22,389 25,658 Subordinated liabilities 10,070 9,301 Financial liabilities designated at fair value 16,888 16,319 Derivative financial instruments 540 43 Other liabilities 104 117 Total liabilities 50,536 51,926 Equity Called up share capital 4,133 4,188 Share premium account 375 348 Other equity instruments 12,347 12,241 Other reserves 616 555 Retained earnings 40,287 40,505 Total equity 57,758 57,837 Total liabilities and equity 108,294 109,763 Investment in subsidiaries The investment in subsidiaries of £63,633m (December 2021: £62,528m) predominantly relates to investments in the ordinary shares of Barclays Bank PLC of £36,340m (December 2021: £35,590m) and their AT1 securities of £9,849m (December 2021: £9,493m), as well as investments in the ordinary shares of Barclays Bank UK PLC of £14,245m (December 2021: £14,245m) and their AT1 securities of £2,570m (December 2021: £2,570m). Barclays PLC considers the carrying value of its investment in subsidiaries to be fully recoverable. Loans and advances to subsidiaries During the period, loans and advances to subsidiaries decreased by £1,703m to £20,369m (December 2021: £22,072m). The decrease was driven by the maturity of £2,296m intragroup loans to Barclays Bank PLC and the maturity of £836m intragroup loans to Barclays Bank UK PLC. There was also a £397m share buyback which took place in Q222. This was partially offset by a foreign exchange impact of £1,326m due to depreciation of GBP against major currencies (although the FX impact is offset across the balance sheet liabilities) and £1,010m dividend receipts from Barclays Bank UK PLC. Financial assets and liabilities designated at fair value Financial liabilities designated at fair value of £16,888m (December 2021: £16,319m) comprise material issuances during the period of €2,250m Fixed Rate Resetting Senior Callable Notes and $400m Zero Coupon Callable Notes. The proceeds raised through these transactions were used to invest in subsidiaries of Barclays PLC which are included within the financial assets designated at fair value through the income statement balance of £24,052m (December 2021: £25,091m). Subordinated liabilities and debt securities in issue During the period, subordinated liabilities have increased to £10,070m (December 2021: £9,301m) largely driven by foreign exchange impact of £819m due to depreciation of GBP against major currencies. Debt securities in issue of £22,389m (December 2021: £25,658m) have reduced in the year due to the maturity of senior issuances. Called up share capital and share premium Called up share capital and share premium of Barclays PLC is £4,508m (December 2021: £4,536m). The decrease in the year is primarily due to 244m shares repurchased with a total nominal value of £61m. This decrease was offset by £33m of shares issued under employee share schemes. Other equity instruments Other equity instruments comprises AT1 securities issued by Barclays PLC. The increase in the year of £106m is driven by one issuance (principal amount of £1,250m) and one redemption (principal amount of $1,500m). Other reserves As at 30 June 2022, there was a balance of £616m (December 2021: £555m) in other reserves. The increase is due to the repurchase of shares as part of the share buyback. Management of internal investments, loans and advances Barclays PLC retains the discretion to manage the nature of its internal investments in subsidiaries according to their regulatory and business needs. Barclays PLC may invest capital and funding into Barclays Bank PLC, Barclays Bank UK PLC and other Group subsidiaries such as Barclays Execution Services Limited and the US Intermediate Holding Company (IHC). |
Credit Risk
Credit Risk | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of credit risk exposure [abstract] | |
Credit Risk | Loans and advances at amortised cost by stage The table below presents an analysis of loans and advances at amortised cost by gross exposure, impairment allowance, impairment charge and coverage ratio by stage allocation and business segment as at 30 June 2022. Also included are off-balance sheet loan commitments and financial guarantee contracts by gross exposure, impairment allowance and coverage ratio by stage allocation as at 30 June 2022. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure, as expected credit loss (ECL) is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 30.06.22 £m £m £m £m £m £m £m £m £m Barclays UK 160,110 23,805 3,012 186,927 218 780 753 1,751 185,176 Barclays International 32,053 3,251 1,674 36,978 679 821 826 2,326 34,652 Head Office 3,852 215 688 4,755 2 16 346 364 4,391 Total Barclays Group retail 196,015 27,271 5,374 228,660 899 1,617 1,925 4,441 224,219 Barclays UK 35,915 2,267 862 39,044 131 49 117 297 38,747 Barclays International 120,470 11,916 1,022 133,408 254 198 287 739 132,669 Head Office 186 1 23 210 — — 21 21 189 Total Barclays Group wholesale 1 156,571 14,184 1,907 172,662 385 247 425 1,057 171,605 Total loans and advances at amortised cost 352,586 41,455 7,281 401,322 1,284 1,864 2,350 5,498 395,824 Off-balance sheet loan commitments and financial guarantee contracts 2 373,544 24,429 1,146 399,119 275 233 17 525 398,594 Total 3 726,130 65,884 8,427 800,441 1,559 2,097 2,367 6,023 794,418 As at 30.06.22 Half year ended 30.06.22 Coverage ratio Loan impairment charge/(release) and loan loss rate Stage 1 Stage 2 Stage 3 Total Loan impairment charge/(release) Loan loss rate % % % % £m bps Barclays UK 0.1 3.3 25.0 0.9 14 2 Barclays International 2.1 25.3 49.3 6.3 253 138 Head Office 0.1 7.4 50.3 7.7 (18) — Total Barclays Group retail 0.5 5.9 35.8 1.9 249 22 Barclays UK 0.4 2.2 13.6 0.8 36 19 Barclays International 0.2 1.7 28.1 0.6 75 11 Head Office — — 91.3 10.0 — — Total Barclays Group wholesale 1 0.2 1.7 22.3 0.6 111 13 Total loans and advances at amortised cost 0.4 4.5 32.3 1.4 360 18 Off-balance sheet loan commitments and financial guarantee contracts 2 0.1 1.0 1.5 0.1 (42) Other financial assets subject to impairment 3 23 Total 4 0.2 3.2 28.1 0.8 341 1 Includes Wealth UK and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures, including lending under the government backed Bounce Back Loan Scheme (BBLS) of £8.1bn that are managed on a collective basis and reported within BUK Retail. The net impact is a difference in total exposure of £4.3bn of balances reported as wholesale loans on page 33 2 Excludes loan commitments and financial guarantees of £21.1bn carried at fair value. 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn and impairment allowance of £149m. This comprises £11m ECL on £195.0bn Stage 1 assets, £2m on £2.1bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £136m on £143m Stage 3 other assets. 4 The loan loss rate is 17bps after applying the total impairment charge of £341m. Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31.12.21 £m £m £m £m £m £m £m £m £m Barclays UK 160,695 22,779 2,915 186,389 261 949 728 1,938 184,451 Barclays International 25,981 2,691 1,566 30,238 603 795 858 2,256 27,982 Head Office 3,735 429 705 4,869 2 36 347 385 4,484 Total Barclays Group retail 190,411 25,899 5,186 221,496 866 1,780 1,933 4,579 216,917 Barclays UK 35,571 1,917 969 38,457 153 43 111 307 38,150 Barclays International 92,341 13,275 1,059 106,675 187 192 458 837 105,838 Head Office 542 2 21 565 — — 19 19 546 Total Barclays Group wholesale 1 128,454 15,194 2,049 145,697 340 235 588 1,163 144,534 Total loans and advances at amortised cost 318,865 41,093 7,235 367,193 1,206 2,015 2,521 5,742 361,451 Off-balance sheet loan commitments and financial guarantee contracts 2 312,142 34,815 1,298 348,255 217 302 23 542 347,713 Total 3 631,007 75,908 8,533 715,448 1,423 2,317 2,544 6,284 709,164 As at 31.12.21 Half year ended 31.12.21 Coverage ratio Loan impairment charge/(release) and loan loss rate Stage 1 Stage 2 Stage 3 Total Loan impairment charge/(release) Loan loss rate % % % % £m bps Barclays UK 0.2 4.2 25.0 1.0 (227) — Barclays International 2.3 29.5 54.8 7.5 181 60 Head Office 0.1 8.4 49.2 7.9 — — Total Barclays Group retail 0.5 6.9 37.3 2.1 (46) — Barclays UK 0.4 2.2 11.5 0.8 122 32 Barclays International 0.2 1.4 43.2 0.8 (197) — Head Office — — 90.5 3.4 — — Total Barclays Group wholesale 1 0.3 1.5 28.7 0.8 (75) — Total loans and advances at amortised cost 0.4 4.9 34.8 1.6 (121) — Off-balance sheet loan commitments and financial guarantee contracts 2 0.1 0.9 1.8 0.2 (514) Other financial assets subject to impairment 3 (18) Total 0.2 3.1 29.8 0.9 (653) 1 Includes Wealth and Private Banking exposures measured on an individual basis, and excludes Business Banking exposures, including BBLS of £9.4bn that are managed on a collective basis and reported within Barclays UK Retail. The net impact is a difference in total exposure of £6.0bn of balances reported as wholesale loans on page 33 2 Excludes loan commitments and financial guarantees of £18.8bn carried at fair value. 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn and impairment allowance of £114m. This comprises £6m ECL on £154.9bn Stage 1 assets, £1m on £157.0bn Stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances and £107m on £110m Stage 3 other assets. Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays PLC Annual Report 2021. Transfers between stages in the table have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 6-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL Home loans £m £m £m £m £m £m £m £m As at 1 January 2022 148,058 19 19,500 59 2,122 397 169,680 475 Transfers from Stage 1 to Stage 2 (5,725) (1) 5,725 1 — — — — Transfers from Stage 2 to Stage 1 5,131 18 (5,131) (18) — — — — Transfers to Stage 3 (197) — (234) (5) 431 5 — — Transfers from Stage 3 19 1 133 3 (152) (4) — — Business activity in the period 1 14,723 4 339 1 1 — 15,063 5 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4,151) (22) (506) 2 (69) 16 (4,726) (4) Final repayments (6,975) — (1,092) (2) (210) (3) (8,277) (5) Disposals — — — — — — — — Write-offs 2 — — — — (13) (13) (13) (13) As at 30 June 2022 3 150,883 19 18,734 41 2,110 398 171,727 458 Credit cards, unsecured loans and other retail lending As at 1 January 2022 37,840 824 5,650 1,701 2,332 1,504 45,822 4,029 Transfers from Stage 1 to Stage 2 (2,572) (67) 2,572 67 — — — — Transfers from Stage 2 to Stage 1 1,689 422 (1,689) (422) — — — — Transfers to Stage 3 (444) (11) (516) (222) 960 233 — — Transfers from Stage 3 30 13 49 9 (79) (22) — — Business activity in the period 1 8,231 354 294 32 20 5 8,545 391 Refinements to models used for calculation 4 — 43 — 187 — 96 — 326 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 5 1,678 (691) 413 240 94 285 2,185 (166) Final repayments (2,673) (23) (251) (27) (140) (29) (3,064) (79) Disposals 6 (151) (4) (28) (10) (122) (69) (301) (83) Write-offs 2 — — — — (555) (555) (555) (555) As at 30 June 2022 3 43,628 860 6,494 1,555 2,510 1,448 52,632 3,863 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. Business activity reported within Credit cards, unsecured loans and other retail lending portfolio includes GAP portfolio acquisition in US cards of £2.7bn. 2 In H122, gross write-offs amounted to £768m (H121: £1,001m) and post write-off recoveries amounted to £36m (H121: £31m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £732m (H121: £970m). 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn (December 21: £155.2bn) and an impairment allowance of £149m (December 21: £114m). This comprises £11m ECL (December 21: £6m) on £195.0bn stage 1 assets (December 21: £154.9bn), £2m (December 21: £1m) on £2.1bn stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances (December 21: £0.2bn) and £136m (FY21: £107m) on £143m stage 3 other assets (December 21: £110m). 4 Refinements to models used for calculation reported within Credit cards, unsecured loans and other retail lending portfolio include a £0.3bn movement in US cards. These reflect methodology changes made during the year. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. 5 Transfers and risk parameter changes include a £0.2bn (December 21: £0.3bn) net release in ECL arising from a reclassification of £1.4bn (December 21: £1.9bn) gross loans and advances from Stage 2 to Stage 1 in Credit cards, unsecured loans and other retail lending portfolio. The reclassification followed a review of back-testing of results which indicated that accuracy of origination probability of default characteristics required management adjustments to correct. The re-classification was first established in Q220. 6 The £0.3bn disposals reported within Credit cards, unsecured loans and other retail lending portfolio includes £0.2bn sale of NFL portfolio within US cards and £0.1bn of debt sales undertaken during the year. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL Wholesale loans £m £m £m £m £m £m £m £m As at 1 January 2022 132,967 363 15,943 255 2,781 620 151,691 1,238 Transfers from Stage 1 to Stage 2 (5,129) (29) 5,129 29 — — — — Transfers from Stage 2 to Stage 1 5,544 41 (5,544) (41) — — — — Transfers to Stage 3 (676) (3) (405) (6) 1,081 9 — — Transfers from Stage 3 114 9 200 17 (314) (26) — — Business activity in the period 1 28,927 40 1,670 14 108 14 30,705 68 Refinements to models used for calculation 2 — (66) — (42) — (374) — (482) Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 3 12,529 79 1,048 70 (634) 555 12,943 704 Final repayments (16,201) (29) (1,783) (28) (115) (48) (18,099) (105) Disposals 4 — — (31) — (46) (46) (77) (46) Write-offs 5 — — — — (200) (200) (200) (200) As at 30 June 2022 6 158,075 405 16,227 268 2,661 504 176,963 1,177 Reconciliation of ECL movement to impairment charge/(release) for the period £m Home loans (4) Credit cards, unsecured loans and other retail lending 472 Wholesale loans 185 ECL movement excluding assets derecognised due to disposals and write-offs 653 Recoveries and reimbursements 7 (47) Exchange and other adjustments 8 (246) Impairment release on loan commitments and other financial guarantees (42) Impairment charge on other financial assets 6 23 Income statement charge for the period 341 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. 2 Refinements to models used for calculation reported within Wholesale loans relates to a £0.5bn movement in Business Banking. This relates to an update in the underlying ECL model that now fully recognises the 100% government guarantee against Barclays Bounce Back Loans exposure. 3 "Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes" reported within Wholesale loans also include assets of £0.5bn de-recognised due to payment received on defaulted loans from government guarantees issued under government’s Bounce Back Loans Scheme. 4 The £0.1bn disposals reported within Wholesale loans relates to debt sales undertaken during the year. 5 In H122, gross write-offs amounted to £768m (H121: £1,001m) and post write-off recoveries amounted to £36m (H121: £31m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £732m (H121: £970m). 6 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn (December 21: £155.2bn) and impairment allowance of £149m (December 21: £114m). This comprises £11m ECL (December 21: £6m) on £195.0bn stage 1 assets (December 21: £154.9bn), £2m (December 21: £1m) on £2.1bn stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances (December 21: £157.0bn) and £136m (December 21: £107m) on £143m stage 3 other assets (December 21: £110m). 7 Recoveries and reimbursements includes a net gain in relation to reimbursements from financial guarantee contracts held with third parties of £11m (H121 loss: £216m) and post write off recoveries of £36m (H121: £31m). 8 Exchange and other adjustments includes foreign exchange and interest and fees in suspense. Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross ECL Gross ECL Gross ECL Gross ECL Home loans £m £m £m £m £m £m £m £m As at 1 January 2022 10,833 — 532 — 3 — 11,368 — Net transfers between stages 39 — (39) — — — — — Business activity in the period 8,146 — — — — — 8,146 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (6,354) — (12) — — — (6,366) — Limit management and final repayments (172) — (22) — — — (194) — As at 30 June 2022 12,492 — 459 — 3 — 12,954 — Credit cards, unsecured loans and other retail lending As at 1 January 2022 122,819 50 5,718 61 218 20 128,755 131 Net transfers between stages (1,277) 23 935 (18) 342 (5) — — Business activity in the period 26,892 1 212 — — — 27,104 1 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 9,385 3 (1,267) 20 (288) 2 7,830 25 Limit management and final repayments (3,740) (1) (209) (3) (36) — (3,985) (4) As at 30 June 2022 154,079 76 5,389 60 236 17 159,704 153 Wholesale loans As at 1 January 2022 178,490 167 28,565 241 1,077 3 208,132 411 Net transfers between stages 9,775 36 (9,709) (37) (66) 1 — — Business activity in the period 37,358 19 2,864 24 1 — 40,223 43 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 17,712 (9) 1,510 (22) 140 (5) 19,362 (36) Limit management and final repayments (36,362) (14) (4,649) (33) (245) 1 (41,256) (46) As at 30 June 2022 206,973 199 18,581 173 907 — 226,461 372 Management adjustments to models for impairment Management adjustments to impairment models are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where applicable. Total management adjustments to impairment allowance are presented by product below: Overview of management adjustments to models for impairment allowance 1 As at 30.06.22 As at 31.12.21 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances £m % £m % Home loans 76 16.6 103 21.7 Credit cards, unsecured loans and other retail lending 785 19.6 1,362 32.7 Wholesale loans 2 426 27.5 21 1.3 Total 1,287 21.4 1,486 23.6 Management adjustments to models for impairment allowance 1 Impairment allowance pre management adjustments 3 Economic uncertainty adjustments Other adjustments Total Adjustments Total impairment allowance 4 (a) (b) (a+b) As at 30.06.22 £m £m £m £m £m Home loans 382 43 33 76 458 Credit cards, unsecured loans and other retail lending 3,229 578 207 785 4,014 Wholesale loans 1,125 417 9 426 1,551 Total 4,736 1,038 249 1,287 6,023 As at 31.12.21 Home loans 372 72 31 103 475 Credit cards, unsecured loans and other retail lending 2,798 1,217 145 1,362 4,160 Wholesale loans 1,628 403 (382) 21 1,649 Total 4,798 1,692 (206) 1,486 6,284 1 Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. 2 Proportion of management adjustments to impairment allowances has increased in wholesale loans primarily driven by release of offsetting PMA to recognise BBLS government guarantees of £0.4bn; now captured through the model. Excluding this, proportion of management adjustments to impairment allowances remain materially stable compare to previous year. 3 Includes £4.1bn (December 2021: £4.1bn) of modelled ECL, £0.4bn (December 2021: £0.5bn) of individually assessed impairments and £0.2bn (December 2021: £0.2bn) ECL from non-modelled exposures. 4 Total impairment allowance consists of ECL stock on drawn and undrawn exposure. Economic uncertainty adjustments Throughout the COVID-19 pandemic in 2020 and 2021, macroeconomic forecasts anticipated lasting impacts to unemployment levels and customer and client stress. However, the most recent macroeconomic outlook suggests the concerns over the spread of COVID-19 in major economies has receded and normalisation of customer behaviour has been observed, but uncertainty persists: Russia’s invasion of Ukraine is affecting global energy markets and food prices; China’s ‘zero-COVID’ policy is putting pressure on stretched supply chains; and labour markets continue to generate inflationary pressures. Credit deterioration could still occur as emerging supply chain disruption and inflationary pressures challenge economic stability; and economic consensus may not capture the range of arising economic uncertainty. Given this backdrop, COVID-19 related expert judgements have been materially replaced by provisions for customers and clients considered most vulnerable to rising costs and supply chain disruption. This uncertainty continues to be captured in two distinct ways. Firstly, customer uncertainty: the identification of customers and clients who may be more vulnerable to the emerging economic instability; and secondly, model uncertainty: to capture the impact from model limitations and sensitivities to specific macroeconomic parameters which are applied at a portfolio level. The economic uncertainty adjustments of £1.0bn (FY21: £1.7bn) include customer and client uncertainty provisions of £0.8bn (FY21: £1.5bn) and model uncertainty provisions of £0.2bn (FY21: £0.2bn). Customer and client uncertainty provisions include an adjustment of £0.8bn (FY21: £1.5bn) which has been applied to customers and clients considered potentially vulnerable to the emerging economic instability in light of inflationary and supply chain concerns. This adjustment is split between credit cards, unsecured loans and other retail lending £0.5bn (FY21: £0.8bn) and wholesale loans £0.3bn (FY21: £0.3bn). The reduction in the credit cards, unsecured loans and other retail lending-related adjustment is due to unwinding of COVID-19 related expert judgements partially offset by provisions booked for customers and clients considered more vulnerable to rising costs and slowing consumer demand. Furthermore, a previously held 2021 adjustment of £0.4bn to amend probabilities of default (PDs), informed by pre COVID-19 levels, is no longer required as the normalisation of customer behaviour is now captured within the modelled output. Model uncertainty provisions £0.2bn (2021: £0.2bn) informed by modelled provisions following the updated Q222 scenario. Other adjustments Other adjustments are operational in nature and are expected to remain in place until they can be corrected in the underlying models. These adjustments result from data limitations and model performance related issues identified through established governance processes. The quantum of adjustments has reduced in response to the macroeconomic variable refresh in Q222 as well as model enhancements made during H122. Material adjustments comprise the following: Home loans: The low average loan to value (LTV) nature of the UK Home Loans portfolio means that modelled ECL estimates are low. An adjustment is made to maintain an appropriate level of ECL informed by model monitoring. Credit cards, unsecured loans and other retail lending: Includes the estimated ECL impact from adoption of the new definition of default under the Capital Requirements Regulation, the Day 1 provision for the GAP portfolio acquisition in US cards, an annual update to the qualitative measures used in high risk account management (HRAM) and adjustments for model inaccuracies informed by model monitoring; partially offset by a reclassification of loans and advances from Stage 2 to Stage 1 in credit cards. The reclassification followed a review of back-testing results which indicated that accuracy of origination probability of default characteristics requires management adjustments to correct and was first established in Q220. This adjustment has been reduced, driven by the improved macroeconomic scenarios in Q222. Wholesale loans: Management adjustments of £(0.4)bn within wholesale loans in 2021 principally comprised an adjustment applied on bounce back loans of £(0.4)bn to reverse out the modelled charge which did not consider the government guarantee when calculating the ECL. This adjustment is no longer needed due to model enhancements. Measurement uncertainty Management has applied economic uncertainty and other adjustments to modelled ECL outputs. Economic uncertainty adjustments have been applied to customers and clients considered most vulnerable to rising costs and supply chain disruption. As a result, ECL is higher than would be the case if it were based on forecast economic scenarios alone. The measurement of modelled ECL involves complexity and judgement, including estimation of probabilities of default (PD), loss given default (LGD), a range of unbiased future economic scenarios, estimation of expected lives, estimation of exposures at default (EAD) and assessing significant increases in credit risk. The Group uses a five-scenario model to calculate ECL. An external consensus forecast is assembled from key sources, including HM Treasury (short and medium term forecasts), Bloomberg (based on median of economic forecasts) and the Urban Land Institute (for US House Prices), which forms the Baseline scenario. In addition, two adverse scenarios (Downside 1 and Downside 2) and two favourable scenarios (Upside 1 and Upside 2) are derived, with associated probability weightings. The adverse scenarios are calibrated to a broadly similar severity to Barclays’ internal stress tests and stress scenarios provided by regulators whilst also considering IFRS 9 specific sensitivities and non-linearity. The favourable scenarios are designed to reflect plausible upside risks to the Baseline scenario which are broadly consistent with the economic narrative approved by the Senior Scenario Review Committee. All scenarios are regenerated at a minimum semi-annually. The scenarios include key economic variables, (including GDP, unemployment, House Price Index (HPI) and base rates in both the UK and US markets), and expanded variables using statistical models based on historical correlations. The upside and downside shocks are designed to evolve over a five-year stress horizon, with all five scenarios converging to a steady state after approximately seven years. Scenarios used to calculate the Group’s ECL charge were refreshed in Q222. The current Baseline scenario reflects the latest consensus economic forecasts. Unemployment rates remain low, close to current levels. As inflation expectations drift higher, central banks tighten monetary policy sharply. In 2023, the UK Bank Rate reaches 2.75%, while the US Federal Funds Rate peaks at 3.25%. Rising borrowing charges and falling real wages subtract from growth through lower investment and household consumption. In the Downside 2 scenario, with inflation expectations rising, the central banks have to raise interest rates very sharply. The UK Bank Rate and the US Federal Funds Rate both reach 5.0% in Q223. Higher borrowing costs derail the economy and unemployment peaks in Q124 at 9.2% in the UK and 9.5% in the US. Given already stretched valuations, the sharp increase in mortgage servicing costs sees house prices decrease very sharply. In the Upside 2 scenario, supply disruptions get resolved, while the aggregate demand is supported by a release of household savings. GDP growth accelerates. Recovering labour force participation limits domestic inflationary pressures, while lower energy prices add some downward pressure on prices globally. The methodology for estimating probability weights used in calculating ECL involves simulating a range of future paths for UK and US GDP using historical data. The five scenarios are mapped against the distribution of these future paths, with the median centred around the Baseline such that scenarios further from the Baseline attract a lower weighting. A single set of five scenarios is used across all portfolios and all five weights are normalised to equate to 100%. The same scenarios and weights that are used in the ECL estimation are also used for Barclays’ internal planning purposes. The impacts across the portfolios are different because of the sensitivities of each of the portfolios to specific macroeconomic variables. For example, mortgages are highly sensitive to house prices; credit cards and unsecured consumer loans are highly sensitive to unemployment. The decrease in the Upside scenario weightings and increase in the Baseline weighting were driven by: (i) continued growth in UK/US GDP which resulted in a narrower fan of future GDP paths; and (ii) generally less favourable GDP projections across scenarios, increasing the distance between Upside 2 and Baseline scenario paths. For further details see page 44 COVID-19 related expert judgements have been materially replaced by provisions for customers and clients considered most vulnerable to rising costs and supply chain disruption. The economic uncertainty adjustments of £1.0bn (FY21: £1.7bn) have been applied as overlays to the modelled ECL output. These adjustments consist of a customer and client uncertainty provision of £0.8bn (FY21: £1.5bn) and a model uncertainty provision of £0.2bn (FY21: £0.2bn). For further details, see pages 38 The tables below show the key consensus macroeconomic variables used in the scenarios (5-year annual paths), the probability weights applied to each scenario and the macroeconomic variables by scenario using ‘specific bases’ i.e. the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios and the lowest unemployment for upside scenarios. The 5-year average table provides additional transparency. Baseline average macroeconomic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.9 1.7 1.6 1.6 1.6 UK unemployment 2 4.0 4.1 3.9 3.9 3.9 UK HPI 3 4.3 1.0 2.2 2.5 2.8 UK bank rate 1.5 2.7 2.4 2.1 2.0 US GDP 1 3.3 2.2 2.1 2.1 2.1 US unemployment 4 3.6 3.5 3.5 3.5 3.5 US HPI 5 4.1 3.4 3.4 3.4 3.4 US federal funds rate 1.5 3.2 2.9 2.7 2.5 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 4.9 2.3 1.9 1.7 UK unemployment 2 4.8 4.7 4.5 4.3 4.2 UK HPI 3 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP 1 5.5 3.9 2.6 2.4 2.4 US unemployment 4 5.5 4.2 3.6 3.6 3.6 US HPI 5 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.1 (4.8) (0.4) 4.3 3.6 UK unemployment 2 5.2 8.4 8.6 6.8 5.9 UK HPI 3 0.2 (26.2) (3.6) 17.9 10.2 UK bank rate 1.8 4.7 4.3 2.6 2.3 US GDP 1 2.4 (4.1) (0.2) 3.4 2.7 US unemployment 4 4.6 8.0 9.0 7.1 5.8 US HPI 5 (0.2) (11.7) (0.2) 5.5 3.5 US federal funds rate 1.8 4.8 4.6 3.6 3.0 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 0.2 (4.0) 2.8 4.3 UK unemployment 2 4.8 7.2 9.0 7.6 6.3 UK HPI 3 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP 1 5.5 (0.8) (3.5) 2.5 3.2 US unemployment 4 5.5 6.4 9.1 8.1 6.4 US HPI 5 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.5 (1.6) 0.6 3.0 2.6 UK unemployment 2 4.6 6.2 6.2 5.3 4.9 UK HPI 3 2.3 (13.2) (0.8) 10.0 6.5 UK bank rate 1.6 3.8 3.4 2.4 2.0 US GDP 1 2.7 (1.0) 1.1 2.9 2.5 US unemployment 4 4.1 5.7 6.2 5.3 4.6 US HPI 5 1.9 (4.4) 1.6 4.4 3.4 US federal funds rate 1.7 3.9 3.8 3.2 2.8 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 2.8 (0.7) 2.3 2.9 UK unemployment 2 4.8 6.2 6.8 6.0 5.3 UK HPI 3 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP 1 5.5 1.6 (0.4) 2.4 2.7 US unemployment 4 5.5 5.4 6.6 6.1 5.2 US HPI 5 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 5.0 5.2 3.1 2.4 2.0 UK unemployment 2 3.8 3.7 3.6 3.6 3.6 UK HPI 3 6.5 11.2 6.2 4.7 3.7 UK bank rate 1.2 1.5 1.4 1.3 1.3 US GDP 1 4.0 4.9 3.6 3.4 3.4 US unemployment 4 3.4 3.0 3.1 3.1 3.1 US HPI 5 5.4 5.5 4.6 4.5 4.5 US federal funds rate 1.1 2.2 1.9 1.7 1.5 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 7.2 4.0 2.7 2.1 UK unemployment 2 4.8 4.5 4.1 4.0 4.0 UK HPI 3 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP 1 5.5 5.3 4.1 3.5 3.4 |
Segmental reporting (Tables)
Segmental reporting (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of operating segments [abstract] | |
Analysis of results by business | Analysis of results by business Barclays Barclays Head Barclays Half year ended 30.06.22 £m £m £m £m Total income 3,373 9,940 (109) 13,204 Credit impairment (charges)/releases (48) (310) 17 (341) Net operating income/(expenses) 3,325 9,630 (92) 12,863 Operating costs (2,083) (5,042) (145) (7,270) Litigation and conduct (25) (1,832) — (1,857) Total operating expenses (2,108) (6,874) (145) (9,127) Other net income/(expenses) 1 — 13 (16) (3) Profit/(loss) before tax 1,217 2,769 (253) 3,733 As at 30.06.22 £bn £bn £bn £bn Total assets 318.8 1,250.6 19.8 1,589.2 Restated 2 Restated 2 Barclays Barclays Head Barclays Half year ended 30.06.21 £m £m £m £m Total income 3,199 8,218 (102) 11,315 Credit impairment releases 443 293 6 742 Net operating income/(expenses) 3,642 8,511 (96) 12,057 Operating costs (2,114) (4,606) (412) (7,132) Litigation and conduct (22) (161) 7 (176) Total operating expenses (2,136) (4,767) (405) (7,308) Other net income 1 — 22 131 153 Profit/(loss) before tax 1,506 3,766 (370) 4,902 As at 31.12.21 £bn £bn £bn £bn Total assets 321.2 1,044.1 19.0 1,384.3 1 Other net income/(expenses) represents the share of post-tax results of associates and joint ventures, profit (or loss) on disposal of subsidiaries, associates and joint ventures and gains on acquisitions. 2 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Split of income by geographic region | Split of income by geographic region 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m United Kingdom 7,972 5,895 Europe 1,311 1,222 Americas 3,200 3,608 Africa and Middle East 31 20 Asia 690 570 Total 13,204 11,315 1 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income (
Net fee and commission income (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fee and commission income (expense) [abstract] | |
Total fees in scope of IFRS 15 Revenues from Contracts with Customers | Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Barclays UK Barclays International Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 1 515 1,448 — 1,963 Advisory 83 511 — 594 Brokerage and execution 125 762 — 887 Underwriting and syndication — 1,102 — 1,102 Other 29 80 2 111 Total revenue from contracts with customers 752 3,903 2 4,657 Other non-contract fee income — 69 — 69 Fee and commission income 1 752 3,972 2 4,726 Fee and commission expense (147) (1,153) (2) (1,302) Net fee and commission income 605 2,819 — 3,424 Barclays UK Barclays International Head Office Total Half year ended 30.06.21 £m £m £m £m Fee type Transactional 408 1,181 — 1,589 Advisory 83 459 1 543 Brokerage and execution 109 553 — 662 Underwriting and syndication — 1,715 — 1,715 Other 35 73 3 111 Total revenue from contracts with customers 635 3,981 4 4,620 Other non-contract fee income — 62 — 62 Fee and commission income 635 4,043 4 4,682 Fee and commission expense 1 (108) (861) (7) (976) Net fee and commission income 527 3,182 (3) 3,706 1 Barclays has corrected the presentation of the scheme fees incurred when Barclays acts as an “acquirer” as part of the payment transaction cycle. From 2022 onwards, the scheme fees reported under "Barclays International" are presented within fees and commission income under "Transactional" fee type, which had previously been recognised in fees and commission expense. The reclassification into Fee and Commission income is a reduction of £103m for H122. The comparatives have not been restated as the effect is not considered material although the effect would have been a reduction of H121: £88m with no impact on Net fee and commission income. There is no impact on Net assets or Cash flows reported. |
Staff costs (Tables)
Staff costs (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Classes of employee benefits expense [abstract] | |
Staff costs | Half year ended 30.06.22 Half year ended 30.06.21 Compensation costs £m £m Upfront bonus charge 705 824 Deferred bonus charge 280 262 Other incentives 44 6 Performance costs 1,029 1,092 Salaries 2,278 2,117 Social security costs 377 336 Post-retirement benefits 282 275 Other compensation costs 241 223 Total compensation costs 4,207 4,043 Other resourcing costs Outsourcing 268 171 Redundancy and restructuring (15) 23 Temporary staff costs 53 55 Other 70 42 Total other resourcing costs 376 291 Total staff costs 4,583 4,334 Barclays Group compensation costs as a % of total income 31.9% 35.7% |
Infrastructure, administratio_2
Infrastructure, administration and general expenses (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Expenses by nature [abstract] | |
Infrastructure, administration and general expenses | Half year ended 30.06.22 Half year ended 30.06.21 Infrastructure costs £m £m Property and equipment 744 709 Depreciation and amortisation 863 832 Lease payments 14 20 Impairment of property, equipment and intangible assets 21 304 Total infrastructure costs 1,642 1,865 Administration and general expenses Consultancy, legal and professional fees 288 262 Marketing and advertising 206 163 Other administration and general expenses 551 508 Total administration and general expenses 1,045 933 Total infrastructure, administration and general expenses 2,687 2,798 |
Tax (Tables)
Tax (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Major components of tax expense (income) [abstract] | |
Disclosure of deferred taxes | As at 30.06.22 As at 31.12.21 Deferred tax assets and liabilities £m £m UK 3,046 2,183 USA 1,530 2,006 Other territories 468 430 Deferred tax assets 5,044 4,619 Deferred tax liabilities (5) (37) Analysis of deferred tax assets Temporary differences 3,871 3,399 Tax losses 1,173 1,220 Deferred tax assets 5,044 4,619 |
Non-controlling interests (Tabl
Non-controlling interests (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Non-controlling interests [Abstract] | |
Non-controlling interest, by group | Profit attributable to Equity attributable to Half year ended 30.06.22 Half year ended 30.06.21 As at 30.06.22 As at 31.12.21 £m £m £m £m Barclays Bank PLC issued: - Preference shares 15 13 529 529 - Upper T2 instruments 6 3 438 458 Other non-controlling interests — 3 2 2 Total 21 19 969 989 |
Earnings per share (Tables)
Earnings per share (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Earnings per share [abstract] | |
Earnings per share | Restated 1 Half year ended 30.06.22 Half year ended 30.06.21 £m £m Profit attributable to ordinary equity holders of the parent 2,475 3,752 m m Basic weighted average number of shares in issue 16,684 17,140 Number of potential ordinary shares 428 467 Diluted weighted average number of shares 17,112 17,607 p p Basic earnings per ordinary share 14.8 21.9 Diluted earnings per ordinary share 14.5 21.3 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Dividends on ordinary shares (T
Dividends on ordinary shares (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Dividends on ordinary shares [Abstract] | |
Dividends on ordinary shares | Half year ended 30.06.22 Half year ended 30.06.21 Per share Total Per share Total Dividends paid during the period p £m p £m Full year dividend paid during period 4.0 664 1.0 173 |
Derivative financial instrume_2
Derivative financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of nature and extent of risks arising from financial instruments [abstract] | |
Total recognised derivative assets/(liabilities) | Contract notional amount Fair value Assets Liabilities As at 30.06.22 £m £m £m Foreign exchange derivatives 6,732,093 135,207 (123,662) Interest rate derivatives 44,275,712 130,628 (116,541) Credit derivatives 1,640,043 8,128 (8,228) Equity and stock index and commodity derivatives 2,510,981 70,066 (71,830) Derivative assets/(liabilities) held for trading 55,158,829 344,029 (320,261) Derivatives in hedge accounting relationships Derivatives designated as cash flow hedges 139,040 701 (21) Derivatives designated as fair value hedges 107,809 106 (1,054) Derivatives designated as hedges of net investments 4,097 19 (60) Derivative assets/(liabilities) designated in hedge accounting relationships 250,946 826 (1,135) Total recognised derivative assets/(liabilities) 55,409,775 344,855 (321,396) As at 31.12.21 Foreign exchange derivatives 5,824,856 76,140 (74,437) Interest rate derivatives 38,816,432 125,846 (114,803) Credit derivatives 1,272,104 5,682 (6,561) Equity and stock index and commodity derivatives 1,899,382 54,010 (59,946) Derivative assets/(liabilities) held for trading 47,812,774 261,678 (255,747) Derivatives in hedge accounting relationships Derivatives designated as cash flow hedges 114,313 798 (3) Derivatives designated as fair value hedges 102,815 59 (1,129) Derivatives designated as hedges of net investments 2,423 37 (4) Derivative assets/(liabilities) designated in hedge accounting relationships 219,551 894 (1,136) Total recognised derivative assets/(liabilities) 48,032,325 262,572 (256,883) |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of fair value measurement of assets [abstract] | |
Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) | The following table shows the Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.22 £m £m £m £m Trading portfolio assets 58,419 64,329 4,256 127,004 Financial assets at fair value through the income statement 1,115 202,026 9,582 212,723 Derivative financial instruments 11,653 329,329 3,873 344,855 Financial assets at fair value through other comprehensive income 22,455 40,696 43 63,194 Investment property — — 5 5 Total assets 93,642 636,380 17,759 747,781 Trading portfolio liabilities (47,870) (28,686) (82) (76,638) Financial liabilities designated at fair value (193) (254,496) (447) (255,136) Derivative financial instruments (12,674) (304,343) (4,379) (321,396) Total liabilities (60,737) (587,525) (4,908) (653,170) As at 31.12.21 Trading portfolio assets 80,926 63,828 2,281 147,035 Financial assets at fair value through the income statement 5,093 177,167 9,712 191,972 Derivative financial instruments 6,150 252,412 4,010 262,572 Financial assets at fair value through other comprehensive income 22,009 39,706 38 61,753 Investment property — — 7 7 Total assets 114,178 533,113 16,048 663,339 Trading portfolio liabilities (27,529) (26,613) (27) (54,169) Financial liabilities designated at fair value (174) (250,376) (410) (250,960) Derivative financial instruments (6,571) (244,253) (6,059) (256,883) Total liabilities (34,274) (521,242) (6,496) (562,012) The following table shows the Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.22 As at 31.12.21 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 1,573 (1,849) 1,091 (1,351) Foreign exchange derivatives 786 (560) 376 (374) Credit derivatives 234 (615) 323 (709) Equity derivatives 1,280 (1,355) 2,220 (3,625) Corporate debt 1,171 (13) 1,205 (21) Reverse repurchase and repurchase agreements 178 (188) 13 (172) Non-asset backed loans 8,660 — 6,405 — Asset backed securities 291 — 558 — Equity cash products 422 (3) 393 — Private equity investments 1,297 (8) 1,095 (6) Other 1 1,867 (317) 2,369 (238) Total 17,759 (4,908) 16,048 (6,496) 1 Other includes commercial real estate loans, funds and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. |
Analysis of movements in Level 3 assets and liabilities | The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 01.01.22 Purchases Sales Issues Settle-ments Trading income Other income In Out As at 30.06.22 £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Asset backed securities 454 72 (80) — (297) (20) — — 100 (66) 163 Equity cash products 303 21 (56) — — 24 — — 52 (17) 327 Other 377 326 (42) — (5) 56 — — 39 (84) 667 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Non-asset backed loans 5,647 1,847 (757) — (484) (334) — — 52 (9) 5,962 Equity cash products 90 — — — — 3 2 — — — 95 Private equity investments 1,095 99 (16) — (1) 84 (26) — 59 (4) 1,290 Other 2,880 4,817 (5,579) — (156) 11 182 — 99 (19) 2,235 Financial assets at fair value through the income statement 9,712 6,763 (6,352) — (641) (236) 158 — 210 (32) 9,582 Private equity investments — — — — — — — 1 6 — 7 Asset backed securities 38 — — — — — — (2) — — 36 Assets at fair value through other comprehensive income 38 — — — — — — (1) 6 — 43 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (410) (5) — (13) 47 (22) — — (81) 37 (447) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 171 980 (1) — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 218 849 (10) — 217 358 (506) Total 9,552 9,586 (7,126) (13) (695) 687 147 (1) 636 78 12,851 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. Level 3 movement analysis As at 01.01.21 Purchases Sales Issues Settle- Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.21 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 151 305 (87) — — 25 — — 40 (11) 423 Non-asset backed loans 709 620 (131) — (84) 13 — — 124 (106) 1,145 Asset backed securities 686 112 (294) — — (10) — — 43 (48) 489 Equity cash products 214 13 (17) — — 32 — — 29 (9) 262 Other 103 21 — — (51) (1) — — 162 (1) 233 Trading portfolio assets 1,863 1,071 (529) — (135) 59 — — 398 (175) 2,552 Non-asset backed loans 5,580 698 (299) — (687) (119) — — 69 (48) 5,194 Equity cash products 326 160 (194) — — (171) 18 — 1 — 140 Private equity investments 874 106 (9) — (8) (5) 92 — — (71) 979 Other 1,726 2,291 (2,389) — (162) (19) 1 — 16 — 1,464 Financial assets at fair value through the income statement 8,506 3,255 (2,891) — (857) (314) 111 — 86 (119) 7,777 Non-asset backed loans 106 — — — — — — — — (106) — Asset backed securities 47 4 — — (5) — — 2 — — 48 Assets at fair value through other comprehensive income 153 4 — — (5) — — 2 — (106) 48 Investment property 10 — (2) — — — — — — — 8 Trading portfolio liabilities (28) (3) 14 — — (7) — — — 7 (17) Financial liabilities designated at fair value (355) — — — 98 7 (2) — (78) 18 (312) Interest rate derivatives (2) 9 — — 33 (121) 4 — 21 (297) (353) Foreign exchange derivatives 1 — — — 58 (6) — — 3 (34) 22 Credit derivatives (155) (117) 2 — (5) 12 (1) — 1 (1) (264) Equity derivatives (1,614) (315) (1) — (32) (221) (1) — 28 808 (1,348) Net derivative financial instruments 1 (1,770) (423) 1 — 54 (336) 2 — 53 476 (1,943) Total 8,379 3,904 (3,407) — (845) (591) 111 2 459 101 8,113 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £3,657m and derivative financial liabilities were £5,600m. |
Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.22 Half year ended 30.06.21 Income statement Other compre hensive income Total Income statement Other compre hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets 121 — — 121 35 — — 35 Financial assets at fair value through the income statement (165) (22) — (187) (201) 114 — (87) Financial assets at fair value through other comprehensive income — — (1) (1) — — — — Investment properties — (1) — (1) — — — — Trading portfolio liabilities (35) — — (35) (6) — — (6) Financial liabilities designated at fair value (14) — — (14) 7 — — 7 Net derivative financial instruments 862 (1) — 861 (367) — — (367) Total 769 (24) (1) 744 (532) 114 — (418) |
Sensitivity analysis of valuations using unobservable inputs | Sensitivity analysis of valuations using unobservable inputs As at 30.06.22 As at 31.12.21 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income statement Equity Income statement Equity Income statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 75 — (108) — 51 — (79) — Foreign exchange derivatives 15 — (22) — 20 — (28) — Credit derivatives 111 — (115) — 111 — (103) — Equity derivatives 107 — (112) — 187 — (195) — Corporate debt 36 — (35) — 38 — (28) — Non-asset backed loans 298 — (334) — 165 — (256) — Equity cash products 73 — (129) — 42 — (61) — Private equity investments 272 1 (286) (1) 246 — (236) — Other 1 27 — (36) — 20 — (19) — Total 1,014 1 (1,177) (1) 880 — (1,005) — 1 Other includes commercial real estate loans, funds and fund-linked products, asset backed loans, issued debt, commercial paper, government sponsored debt and investment property. |
Fair value adjustments | Key balance sheet valuation adjustments are quantified below: As at 30.06.22 As at 31.12.21 £m £m Exit price adjustments derived from market bid-offer spreads (539) (506) Uncollateralised derivative funding (82) (127) Derivative credit valuation adjustments (388) (212) Derivative debit valuation adjustments 208 91 |
Comparison of carrying amounts and fair values for assets and liabilities not held at fair value | The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Group’s balance sheet. As at 30.06.22 As at 31.12.21 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Loans and advances at amortised cost 395,824 396,475 361,451 362,424 Reverse repurchase agreements and other similar secured lending 1,639 1,639 3,227 3,227 Financial liabilities Deposits at amortised cost (568,670) (568,715) (519,433) (519,436) Repurchase agreements and other similar secured borrowing (28,566) (28,569) (28,352) (28,358) Debt securities in issue (115,906) (115,777) (98,867) (100,657) Subordinated liabilities (11,871) (11,799) (12,759) (13,334) |
Loans and advances and deposi_2
Loans and advances and deposits at amortised cost (Table) | 6 Months Ended |
Jun. 30, 2022 | |
Loans and advances and deposits at amortised cost [Abstract] | |
Loans and advances and deposits at amortised cost | As at 30.06.22 As at 31.12.21 £m £m Loans and advances at amortised cost to banks 12,532 9,698 Loans and advances at amortised cost to customers 337,220 319,922 Debt securities at amortised cost 46,072 31,831 Total loans and advances at amortised cost 395,824 361,451 Deposits at amortised cost from banks 29,891 17,819 Deposits at amortised cost from customers 538,779 501,614 Total deposits at amortised cost 568,670 519,433 |
Goodwill and intangible assets
Goodwill and intangible assets (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Intangible assets and goodwill [abstract] | |
Disclosure of goodwill and intangible assets | Goodwill and intangible assets are allocated to business operations according to business segments as follows: As at 30.06.22 As at 31.12.21 Goodwill Intangibles Total Goodwill Intangibles Total £m £m £m £m £m £m Barclays UK 3,560 1,247 4,807 3,560 1,233 4,793 Barclays International 308 3,079 3,387 291 2,930 3,221 Head Office 44 7 51 42 5 47 Total 3,912 4,333 8,245 3,893 4,168 8,061 |
Subordinated liabilities (Table
Subordinated liabilities (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance as at 1 January 12,759 16,341 Issuances 259 1,890 Redemptions (1,180) (4,807) Other 33 (665) Closing balance 11,871 12,759 |
Provisions (Tables)
Provisions (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Provisions [abstract] | |
Provisions | Restated 1 As at 30.06.22 As at 31.12.21 £m £m Customer redress 1,985 530 Legal, competition and regulatory matters 418 226 Redundancy and restructuring 216 326 Undrawn contractually committed facilities and guarantees 526 542 Onerous contracts — 5 Sundry provisions 281 279 Total 3,426 1,908 1 2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Called up share capital (Tables
Called up share capital (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Equity [abstract] | |
Called up share capital | Ordinary share capital Share premium Total share capital and share premium Half year ended 30.06.22 £m £m £m Opening balance as at 1 January 4,188 348 4,536 Issue of shares under employee share schemes 6 27 33 Repurchase of shares (61) — (61) Closing balance 4,133 375 4,508 |
Other equity instruments (Table
Other equity instruments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Miscellaneous components of equity [abstract] | |
Other equity instruments | Half year ended 30.06.22 Year ended 31.12.21 £m £m Opening balance as at 1 January 12,259 11,172 Issuances 1,247 1,078 Redemptions (1,132) — Securities held by the Group (17) 9 Closing balance 12,357 12,259 |
Other reserves (Tables)
Other reserves (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | As at 30.06.22 As at 31.12.21 £m £m Currency translation reserve 4,443 2,740 Fair value through other comprehensive income reserve (1,081) (283) Cash flow hedging reserve (4,671) (853) Own credit reserve (103) (960) Other reserves and treasury shares 1,194 1,126 Total (218) 1,770 |
Contingent liabilities and co_2
Contingent liabilities and commitments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | As at 30.06.22 As at 31.12.21 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 16,463 15,549 Performance guarantees, acceptances and endorsements 5,877 5,797 Total 22,340 21,346 Commitments Documentary credits and other short-term trade related transactions 1,888 1,584 Standby facilities, credit lines and other commitments 396,038 344,127 Total 397,926 345,711 |
Barclays PLC parent company b_2
Barclays PLC parent company balance sheet (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of subsidiaries [abstract] | |
Barclays PLC parent company balance sheet | As at 30.06.22 As at 31.12.21 Assets £m £m Investment in subsidiaries 63,633 62,528 Loans and advances to subsidiaries 20,369 22,072 Financial assets at fair value through the income statement 24,052 25,091 Derivative financial instruments 5 4 Other assets 235 68 Total assets 108,294 109,763 Liabilities Deposits at amortised cost 545 488 Debt securities in issue 22,389 25,658 Subordinated liabilities 10,070 9,301 Financial liabilities designated at fair value 16,888 16,319 Derivative financial instruments 540 43 Other liabilities 104 117 Total liabilities 50,536 51,926 Equity Called up share capital 4,133 4,188 Share premium account 375 348 Other equity instruments 12,347 12,241 Other reserves 616 555 Retained earnings 40,287 40,505 Total equity 57,758 57,837 Total liabilities and equity 108,294 109,763 |
Credit Risk (Tables)
Credit Risk (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Disclosure of credit risk exposure [abstract] | |
Disclosure of provision matrix | The table below presents an analysis of loans and advances at amortised cost by gross exposure, impairment allowance, impairment charge and coverage ratio by stage allocation and business segment as at 30 June 2022. Also included are off-balance sheet loan commitments and financial guarantee contracts by gross exposure, impairment allowance and coverage ratio by stage allocation as at 30 June 2022. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the drawn exposure to the extent that the allowance does not exceed the exposure, as expected credit loss (ECL) is not reported separately. Any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios, the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 30.06.22 £m £m £m £m £m £m £m £m £m Barclays UK 160,110 23,805 3,012 186,927 218 780 753 1,751 185,176 Barclays International 32,053 3,251 1,674 36,978 679 821 826 2,326 34,652 Head Office 3,852 215 688 4,755 2 16 346 364 4,391 Total Barclays Group retail 196,015 27,271 5,374 228,660 899 1,617 1,925 4,441 224,219 Barclays UK 35,915 2,267 862 39,044 131 49 117 297 38,747 Barclays International 120,470 11,916 1,022 133,408 254 198 287 739 132,669 Head Office 186 1 23 210 — — 21 21 189 Total Barclays Group wholesale 1 156,571 14,184 1,907 172,662 385 247 425 1,057 171,605 Total loans and advances at amortised cost 352,586 41,455 7,281 401,322 1,284 1,864 2,350 5,498 395,824 Off-balance sheet loan commitments and financial guarantee contracts 2 373,544 24,429 1,146 399,119 275 233 17 525 398,594 Total 3 726,130 65,884 8,427 800,441 1,559 2,097 2,367 6,023 794,418 As at 30.06.22 Half year ended 30.06.22 Coverage ratio Loan impairment charge/(release) and loan loss rate Stage 1 Stage 2 Stage 3 Total Loan impairment charge/(release) Loan loss rate % % % % £m bps Barclays UK 0.1 3.3 25.0 0.9 14 2 Barclays International 2.1 25.3 49.3 6.3 253 138 Head Office 0.1 7.4 50.3 7.7 (18) — Total Barclays Group retail 0.5 5.9 35.8 1.9 249 22 Barclays UK 0.4 2.2 13.6 0.8 36 19 Barclays International 0.2 1.7 28.1 0.6 75 11 Head Office — — 91.3 10.0 — — Total Barclays Group wholesale 1 0.2 1.7 22.3 0.6 111 13 Total loans and advances at amortised cost 0.4 4.5 32.3 1.4 360 18 Off-balance sheet loan commitments and financial guarantee contracts 2 0.1 1.0 1.5 0.1 (42) Other financial assets subject to impairment 3 23 Total 4 0.2 3.2 28.1 0.8 341 1 Includes Wealth UK and Private Banking exposures measured on an individual customer exposure basis, and excludes Business Banking exposures, including lending under the government backed Bounce Back Loan Scheme (BBLS) of £8.1bn that are managed on a collective basis and reported within BUK Retail. The net impact is a difference in total exposure of £4.3bn of balances reported as wholesale loans on page 33 2 Excludes loan commitments and financial guarantees of £21.1bn carried at fair value. 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn and impairment allowance of £149m. This comprises £11m ECL on £195.0bn Stage 1 assets, £2m on £2.1bn Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £136m on £143m Stage 3 other assets. 4 The loan loss rate is 17bps after applying the total impairment charge of £341m. Gross exposure Impairment allowance Net exposure Stage 1 Stage 2 Stage 3 Total Stage 1 Stage 2 Stage 3 Total As at 31.12.21 £m £m £m £m £m £m £m £m £m Barclays UK 160,695 22,779 2,915 186,389 261 949 728 1,938 184,451 Barclays International 25,981 2,691 1,566 30,238 603 795 858 2,256 27,982 Head Office 3,735 429 705 4,869 2 36 347 385 4,484 Total Barclays Group retail 190,411 25,899 5,186 221,496 866 1,780 1,933 4,579 216,917 Barclays UK 35,571 1,917 969 38,457 153 43 111 307 38,150 Barclays International 92,341 13,275 1,059 106,675 187 192 458 837 105,838 Head Office 542 2 21 565 — — 19 19 546 Total Barclays Group wholesale 1 128,454 15,194 2,049 145,697 340 235 588 1,163 144,534 Total loans and advances at amortised cost 318,865 41,093 7,235 367,193 1,206 2,015 2,521 5,742 361,451 Off-balance sheet loan commitments and financial guarantee contracts 2 312,142 34,815 1,298 348,255 217 302 23 542 347,713 Total 3 631,007 75,908 8,533 715,448 1,423 2,317 2,544 6,284 709,164 As at 31.12.21 Half year ended 31.12.21 Coverage ratio Loan impairment charge/(release) and loan loss rate Stage 1 Stage 2 Stage 3 Total Loan impairment charge/(release) Loan loss rate % % % % £m bps Barclays UK 0.2 4.2 25.0 1.0 (227) — Barclays International 2.3 29.5 54.8 7.5 181 60 Head Office 0.1 8.4 49.2 7.9 — — Total Barclays Group retail 0.5 6.9 37.3 2.1 (46) — Barclays UK 0.4 2.2 11.5 0.8 122 32 Barclays International 0.2 1.4 43.2 0.8 (197) — Head Office — — 90.5 3.4 — — Total Barclays Group wholesale 1 0.3 1.5 28.7 0.8 (75) — Total loans and advances at amortised cost 0.4 4.9 34.8 1.6 (121) — Off-balance sheet loan commitments and financial guarantee contracts 2 0.1 0.9 1.8 0.2 (514) Other financial assets subject to impairment 3 (18) Total 0.2 3.1 29.8 0.9 (653) 1 Includes Wealth and Private Banking exposures measured on an individual basis, and excludes Business Banking exposures, including BBLS of £9.4bn that are managed on a collective basis and reported within Barclays UK Retail. The net impact is a difference in total exposure of £6.0bn of balances reported as wholesale loans on page 33 2 Excludes loan commitments and financial guarantees of £18.8bn carried at fair value. 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £155.2bn and impairment allowance of £114m. This comprises £6m ECL on £154.9bn Stage 1 assets, £1m on £157.0bn Stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances and £107m on £110m Stage 3 other assets. |
Disclosure of credit risk | The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays PLC Annual Report 2021. Transfers between stages in the table have been reflected as if they had taken place at the beginning of the year. The movements are measured over a 6-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL Home loans £m £m £m £m £m £m £m £m As at 1 January 2022 148,058 19 19,500 59 2,122 397 169,680 475 Transfers from Stage 1 to Stage 2 (5,725) (1) 5,725 1 — — — — Transfers from Stage 2 to Stage 1 5,131 18 (5,131) (18) — — — — Transfers to Stage 3 (197) — (234) (5) 431 5 — — Transfers from Stage 3 19 1 133 3 (152) (4) — — Business activity in the period 1 14,723 4 339 1 1 — 15,063 5 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4,151) (22) (506) 2 (69) 16 (4,726) (4) Final repayments (6,975) — (1,092) (2) (210) (3) (8,277) (5) Disposals — — — — — — — — Write-offs 2 — — — — (13) (13) (13) (13) As at 30 June 2022 3 150,883 19 18,734 41 2,110 398 171,727 458 Credit cards, unsecured loans and other retail lending As at 1 January 2022 37,840 824 5,650 1,701 2,332 1,504 45,822 4,029 Transfers from Stage 1 to Stage 2 (2,572) (67) 2,572 67 — — — — Transfers from Stage 2 to Stage 1 1,689 422 (1,689) (422) — — — — Transfers to Stage 3 (444) (11) (516) (222) 960 233 — — Transfers from Stage 3 30 13 49 9 (79) (22) — — Business activity in the period 1 8,231 354 294 32 20 5 8,545 391 Refinements to models used for calculation 4 — 43 — 187 — 96 — 326 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 5 1,678 (691) 413 240 94 285 2,185 (166) Final repayments (2,673) (23) (251) (27) (140) (29) (3,064) (79) Disposals 6 (151) (4) (28) (10) (122) (69) (301) (83) Write-offs 2 — — — — (555) (555) (555) (555) As at 30 June 2022 3 43,628 860 6,494 1,555 2,510 1,448 52,632 3,863 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. Business activity reported within Credit cards, unsecured loans and other retail lending portfolio includes GAP portfolio acquisition in US cards of £2.7bn. 2 In H122, gross write-offs amounted to £768m (H121: £1,001m) and post write-off recoveries amounted to £36m (H121: £31m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £732m (H121: £970m). 3 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn (December 21: £155.2bn) and an impairment allowance of £149m (December 21: £114m). This comprises £11m ECL (December 21: £6m) on £195.0bn stage 1 assets (December 21: £154.9bn), £2m (December 21: £1m) on £2.1bn stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances (December 21: £0.2bn) and £136m (FY21: £107m) on £143m stage 3 other assets (December 21: £110m). 4 Refinements to models used for calculation reported within Credit cards, unsecured loans and other retail lending portfolio include a £0.3bn movement in US cards. These reflect methodology changes made during the year. Barclays continually review the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This ensures that the models used continue to reflect the risks inherent across the businesses. 5 Transfers and risk parameter changes include a £0.2bn (December 21: £0.3bn) net release in ECL arising from a reclassification of £1.4bn (December 21: £1.9bn) gross loans and advances from Stage 2 to Stage 1 in Credit cards, unsecured loans and other retail lending portfolio. The reclassification followed a review of back-testing of results which indicated that accuracy of origination probability of default characteristics required management adjustments to correct. The re-classification was first established in Q220. 6 The £0.3bn disposals reported within Credit cards, unsecured loans and other retail lending portfolio includes £0.2bn sale of NFL portfolio within US cards and £0.1bn of debt sales undertaken during the year. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL Wholesale loans £m £m £m £m £m £m £m £m As at 1 January 2022 132,967 363 15,943 255 2,781 620 151,691 1,238 Transfers from Stage 1 to Stage 2 (5,129) (29) 5,129 29 — — — — Transfers from Stage 2 to Stage 1 5,544 41 (5,544) (41) — — — — Transfers to Stage 3 (676) (3) (405) (6) 1,081 9 — — Transfers from Stage 3 114 9 200 17 (314) (26) — — Business activity in the period 1 28,927 40 1,670 14 108 14 30,705 68 Refinements to models used for calculation 2 — (66) — (42) — (374) — (482) Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 3 12,529 79 1,048 70 (634) 555 12,943 704 Final repayments (16,201) (29) (1,783) (28) (115) (48) (18,099) (105) Disposals 4 — — (31) — (46) (46) (77) (46) Write-offs 5 — — — — (200) (200) (200) (200) As at 30 June 2022 6 158,075 405 16,227 268 2,661 504 176,963 1,177 Reconciliation of ECL movement to impairment charge/(release) for the period £m Home loans (4) Credit cards, unsecured loans and other retail lending 472 Wholesale loans 185 ECL movement excluding assets derecognised due to disposals and write-offs 653 Recoveries and reimbursements 7 (47) Exchange and other adjustments 8 (246) Impairment release on loan commitments and other financial guarantees (42) Impairment charge on other financial assets 6 23 Income statement charge for the period 341 1 Business activity in the period does not include additional drawdowns on the existing facility which are reported under 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes'. 2 Refinements to models used for calculation reported within Wholesale loans relates to a £0.5bn movement in Business Banking. This relates to an update in the underlying ECL model that now fully recognises the 100% government guarantee against Barclays Bounce Back Loans exposure. 3 "Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes" reported within Wholesale loans also include assets of £0.5bn de-recognised due to payment received on defaulted loans from government guarantees issued under government’s Bounce Back Loans Scheme. 4 The £0.1bn disposals reported within Wholesale loans relates to debt sales undertaken during the year. 5 In H122, gross write-offs amounted to £768m (H121: £1,001m) and post write-off recoveries amounted to £36m (H121: £31m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £732m (H121: £970m). 6 Other financial assets subject to impairment not included in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. These have a total gross exposure of £197.3bn (December 21: £155.2bn) and impairment allowance of £149m (December 21: £114m). This comprises £11m ECL (December 21: £6m) on £195.0bn stage 1 assets (December 21: £154.9bn), £2m (December 21: £1m) on £2.1bn stage 2 fair value through other comprehensive income assets, other assets and cash collateral and settlement balances (December 21: £157.0bn) and £136m (December 21: £107m) on £143m stage 3 other assets (December 21: £110m). 7 Recoveries and reimbursements includes a net gain in relation to reimbursements from financial guarantee contracts held with third parties of £11m (H121 loss: £216m) and post write off recoveries of £36m (H121: £31m). 8 Exchange and other adjustments includes foreign exchange and interest and fees in suspense. Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross ECL Gross ECL Gross ECL Gross ECL Home loans £m £m £m £m £m £m £m £m As at 1 January 2022 10,833 — 532 — 3 — 11,368 — Net transfers between stages 39 — (39) — — — — — Business activity in the period 8,146 — — — — — 8,146 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (6,354) — (12) — — — (6,366) — Limit management and final repayments (172) — (22) — — — (194) — As at 30 June 2022 12,492 — 459 — 3 — 12,954 — Credit cards, unsecured loans and other retail lending As at 1 January 2022 122,819 50 5,718 61 218 20 128,755 131 Net transfers between stages (1,277) 23 935 (18) 342 (5) — — Business activity in the period 26,892 1 212 — — — 27,104 1 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 9,385 3 (1,267) 20 (288) 2 7,830 25 Limit management and final repayments (3,740) (1) (209) (3) (36) — (3,985) (4) As at 30 June 2022 154,079 76 5,389 60 236 17 159,704 153 Wholesale loans As at 1 January 2022 178,490 167 28,565 241 1,077 3 208,132 411 Net transfers between stages 9,775 36 (9,709) (37) (66) 1 — — Business activity in the period 37,358 19 2,864 24 1 — 40,223 43 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 17,712 (9) 1,510 (22) 140 (5) 19,362 (36) Limit management and final repayments (36,362) (14) (4,649) (33) (245) 1 (41,256) (46) As at 30 June 2022 206,973 199 18,581 173 907 — 226,461 372 |
Drivers of loan impairment charge | Overview of management adjustments to models for impairment allowance 1 As at 30.06.22 As at 31.12.21 Management adjustments to impairment allowances Proportion of total impairment allowances Management adjustments to impairment allowances Proportion of total impairment allowances £m % £m % Home loans 76 16.6 103 21.7 Credit cards, unsecured loans and other retail lending 785 19.6 1,362 32.7 Wholesale loans 2 426 27.5 21 1.3 Total 1,287 21.4 1,486 23.6 Management adjustments to models for impairment allowance 1 Impairment allowance pre management adjustments 3 Economic uncertainty adjustments Other adjustments Total Adjustments Total impairment allowance 4 (a) (b) (a+b) As at 30.06.22 £m £m £m £m £m Home loans 382 43 33 76 458 Credit cards, unsecured loans and other retail lending 3,229 578 207 785 4,014 Wholesale loans 1,125 417 9 426 1,551 Total 4,736 1,038 249 1,287 6,023 As at 31.12.21 Home loans 372 72 31 103 475 Credit cards, unsecured loans and other retail lending 2,798 1,217 145 1,362 4,160 Wholesale loans 1,628 403 (382) 21 1,649 Total 4,798 1,692 (206) 1,486 6,284 1 Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. 2 Proportion of management adjustments to impairment allowances has increased in wholesale loans primarily driven by release of offsetting PMA to recognise BBLS government guarantees of £0.4bn; now captured through the model. Excluding this, proportion of management adjustments to impairment allowances remain materially stable compare to previous year. 3 Includes £4.1bn (December 2021: £4.1bn) of modelled ECL, £0.4bn (December 2021: £0.5bn) of individually assessed impairments and £0.2bn (December 2021: £0.2bn) ECL from non-modelled exposures. 4 Total impairment allowance consists of ECL stock on drawn and undrawn exposure. |
Macroeconomic variables used in the calculation of ECL and the respective scenario probability weighting | 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.9 1.7 1.6 1.6 1.6 UK unemployment 2 4.0 4.1 3.9 3.9 3.9 UK HPI 3 4.3 1.0 2.2 2.5 2.8 UK bank rate 1.5 2.7 2.4 2.1 2.0 US GDP 1 3.3 2.2 2.1 2.1 2.1 US unemployment 4 3.6 3.5 3.5 3.5 3.5 US HPI 5 4.1 3.4 3.4 3.4 3.4 US federal funds rate 1.5 3.2 2.9 2.7 2.5 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 4.9 2.3 1.9 1.7 UK unemployment 2 4.8 4.7 4.5 4.3 4.2 UK HPI 3 4.7 1.0 1.9 1.9 2.3 UK bank rate 0.1 0.8 1.0 1.0 0.8 US GDP 1 5.5 3.9 2.6 2.4 2.4 US unemployment 4 5.5 4.2 3.6 3.6 3.6 US HPI 5 11.8 4.5 5.2 4.9 5.0 US federal funds rate 0.2 0.3 0.9 1.2 1.3 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.1 (4.8) (0.4) 4.3 3.6 UK unemployment 2 5.2 8.4 8.6 6.8 5.9 UK HPI 3 0.2 (26.2) (3.6) 17.9 10.2 UK bank rate 1.8 4.7 4.3 2.6 2.3 US GDP 1 2.4 (4.1) (0.2) 3.4 2.7 US unemployment 4 4.6 8.0 9.0 7.1 5.8 US HPI 5 (0.2) (11.7) (0.2) 5.5 3.5 US federal funds rate 1.8 4.8 4.6 3.6 3.0 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 0.2 (4.0) 2.8 4.3 UK unemployment 2 4.8 7.2 9.0 7.6 6.3 UK HPI 3 4.7 (14.3) (21.8) 11.9 15.2 UK bank rate 0.1 2.2 3.9 3.1 2.2 US GDP 1 5.5 (0.8) (3.5) 2.5 3.2 US unemployment 4 5.5 6.4 9.1 8.1 6.4 US HPI 5 11.8 (6.6) (9.0) 5.9 6.7 US federal funds rate 0.2 2.1 3.4 2.6 2.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Downside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 3.5 (1.6) 0.6 3.0 2.6 UK unemployment 2 4.6 6.2 6.2 5.3 4.9 UK HPI 3 2.3 (13.2) (0.8) 10.0 6.5 UK bank rate 1.6 3.8 3.4 2.4 2.0 US GDP 1 2.7 (1.0) 1.1 2.9 2.5 US unemployment 4 4.1 5.7 6.2 5.3 4.6 US HPI 5 1.9 (4.4) 1.6 4.4 3.4 US federal funds rate 1.7 3.9 3.8 3.2 2.8 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 2.8 (0.7) 2.3 2.9 UK unemployment 2 4.8 6.2 6.8 6.0 5.3 UK HPI 3 4.7 (6.8) (10.5) 6.9 8.6 UK bank rate 0.1 1.6 2.7 2.3 1.6 US GDP 1 5.5 1.6 (0.4) 2.4 2.7 US unemployment 4 5.5 5.4 6.6 6.1 5.2 US HPI 5 11.8 (1.2) (2.1) 4.8 5.2 US federal funds rate 0.2 1.3 2.3 2.1 1.8 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 2 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 5.0 5.2 3.1 2.4 2.0 UK unemployment 2 3.8 3.7 3.6 3.6 3.6 UK HPI 3 6.5 11.2 6.2 4.7 3.7 UK bank rate 1.2 1.5 1.4 1.3 1.3 US GDP 1 4.0 4.9 3.6 3.4 3.4 US unemployment 4 3.4 3.0 3.1 3.1 3.1 US HPI 5 5.4 5.5 4.6 4.5 4.5 US federal funds rate 1.1 2.2 1.9 1.7 1.5 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 7.2 4.0 2.7 2.1 UK unemployment 2 4.8 4.5 4.1 4.0 4.0 UK HPI 3 4.7 8.5 9.0 5.2 4.2 UK bank rate 0.1 0.2 0.5 0.5 0.3 US GDP 1 5.5 5.3 4.1 3.5 3.4 US unemployment 4 5.5 3.9 3.4 3.3 3.3 US HPI 5 11.8 10.6 8.5 7.2 6.6 US federal funds rate 0.2 0.3 0.4 0.7 1.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Upside 1 average economic variables used in the calculation of ECL 2022 2023 2024 2025 2026 As at 30.06.22 % % % % % UK GDP 1 4.5 3.5 2.4 2.0 1.8 UK unemployment 2 3.9 3.8 3.8 3.8 3.8 UK HPI 3 5.4 6.3 4.1 3.6 3.2 UK bank rate 1.3 2.0 1.6 1.5 1.5 US GDP 1 3.7 3.7 3.0 2.9 2.9 US unemployment 4 3.5 3.2 3.3 3.3 3.3 US HPI 5 4.7 4.4 4.0 3.9 3.9 US federal funds rate 1.3 2.4 2.2 1.9 1.8 2021 2022 2023 2024 2025 As at 31.12.21 % % % % % UK GDP 1 6.2 6.0 3.1 2.3 1.9 UK unemployment 2 4.8 4.6 4.3 4.2 4.1 UK HPI 3 4.7 5.0 5.0 3.9 3.3 UK bank rate 0.1 0.6 0.8 0.8 0.5 US GDP 1 5.5 4.6 3.4 2.9 2.9 US unemployment 4 5.5 4.0 3.5 3.5 3.5 US HPI 5 11.8 8.3 7.0 6.0 5.7 US federal funds rate 0.2 0.3 0.6 1.0 1.1 Specific bases show the most extreme position of each variable in the context of the scenario, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest points relative to the start point in the 20 quarter period. Macroeconomic variables (specific bases) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30.06.22 % % % % % UK GDP 2 16.8 12.8 2.1 (1.1) (5.9) UK unemployment 3 3.6 3.8 4.0 6.6 9.2 UK HPI 4 36.7 24.8 2.6 (13.6) (30.8) UK bank rate 0.8 0.8 2.1 4.0 5.0 US GDP 2 20.2 16.1 2.4 (0.5) (5.0) US unemployment 3 3.0 3.2 3.5 6.5 9.5 US HPI 4 27.0 22.9 3.5 (2.6) (13.4) US federal funds rate 0.3 0.3 2.6 4.1 5.0 As at 31.12.21 UK GDP 2 21.4 18.3 3.4 (1.6) (1.6) UK unemployment 3 4.0 4.1 4.5 7.0 9.2 UK HPI 4 35.7 23.8 2.4 (12.7) (29.9) UK bank rate 0.1 0.1 0.7 2.8 4.0 US GDP 2 22.8 19.6 3.4 1.5 (1.3) US unemployment 3 3.3 3.5 4.1 6.8 9.5 US HPI 4 53.3 45.2 6.2 2.2 (5.0) US federal funds rate 0.1 0.1 0.8 2.3 3.5 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 20 quarter period starts from Q122 (2021: Q121). 2 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year yearly average Compound Annual Growth Rate (CAGR) in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. 3 Lowest quarter in 20 quarter period in Upside scenarios; 5-year average in Baseline; highest quarter 20 quarter period in Downside scenarios. 4 Maximum growth relative to Q421 (2021: Q420), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q421 (2021: Q420), based on 20 quarter period in Downside scenarios. Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables (5-year averages) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30.06.22 % % % % % UK GDP 2 3.5 2.8 2.1 1.6 1.1 UK unemployment 3 3.7 3.8 4.0 5.5 7.0 UK HPI 4 6.4 4.5 2.6 0.6 (1.5) UK bank rate 1.3 1.6 2.1 2.7 3.1 US GDP 2 3.9 3.2 2.4 1.6 0.8 US unemployment 3 3.1 3.3 3.5 5.2 6.9 US HPI 4 4.9 4.2 3.5 1.4 (0.8) US federal funds rate 1.7 1.9 2.6 3.1 3.6 As at 31.12.21 UK GDP 2 4.4 3.9 3.4 2.7 1.8 UK unemployment 3 4.3 4.4 4.5 5.8 7.0 UK HPI 4 6.3 4.4 2.4 0.3 (2.0) UK bank rate 0.3 0.5 0.7 1.7 2.3 US GDP 2 4.4 3.9 3.4 2.4 1.3 US unemployment 3 3.9 4.0 4.1 5.7 7.1 US HPI 4 8.9 7.7 6.2 3.6 1.4 US federal funds rate 0.5 0.6 0.8 1.5 2.1 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 2 5-year yearly average CAGR, starting 2021 (2021: 2020). 3 5-year average. Period based on 20 quarters from Q122 (2021: Q121). 4 5-year quarter end CAGR, starting Q421 (2021: Q420). |
ECL under 100% weighted scenarios for key principal portfolios | Scenarios As at 30 June 2022 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model Exposure (£m) Home loans 142,668 144,569 143,881 142,882 141,536 139,553 Credit cards, unsecured loans and other retail lending 46,225 46,906 46,692 46,446 45,324 44,057 Wholesale loans 183,356 189,252 187,709 183,570 178,233 167,303 Stage 1 Model ECL (£m) Home loans 3 2 2 2 4 10 Credit cards, unsecured loans and other retail lending 341 329 333 338 353 372 Wholesale loans 250 210 224 237 296 329 Stage 1 Coverage (%) Home loans — — — — — — Credit cards, unsecured loans and other retail lending 0.7 0.7 0.7 0.7 0.8 0.8 Wholesale loans 0.1 0.1 0.1 0.1 0.2 0.2 Stage 2 Model Exposure (£m) Home loans 18,684 16,783 17,471 18,470 19,815 21,799 Credit cards, unsecured loans and other retail lending 8,699 7,741 8,048 8,448 9,932 11,658 Wholesale loans 23,702 17,806 19,349 23,489 28,825 39,755 Stage 2 Model ECL (£m) Home loans 13 8 9 11 20 40 Credit cards, unsecured loans and other retail lending 1,531 1,306 1,378 1,468 1,840 2,318 Wholesale loans 463 348 382 438 604 1,091 Stage 2 Coverage (%) Home loans 0.1 — 0.1 0.1 0.1 0.2 Credit cards, unsecured loans and other retail lending 17.6 16.9 17.1 17.4 18.5 19.9 Wholesale loans 2.0 2.0 2.0 1.9 2.1 2.7 Stage 3 Model Exposure (£m) Home loans 1,631 1,631 1,631 1,631 1,631 1,631 Credit cards, unsecured loans and other retail lending 1,797 1,797 1,797 1,797 1,797 1,797 Wholesale loans 1 2,431 2,431 2,431 2,431 2,431 2,431 Stage 3 Model ECL (£m) Home loans 313 301 305 309 328 357 Credit cards, unsecured loans and other retail lending 1,207 1,183 1,191 1,222 1,218 1,212 Wholesale loans 1 61 56 58 60 66 73 Stage 3 Coverage (%) Home loans 19.2 18.5 18.7 18.9 20.1 21.9 Credit cards, unsecured loans and other retail lending 67.2 65.8 66.3 68.0 67.8 67.4 Wholesale loans 1 2.5 2.3 2.4 2.5 2.7 3.0 Total Model ECL (£m) Home loans 329 311 316 322 352 407 Credit cards, unsecured loans and other retail lending 3,079 2,818 2,902 3,028 3,411 3,902 Wholesale loans 1 774 614 664 735 966 1,493 Total Model ECL 4,182 3,743 3,882 4,085 4,729 5,802 1 Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £376m is reported as individually assessed impairments in the table below. Reconciliation to total ECL £m Total model ECL 4,182 ECL from individually assessed impairments 376 ECL from non-modelled and other management adjustments 1 1,465 Total ECL 6,023 1 Includes £1.3bn post-model adjustments of which £0.1bn is included as part of total model ECL and £0.2bn ECL from non-modelled exposures. The dispersion of results around the Baseline is an indication of uncertainty around the future projections. The disclosure highlights the results of the alternative scenarios enabling the reader to understand the extent of the impact on exposure and ECL from the upside/downside scenarios. Consequently, the use of five scenarios with associated weightings results in a total weighted ECL uplift from the Baseline ECL of 2.4%, largely driven by credit card losses which have more linear loss profiles than UK home loans and wholesale loan positions. Home loans: Total weighted ECL of £329m represents a 2.2% increase over the Baseline ECL (£322m), and coverage ratios remain steady across the Upside scenarios, Baseline and Downside 1 scenario. However, total ECL increases in the Downside 2 scenario to £407m, driven by a significant fall in UK HPI (30.8%) reflecting the non-linearity of the UK portfolio. Credit cards, unsecured loans and other retail lending: Total weighted ECL of £3,079m represents a 1.7% increase over the Baseline ECL (£3,028m) reflecting the range of economic scenarios used, mainly impacted by unemployment and other key retail variables. Total ECL increases to £3,902m under Downside 2 scenario, mainly driven by Stage 2, where coverage rates increase to 19.9% from a weighted scenario approach of 17.6% and circa £3.0bn increase in model exposure that meets the Significant Increase in Credit Risk criteria and transitions from Stage 1 to Stage 2. Wholesale loans: Total weighted ECL of £774m represents an 5.3% increase over the Baseline ECL (£735m) reflecting the range of economic scenarios used, with exposures in the Corporate and Investment Bank particularly sensitive to the Downside 2 scenario. Scenarios As at 31 December 2021 Weighted Upside 2 Upside 1 Baseline Downside 1 Downside 2 Stage 1 Model Exposure (£m) Home loans 137,279 139,117 138,424 137,563 135,544 133,042 Credit cards, unsecured loans and other retail lending 45,503 46,170 45,963 45,751 43,131 38,820 Wholesale loans 174,249 177,453 176,774 175,451 169,814 161,998 Stage 1 Model ECL (£m) Home loans 4 2 2 3 6 14 Credit cards, unsecured loans and other retail lending 324 266 272 279 350 418 Wholesale loans 290 240 262 286 327 350 Stage 1 Coverage (%) Home loans — — — — — — Credit cards, unsecured loans and other retail lending 0.7 0.6 0.6 0.6 0.8 1.1 Wholesale loans 0.2 0.1 0.1 0.2 0.2 0.2 Stage 2 Model Exposure (£m) Home loans 22,915 21,076 21,769 22,631 24,649 27,151 Credit cards, unsecured loans and other retail lending 7,200 6,260 6,521 6,795 9,708 14,290 Wholesale loans 32,256 29,052 29,732 31,054 36,692 44,507 Stage 2 Model ECL (£m) Home loans 15 10 11 12 22 47 Credit cards, unsecured loans and other retail lending 1,114 925 988 1,058 1,497 3,295 Wholesale loans 572 431 467 528 851 1,510 Stage 2 Coverage (%) Home loans 0.1 — 0.1 0.1 0.1 0.2 Credit cards, unsecured loans and other retail lending 15.5 14.8 15.2 15.6 15.4 23.1 Wholesale loans 1.8 1.5 1.6 1.7 2.3 3.4 Stage 3 Model Exposure (£m) Home loans 1,724 1,724 1,724 1,724 1,724 1,724 Credit cards, unsecured loans and other retail lending 1,922 1,922 1,922 1,922 1,922 1,922 Wholesale loans 1 1,811 1,811 1,811 1,811 1,811 1,811 Stage 3 Model ECL (£m) Home loans 303 292 295 299 320 346 Credit cards, unsecured loans and other retail lending 1,255 1,236 1,245 1,255 1,277 1,297 Wholesale loans 1 323 321 322 323 326 332 Stage 3 Coverage (%) Home loans 17.6 16.9 17.1 17.3 18.6 20.1 Credit cards, unsecured loans and other retail lending 65.3 64.3 64.8 65.3 66.4 67.5 Wholesale loans 1 17.8 17.7 17.8 17.8 18.0 18.3 Total Model ECL (£m) Home loans 322 304 308 314 348 407 Credit cards, unsecured loans and other retail lending 2,693 2,427 2,505 2,592 3,124 5,010 Wholesale loans 1 1,185 992 1,051 1,137 1,504 2,192 Total Model ECL 4,200 3,723 3,864 4,043 4,976 7,609 1 Material wholesale loan defaults are individually assessed across different recovery strategies. As a result, ECL of £524m is reported as individually assessed impairments in the table below. Reconciliation to total ECL 1 £m Total model ECL 4,200 ECL from individually assessed impairments 524 ECL from non-modelled and other management adjustments 1,560 Total ECL 6,284 1 Includes £1.5bn of post-model adjustments and £0.2bn ECL from non-modelled exposures. |
Management Value at Risk | Management VaR (95%) by asset class Half year ended 30.06.22 Half year ended 31.12.21 Half year ended 30.06.21 Average High Low Average High Low Average High Low £m £m £m £m £m £m £m £m £m Credit risk 16 24 8 10 13 7 18 30 9 Interest rate risk 10 19 4 5 9 4 8 15 4 Equity risk 10 29 4 8 29 4 10 15 6 Basis risk 9 24 4 4 7 3 7 10 4 Spread risk 5 10 3 4 6 3 4 6 3 Foreign exchange risk 10 25 2 4 16 1 3 6 2 Commodity risk — 1 — — 1 — — 1 — Inflation risk 6 17 3 3 5 2 2 3 2 Diversification effect 1 (39) n/a n/a (23) n/a n/a (30) n/a n/a Total management VaR 27 43 13 15 34 6 22 36 13 1 Diversification effects recognise that forecast losses from different assets or businesses are unlikely to occur concurrently, hence the expected aggregate loss is lower than the sum of the expected losses from each area. Historical correlations between losses are taken into account in making these assessments. The high and low VaR figures reported for each category did not necessarily occur on the same day as the high and low VaR reported as a whole. Consequently, a diversification effect balance for the high and low VaR figures would not be meaningful and is therefore omitted from the above table. |
Disclosure of financial risk management | Restated 1 Capital ratios 2,3,4 As at 30.06.22 As at 31.03.22 As at 31.12.21 CET1 13.6% 13.8% 15.1% T1 17.1% 17.1% 19.1% Total regulatory capital 19.9% 20.1% 22.2% Capital resources £m £m £m Total equity excluding non-controlling interests per the balance sheet 69,627 68,465 69,052 Less: other equity instruments (recognised as AT1 capital) (12,357) (11,119) (12,259) Adjustment to retained earnings for foreseeable ordinary share dividends (595) (968) (666) Adjustment to retained earnings for foreseeable repurchase of shares (568) (1,000) — Adjustment to retained earnings for foreseeable other equity coupons (32) (39) (32) Other regulatory adjustments and deductions Additional value adjustments (PVA) (1,810) (1,864) (1,585) Goodwill and intangible assets (8,232) (8,035) (6,804) Deferred tax assets that rely on future profitability excluding temporary differences (1,010) (938) (1,028) Fair value reserves related to gains or losses on cash flow hedges 4,673 3,343 852 Gains or losses on liabilities at fair value resulting from own credit (62) 4 892 Defined benefit pension fund assets (3,785) (3,225) (2,619) Direct and indirect holdings by an institution of own CET1 instruments (20) (20) (50) Adjustment under IFRS 9 transitional arrangements 642 601 1,229 Other regulatory adjustments 220 64 345 CET1 capital 46,691 45,269 47,327 AT1 capital Capital instruments and related share premium accounts 12,357 11,119 12,259 Qualifying AT1 capital (including minority interests) issued by subsidiaries — — 637 Other regulatory adjustments and deductions (60) (60) (80) AT1 capital 12,297 11,059 12,816 T1 capital 58,988 56,328 60,143 T2 capital Capital instruments and related share premium accounts 8,442 8,334 8,713 Qualifying T2 capital (including minority interests) issued by subsidiaries 1,277 1,540 1,113 Credit risk adjustments (excess of impairment over expected losses) 73 98 73 Other regulatory adjustments and deductions (160) (160) (160) Total regulatory capital 68,620 66,140 69,882 Total RWAs 344,516 328,830 314,136 1 Capital metrics as at 31 December 2021 have been restated to reflect the impact of the Over-issuance of Securities. See Basis of preparation on page 59 2 CET1, T1 and T2 capital, and RWAs are calculated applying the transitional arrangements of the CRR as amended by CRR II. This includes IFRS 9 transitional arrangements and the grandfathering of CRR II non-compliant capital instruments. December 2021 comparatives include the grandfathering of CRR non-compliant capital instruments. 3 The fully loaded CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays PLC AT1 securities, was 13.4%, with £46.0bn of CET1 capital and £344.3bn of RWAs calculated without applying the transitional arrangements of the CRR as amended by CRR II. 4 The Group’s CET1 ratio, as is relevant for assessing against the conversion trigger in Barclays Bank PLC 7.625% Contingent Capital Notes, was 13.6%. For this calculation CET1 capital and RWAs are calculated applying the transitional arrangements under the CRR as amended by CRR II, including the IFRS 9 transitional arrangements. The benefit of the Financial Services Authority (FSA) October 2012 interpretation of the transitional provisions, relating to the implementation of CRD IV, expired in December 2017. |
Basis of preparation (Details)
Basis of preparation (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||||||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | [3] | ||||
As reported | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | £ (99) | £ (177) | |||||||
Operating expenses | (7,231) | (14,439) | |||||||
Profit before tax | 4,979 | 8,414 | |||||||
Taxation | (759) | (1,188) | |||||||
Profit after tax | 4,220 | 7,226 | |||||||
Total comprehensive income for the period | 2,620 | 5,008 | |||||||
Adjustment for non-cash items | 6,900 | ||||||||
Current tax liabilities | £ 739 | 739 | |||||||
Provisions | 1,688 | 1,688 | |||||||
Total liabilities | 1,314,074 | 1,314,074 | |||||||
Retained earnings | 50,657 | 50,657 | |||||||
Total equity | 70,211 | 70,211 | |||||||
Restatement | |||||||||
Disclosure of retrospective restatement [Line Items] | |||||||||
Litigation and conduct | (77) | (220) | |||||||
Operating expenses | (77) | (220) | |||||||
Profit before tax | (77) | (220) | |||||||
Taxation | 17 | 50 | |||||||
Profit after tax | (60) | (170) | |||||||
Total comprehensive income for the period | (60) | (170) | |||||||
Adjustment for non-cash items | 77 | ||||||||
Current tax liabilities | (50) | (50) | |||||||
Provisions | 220 | 220 | |||||||
Total liabilities | 170 | 170 | |||||||
Retained earnings | (170) | (170) | |||||||
Total equity | (170) | (170) | |||||||
Litigation and conduct | £ (1,857) | (176) | [1] | (397) | |||||
Operating expenses | (9,127) | (7,308) | [1] | (14,659) | |||||
Profit before tax | 3,733 | 4,902 | [2] | 8,194 | |||||
Taxation | (823) | (742) | [1] | (1,138) | |||||
Profit after tax | 2,910 | 2,896 | 4,160 | [3] | 7,056 | ||||
Total comprehensive income for the period | 1,981 | 2,278 | 2,560 | [3] | 4,838 | ||||
Adjustment for non-cash items | 6,977 | ||||||||
Current tax liabilities | 449 | 689 | [4] | 689 | [4] | ||||
Provisions | 3,426 | 1,908 | [4] | 1,908 | [4] | ||||
Total liabilities | 1,518,634 | 1,314,244 | [4] | 1,314,244 | [4] | ||||
Retained earnings | 52,980 | 50,487 | [4] | 50,487 | [4] | ||||
Total equity | £ 70,596 | £ 70,041 | [4] | £ 68,056 | [3] | £ 70,041 | [4] | £ 66,882 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 73 73 |
Segmental reporting - Analysis
Segmental reporting - Analysis of results by business (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |||
Disclosure of operating segments [line items] | |||||
Total income | £ 13,204 | £ 11,315 | [1] | ||
Credit impairment (charges)/releases | (341) | 742 | [1] | £ 653 | |
Net operating income | 12,863 | 12,057 | [1] | ||
Operating costs | (7,270) | (7,132) | |||
Litigation and conduct | (1,857) | (176) | |||
Total operating expenses | (9,127) | (7,308) | [1] | (14,659) | |
Other net income/(expenses) | (3) | 153 | |||
Profit before tax | 3,733 | 4,902 | [2] | 8,194 | |
Total assets | 1,589,230 | 1,384,285 | [3] | ||
Operating segments | Barclays UK | |||||
Disclosure of operating segments [line items] | |||||
Total income | 3,373 | 3,199 | |||
Credit impairment (charges)/releases | (48) | 443 | |||
Net operating income | 3,325 | 3,642 | |||
Operating costs | (2,083) | (2,114) | |||
Litigation and conduct | (25) | (22) | |||
Total operating expenses | (2,108) | (2,136) | |||
Other net income/(expenses) | 0 | 0 | |||
Profit before tax | 1,217 | 1,506 | |||
Total assets | 318,800 | 321,200 | |||
Operating segments | Barclays International | |||||
Disclosure of operating segments [line items] | |||||
Total income | 9,940 | 8,218 | |||
Credit impairment (charges)/releases | (310) | 293 | |||
Net operating income | 9,630 | 8,511 | |||
Operating costs | (5,042) | (4,606) | |||
Litigation and conduct | (1,832) | (161) | |||
Total operating expenses | (6,874) | (4,767) | |||
Other net income/(expenses) | 13 | 22 | |||
Profit before tax | 2,769 | 3,766 | |||
Total assets | 1,250,600 | 1,044,100 | |||
Head Office | |||||
Disclosure of operating segments [line items] | |||||
Total income | (109) | (102) | |||
Credit impairment (charges)/releases | 17 | 6 | |||
Net operating income | (92) | (96) | |||
Operating costs | (145) | (412) | |||
Litigation and conduct | 0 | 7 | |||
Total operating expenses | (145) | (405) | |||
Other net income/(expenses) | (16) | 131 | |||
Profit before tax | (253) | £ (370) | |||
Total assets | £ 19,800 | £ 19,000 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 73 |
Segmental reporting - Split of
Segmental reporting - Split of income by geographic region (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Disclosure of operating segments [line items] | |||
Total income | £ 13,204 | £ 11,315 | [1] |
United Kingdom | |||
Disclosure of operating segments [line items] | |||
Total income | 7,972 | 5,895 | |
Europe | |||
Disclosure of operating segments [line items] | |||
Total income | 1,311 | 1,222 | |
Americas | |||
Disclosure of operating segments [line items] | |||
Total income | 3,200 | 3,608 | |
Africa and Middle East | |||
Disclosure of operating segments [line items] | |||
Total income | 31 | 20 | |
Asia | |||
Disclosure of operating segments [line items] | |||
Total income | £ 690 | £ 570 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Net fee and commission income_2
Net fee and commission income (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | £ 4,657 | £ 4,620 | |
Other non-contract fee income | 69 | 62 | |
Fee and commission income | 4,726 | 4,682 | [1] |
Fee and commission expense | (1,302) | (976) | [1] |
Net fee and commission income | 3,424 | 3,706 | [1] |
Decrease in fee and commission expense | 103 | 88 | |
Increase in fee and commission income | 103 | 88 | |
Transactional | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 1,963 | 1,589 | |
Advisory | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 594 | 543 | |
Brokerage and execution | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 887 | 662 | |
Underwriting and syndication | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 1,102 | 1,715 | |
Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 111 | 111 | |
Operating segments | Barclays UK | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 752 | 635 | |
Other non-contract fee income | 0 | 0 | |
Fee and commission income | 752 | 635 | |
Fee and commission expense | (147) | (108) | |
Net fee and commission income | 605 | 527 | |
Operating segments | Barclays UK | Transactional | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 515 | 408 | |
Operating segments | Barclays UK | Advisory | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 83 | 83 | |
Operating segments | Barclays UK | Brokerage and execution | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 125 | 109 | |
Operating segments | Barclays UK | Underwriting and syndication | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 0 | 0 | |
Operating segments | Barclays UK | Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 29 | 35 | |
Operating segments | Barclays International | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 3,903 | 3,981 | |
Other non-contract fee income | 69 | 62 | |
Fee and commission income | 3,972 | 4,043 | |
Fee and commission expense | (1,153) | (861) | |
Net fee and commission income | 2,819 | 3,182 | |
Operating segments | Barclays International | Transactional | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 1,448 | 1,181 | |
Operating segments | Barclays International | Advisory | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 511 | 459 | |
Operating segments | Barclays International | Brokerage and execution | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 762 | 553 | |
Operating segments | Barclays International | Underwriting and syndication | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 1,102 | 1,715 | |
Operating segments | Barclays International | Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 80 | 73 | |
Head Office | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 2 | 4 | |
Other non-contract fee income | 0 | 0 | |
Fee and commission income | 2 | 4 | |
Fee and commission expense | (2) | (7) | |
Net fee and commission income | 0 | (3) | |
Head Office | Transactional | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 0 | 0 | |
Head Office | Advisory | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 0 | 1 | |
Head Office | Brokerage and execution | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 0 | 0 | |
Head Office | Underwriting and syndication | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | 0 | 0 | |
Head Office | Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Total revenue from contracts with customers | £ 2 | £ 3 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Staff costs (Details)
Staff costs (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Compensation costs | |||
Upfront bonus charge | £ 705 | £ 824 | |
Deferred bonus charge | 280 | 262 | |
Other incentives | 44 | 6 | |
Performance costs | 1,029 | 1,092 | |
Salaries | 2,278 | 2,117 | |
Social security costs | 377 | 336 | |
Post-retirement benefits | 282 | 275 | |
Other compensation costs | 241 | 223 | |
Total compensation costs | 4,207 | 4,043 | |
Other resourcing costs | |||
Outsourcing | 268 | 171 | |
Redundancy and restructuring | (15) | ||
Redundancy and restructuring | 23 | ||
Temporary staff costs | 53 | 55 | |
Other | 70 | 42 | |
Total other resourcing costs | 376 | 291 | |
Total staff costs | £ 4,583 | £ 4,334 | [1] |
Barclays Group compensation costs as a % of total income | 31.90% | 35.70% | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Staff costs - Narrative (Detail
Staff costs - Narrative (Details) £ in Millions | Jun. 30, 2022 GBP (£) |
Forward contract | Share-based payment arrangements | Fair value | |
Disclosure of attribution of expenses by nature to their function [line items] | |
Financial instruments designated as hedging instruments, at fair value | £ 287 |
Infrastructure, administratio_3
Infrastructure, administration and general expenses (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Infrastructure costs | |||
Property and equipment | £ 744 | £ 709 | |
Depreciation and amortisation | 863 | 832 | |
Lease payments | 14 | 20 | |
Impairment of property, equipment and intangible assets | 21 | 304 | |
Total infrastructure costs | 1,642 | 1,865 | |
Administration and general expenses | |||
Consultancy, legal and professional fees | 288 | 262 | |
Marketing and advertising | 206 | 163 | |
Other administration and general expenses | 551 | 508 | |
Total administration and general expenses | 1,045 | 933 | |
Total infrastructure, administration and general expenses | £ 2,687 | £ 2,798 | [1] |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Tax (Narrative) (Details)
Tax (Narrative) (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | ||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Tax charge | £ 823 | £ 742 | [1] | £ 1,138 |
Effective tax rate | 22% | 15.10% | ||
Average effective tax rate excluding effect of tax rate change | 12.80% | |||
Average effective tax rate, prior period adjustments | 5.80% | |||
AT1 Securities | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Tax charge | £ (110) | £ (104) | ||
UK | ||||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | ||||
Increase (decrease) relating to tax rate changes or imposition of new taxes, deferred tax liability (asset) | (318) | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes | 346 | |||
Deferred tax expense (income) relating to tax rate changes or imposition of new taxes, other comprehensive income | £ 28 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Tax - Deferred tax assets and l
Tax - Deferred tax assets and liabilities (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | £ 5,044 | £ 4,619 | [1] |
Deferred tax liabilities | (5) | (37) | [1] |
Temporary differences | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 3,871 | 3,399 | |
Tax losses | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 1,173 | 1,220 | |
US | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 3,046 | 2,183 | |
UK | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | 1,530 | 2,006 | |
Other territories | |||
Disclosure of temporary difference, unused tax losses and unused tax credits [line items] | |||
Deferred tax assets | £ 468 | £ 430 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Non-controlling interests (Deta
Non-controlling interests (Details) - GBP (£) £ in Millions | 6 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |||
Profit attributable to non-controlling interests | £ 21 | £ 19 | [1] | ||
Equity attributable to non-controlling interests | 969 | £ 989 | [2] | ||
Other non-controlling interests | |||||
Profit attributable to non-controlling interests | 0 | 3 | |||
Equity attributable to non-controlling interests | 2 | 2 | |||
Barclays Bank PLC | - Preference shares | |||||
Profit attributable to non-controlling interests | 15 | 13 | |||
Equity attributable to non-controlling interests | 529 | 529 | |||
Barclays Bank PLC | - Upper T2 instruments | |||||
Profit attributable to non-controlling interests | 6 | £ 3 | |||
Equity attributable to non-controlling interests | £ 438 | £ 458 | |||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Earnings per share (Details)
Earnings per share (Details) - GBP (£) £ / shares in Units, £ in Millions, shares in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Earnings per share [abstract] | |||
Profit attributable to ordinary equity holders of the parent | £ 2,475 | £ 3,752 | [1] |
Basic weighted average number of shares in issue (in shares) | 16,684 | 17,140 | |
Number of potential ordinary shares (in shares) | 428 | 467 | |
Diluted weighted average number of shares (in shares) | 17,112 | 17,607 | |
Basic earnings per ordinary share (in GBP per share) | £ 0.148 | £ 0.219 | [1] |
Diluted earnings per ordinary share (in GBP per share) | £ 0.145 | £ 0.213 | [1] |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Dividends on ordinary shares (D
Dividends on ordinary shares (Details) - GBP (£) £ / shares in Units, £ in Millions | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Dividends on ordinary shares [Abstract] | ||
Dividends paid, ordinary shares per share (in GBP per share) | £ 0.040 | £ 0.010 |
Dividends paid, ordinary shares | £ 664 | £ 173 |
Dividends on ordinary shares (N
Dividends on ordinary shares (Narrative) (Details) - GBP (£) | 3 Months Ended | 6 Months Ended | |||
Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | ||
Disclosure of classes of share capital [line items] | |||||
Repurchase of shares | £ (432,000,000) | £ (500,000,000) | £ (700,000,000) | [1] | |
Share buyback | Maximum | |||||
Disclosure of classes of share capital [line items] | |||||
Repurchase of shares | £ 500,000,000 | ||||
Ordinary share capital | |||||
Disclosure of classes of share capital [line items] | |||||
Interim dividends, per share | £ 0.0225 | £ 2 | |||
Number of shares comprising, one american depository share | 4 | ||||
Repurchase of shares | £ (61,000,000) | ||||
Qualifying American depository shares | |||||
Disclosure of classes of share capital [line items] | |||||
Interim dividends, per share | £ 0.090 | ||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Derivative financial instrume_3
Derivative financial instruments - Total recognised derivative assets/(liabilities) (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets | £ 344,855 | £ 262,572 | [1] |
Derivative liabilities | (321,396) | (256,883) | [1] |
Derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 55,409,775 | 48,032,325 | |
Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets | 344,855 | 262,572 | |
Derivative liabilities | (321,396) | (256,883) | |
Derivatives in hedge accounting relationships | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 250,946 | 219,551 | |
Derivatives in hedge accounting relationships | Derivatives designated as cash flow hedges | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 139,040 | 114,313 | |
Derivatives in hedge accounting relationships | Derivatives designated as fair value hedges | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 107,809 | 102,815 | |
Derivatives in hedge accounting relationships | Derivatives designated as hedges of net investments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 4,097 | 2,423 | |
Derivatives in hedge accounting relationships | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets designated in hedge accounting relationships | 826 | 894 | |
Derivative liabilities designated in hedge accounting relationships | (1,135) | (1,136) | |
Derivatives in hedge accounting relationships | Fair value | Derivatives designated as cash flow hedges | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets designated in hedge accounting relationships | 701 | 798 | |
Derivative liabilities designated in hedge accounting relationships | (21) | (3) | |
Derivatives in hedge accounting relationships | Fair value | Derivatives designated as fair value hedges | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets designated in hedge accounting relationships | 106 | 59 | |
Derivative liabilities designated in hedge accounting relationships | (1,054) | (1,129) | |
Derivatives in hedge accounting relationships | Fair value | Derivatives designated as hedges of net investments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative assets designated in hedge accounting relationships | 19 | 37 | |
Derivative liabilities designated in hedge accounting relationships | (60) | (4) | |
Held for trading | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 55,158,829 | 47,812,774 | |
Held for trading | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative financial assets held for trading | 344,029 | 261,678 | |
Derivative liabilities held for trading | (320,261) | (255,747) | |
Held for trading | Foreign exchange derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 6,732,093 | 5,824,856 | |
Held for trading | Foreign exchange derivatives | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative financial assets held for trading | 135,207 | 76,140 | |
Derivative liabilities held for trading | (123,662) | (74,437) | |
Held for trading | Interest rate derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 44,275,712 | 38,816,432 | |
Held for trading | Interest rate derivatives | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative financial assets held for trading | 130,628 | 125,846 | |
Derivative liabilities held for trading | (116,541) | (114,803) | |
Held for trading | Credit derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 1,640,043 | 1,272,104 | |
Held for trading | Credit derivatives | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative financial assets held for trading | 8,128 | 5,682 | |
Derivative liabilities held for trading | (8,228) | (6,561) | |
Held for trading | Equity and stock index and commodity derivatives | |||
Disclosure of detailed information about financial instruments [line items] | |||
Contract notional amount | 2,510,981 | 1,899,382 | |
Held for trading | Equity and stock index and commodity derivatives | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Derivative financial assets held for trading | 70,066 | 54,010 | |
Derivative liabilities held for trading | £ (71,830) | £ (59,946) | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Derivative financial instrume_4
Derivative financial instruments, narrative (Details) - GBP (£) £ in Billions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Derivative financial liabilities | ||
Disclosure of offsetting of financial assets [line items] | ||
Gross financial assets set off against financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements | £ 55 | £ 24 |
Derivative liability expsoures | 293 | 235 |
Non-cash assets pledged as collateral | 3 | 2 |
Cash collateral netted | Derivative financial liabilities | ||
Disclosure of offsetting of financial assets [line items] | ||
Gross financial assets set off against financial liabilities subject to offsetting, enforceable master netting arrangements or similar agreements | 12 | 4 |
Derivative liability expsoures | 26 | 32 |
Derivative financial assets | ||
Disclosure of offsetting of financial assets [line items] | ||
IFRS netting posted against derivative assets | 55 | 24 |
Derivative asset exposures | 306 | 237 |
Non-cash collateral | 13 | 6 |
Derivative financial assets | Cash collateral netted | ||
Disclosure of offsetting of financial assets [line items] | ||
IFRS netting posted against derivative assets | 12 | 4 |
Derivative asset exposures | £ 40 | £ 35 |
Fair value of financial instr_3
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | £ 127,004 | £ 147,035 | [1] |
Financial assets at fair value through the income statement | 212,723 | 191,972 | [1] |
Derivative financial instruments | 344,855 | 262,572 | [1] |
Financial assets at fair value through other comprehensive income | 63,194 | 61,753 | [1] |
Trading portfolio liabilities | (76,638) | (54,169) | [1] |
Financial liabilities designated at fair value | (255,136) | (250,960) | [1] |
Derivative financial instruments | (321,396) | (256,883) | [1] |
Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 127,004 | 147,035 | |
Financial assets at fair value through the income statement | 212,723 | 191,972 | |
Derivative financial instruments | 344,855 | 262,572 | |
Financial assets at fair value through other comprehensive income | 63,194 | 61,753 | |
Investment property | 5 | 7 | |
Total assets | 747,781 | 663,339 | |
Trading portfolio liabilities | (76,638) | (54,169) | |
Financial liabilities designated at fair value | (255,136) | (250,960) | |
Derivative financial instruments | (321,396) | (256,883) | |
Total liabilities | (653,170) | (562,012) | |
(Level 1) | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 58,419 | 80,926 | |
Financial assets at fair value through the income statement | 1,115 | 5,093 | |
Derivative financial instruments | 11,653 | 6,150 | |
Financial assets at fair value through other comprehensive income | 22,455 | 22,009 | |
Investment property | 0 | 0 | |
Total assets | 93,642 | 114,178 | |
Trading portfolio liabilities | (47,870) | (27,529) | |
Financial liabilities designated at fair value | (193) | (174) | |
Derivative financial instruments | (12,674) | (6,571) | |
Total liabilities | (60,737) | (34,274) | |
(Level 2) | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 64,329 | 63,828 | |
Financial assets at fair value through the income statement | 202,026 | 177,167 | |
Derivative financial instruments | 329,329 | 252,412 | |
Financial assets at fair value through other comprehensive income | 40,696 | 39,706 | |
Investment property | 0 | 0 | |
Total assets | 636,380 | 533,113 | |
Trading portfolio liabilities | (28,686) | (26,613) | |
Financial liabilities designated at fair value | (254,496) | (250,376) | |
Derivative financial instruments | (304,343) | (244,253) | |
Total liabilities | (587,525) | (521,242) | |
(Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Total assets | 17,759 | 16,048 | |
Total liabilities | (4,908) | (6,496) | |
(Level 3) | Fair value | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading portfolio assets | 4,256 | 2,281 | |
Financial assets at fair value through the income statement | 9,582 | 9,712 | |
Derivative financial instruments | 3,873 | 4,010 | |
Financial assets at fair value through other comprehensive income | 43 | 38 | |
Investment property | 5 | 7 | |
Total assets | 17,759 | 16,048 | |
Trading portfolio liabilities | (82) | (27) | |
Financial liabilities designated at fair value | (447) | (410) | |
Derivative financial instruments | (4,379) | (6,059) | |
Total liabilities | £ (4,908) | £ (6,496) | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Fair value of financial instr_4
Fair value of financial instruments - Level 3 assets and liabilities held at fair value disaggregated by product type (Details) - (Level 3) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | £ 17,759 | £ 16,048 |
Financial liabilities, at fair value | (4,908) | (6,496) |
Asset backed securities | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 291 | 558 |
Financial liabilities, at fair value | 0 | 0 |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 1,171 | 1,205 |
Financial liabilities, at fair value | (13) | (21) |
Reverse repurchase and repurchase agreements | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 178 | 13 |
Financial liabilities, at fair value | (188) | (172) |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 8,660 | 6,405 |
Financial liabilities, at fair value | 0 | 0 |
Equity cash products | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 422 | 393 |
Financial liabilities, at fair value | (3) | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 1,297 | 1,095 |
Financial liabilities, at fair value | (8) | (6) |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 1,867 | 2,369 |
Financial liabilities, at fair value | (317) | (238) |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 1,573 | 1,091 |
Financial liabilities, at fair value | (1,849) | (1,351) |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 786 | 376 |
Financial liabilities, at fair value | (560) | (374) |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 234 | 323 |
Financial liabilities, at fair value | (615) | (709) |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Financial assets, at fair value | 1,280 | 2,220 |
Financial liabilities, at fair value | £ (1,355) | £ (3,625) |
Fair value of financial instr_5
Fair value of financial instruments - Analysis of movements in Level 3 assets and liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | [1] | |
Net assets (liabilities) [abstract] | ||||
Derivative financial assets | £ 344,855 | £ 262,572 | ||
Derivative financial instruments | 321,396 | £ 256,883 | ||
(Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 16,048 | |||
Ending balance, financial assets | 17,759 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (6,496) | |||
Ending balance, financial liabilities | (4,908) | |||
Recurring fair value measurement | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | 9,552 | £ 8,379 | ||
Purchases, fair value measurement, assets (liabilities) net | 9,586 | 3,904 | ||
Sales, fair value measurement, assets (liabilities) net | (7,126) | (3,407) | ||
Issues, fair value measurement, assets (liabilities) net | (13) | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (695) | (845) | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (1) | 2 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 636 | 459 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 78 | 101 | ||
Ending balance, assets (liabilities) | 12,851 | 8,113 | ||
Derivative financial assets | 3,873 | 3,657 | ||
Derivative financial instruments | 4,379 | 5,600 | ||
Recurring fair value measurement | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 687 | (591) | ||
Recurring fair value measurement | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 147 | 111 | ||
Recurring fair value measurement | Investment property | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 7 | 10 | ||
Purchases, fair value measurement, assets | 0 | 0 | ||
Sales, fair value measurement, assets | (1) | (2) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 5 | 8 | ||
Recurring fair value measurement | Investment property | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Recurring fair value measurement | Investment property | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | (1) | 0 | ||
Recurring fair value measurement | Net derivative financial instruments | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | (2,049) | (1,770) | ||
Purchases, fair value measurement, assets (liabilities) net | (94) | (423) | ||
Sales, fair value measurement, assets (liabilities) net | 5 | 1 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 218 | 54 | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 217 | 53 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 358 | 476 | ||
Ending balance, assets (liabilities) | (506) | (1,943) | ||
Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 849 | (336) | ||
Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (10) | 2 | ||
Trading portfolio liabilities | Recurring fair value measurement | (Level 3) | ||||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (27) | (28) | ||
Purchases, fair value measurement, liabilities | (35) | (3) | ||
Sales, fair value measurement, liabilities | 3 | 14 | ||
Issues, fair value measurement, liabilities | 0 | 0 | ||
Settlements, fair value measurement, liabilities | 0 | 0 | ||
Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, liabilities | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, liabilities | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, liabilities | 6 | 7 | ||
Ending balance, financial liabilities | (82) | (17) | ||
Trading portfolio liabilities | Recurring fair value measurement | (Level 3) | Financial liabilities at fair value through profit or loss, category trading | ||||
Categories of financial liabilities [abstract] | ||||
Total gains and losses in the period recognised in the income statement, liabilities | (29) | (7) | ||
Trading portfolio liabilities | Recurring fair value measurement | (Level 3) | Financial liabilities at fair value through profit or loss, category other income | ||||
Categories of financial liabilities [abstract] | ||||
Total gains and losses in the period recognised in the income statement, liabilities | 0 | 0 | ||
Financial liabilities designated at fair value | Recurring fair value measurement | (Level 3) | ||||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (410) | (355) | ||
Purchases, fair value measurement, liabilities | (5) | 0 | ||
Sales, fair value measurement, liabilities | 0 | 0 | ||
Issues, fair value measurement, liabilities | (13) | 0 | ||
Settlements, fair value measurement, liabilities | 47 | 98 | ||
Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, liabilities | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, liabilities | (81) | (78) | ||
Transfers out of Level 3 of fair value hierarchy, liabilities | 37 | 18 | ||
Ending balance, financial liabilities | (447) | (312) | ||
Financial liabilities designated at fair value | Recurring fair value measurement | (Level 3) | Financial liabilities at fair value through profit or loss, category trading | ||||
Categories of financial liabilities [abstract] | ||||
Total gains and losses in the period recognised in the income statement, liabilities | (22) | 7 | ||
Financial liabilities designated at fair value | Recurring fair value measurement | (Level 3) | Financial liabilities at fair value through profit or loss, category other income | ||||
Categories of financial liabilities [abstract] | ||||
Total gains and losses in the period recognised in the income statement, liabilities | 0 | (2) | ||
Asset backed securities | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 558 | |||
Ending balance, financial assets | 291 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | 0 | |||
Interest rate derivatives | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 1,091 | |||
Ending balance, financial assets | 1,573 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (1,351) | |||
Ending balance, financial liabilities | (1,849) | |||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | (260) | (2) | ||
Purchases, fair value measurement, assets (liabilities) net | 25 | 9 | ||
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (4) | 33 | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 271 | 21 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 6 | (297) | ||
Ending balance, assets (liabilities) | (276) | (353) | ||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (305) | (121) | ||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (9) | 4 | ||
Foreign exchange derivatives | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 376 | |||
Ending balance, financial assets | 786 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (374) | |||
Ending balance, financial liabilities | (560) | |||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | 2 | 1 | ||
Purchases, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Sales, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | (9) | 58 | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (65) | 3 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 25 | (34) | ||
Ending balance, assets (liabilities) | 226 | 22 | ||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 273 | (6) | ||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Credit derivatives | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 323 | |||
Ending balance, financial assets | 234 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (709) | |||
Ending balance, financial liabilities | (615) | |||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | (386) | (155) | ||
Purchases, fair value measurement, assets (liabilities) net | (36) | (117) | ||
Sales, fair value measurement, assets (liabilities) net | 5 | 2 | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 60 | (5) | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | 20 | 1 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 55 | (1) | ||
Ending balance, assets (liabilities) | (381) | (264) | ||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (99) | 12 | ||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | (1) | ||
Equity derivatives | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 2,220 | |||
Ending balance, financial assets | 1,280 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (3,625) | |||
Ending balance, financial liabilities | (1,355) | |||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | ||||
Net assets (liabilities) [abstract] | ||||
Beginning balance, assets (liabilities) | (1,405) | (1,614) | ||
Purchases, fair value measurement, assets (liabilities) net | (83) | (315) | ||
Sales, fair value measurement, assets (liabilities) net | 0 | (1) | ||
Issues, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Settlements, fair value measurement, assets (liabilities) net | 171 | (32) | ||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets (liabilities) net | (9) | 28 | ||
Transfers out of Level 3 of fair value hierarchy, assets (liabilities) net | 272 | 808 | ||
Ending balance, assets (liabilities) | (75) | (1,348) | ||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | 980 | (221) | ||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | ||||
Net assets (liabilities) [abstract] | ||||
Gains (losses) recognised in profit or loss, fair value measurement, assets (liabilities) net | (1) | (1) | ||
Corporate debt | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 1,205 | |||
Ending balance, financial assets | 1,171 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (21) | |||
Ending balance, financial liabilities | (13) | |||
Non-asset backed loans | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 6,405 | |||
Ending balance, financial assets | 8,660 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | 0 | |||
Equity cash products | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 393 | |||
Ending balance, financial assets | 422 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | 0 | |||
Ending balance, financial liabilities | (3) | |||
Private equity investments | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 1,095 | |||
Ending balance, financial assets | 1,297 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (6) | |||
Ending balance, financial liabilities | (8) | |||
Other | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 2,369 | |||
Ending balance, financial assets | 1,867 | |||
Categories of financial liabilities [abstract] | ||||
Beginning balance, financial liabilities | (238) | |||
Ending balance, financial liabilities | (317) | |||
Trading portfolio assets | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 2,281 | 1,863 | ||
Purchases, fair value measurement, assets | 2,957 | 1,071 | ||
Sales, fair value measurement, assets | (781) | (529) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (319) | (135) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 284 | 398 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (291) | (175) | ||
Ending balance, financial assets | 4,256 | 2,552 | ||
Trading portfolio assets | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 125 | 59 | ||
Trading portfolio assets | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 454 | 686 | ||
Purchases, fair value measurement, assets | 72 | 112 | ||
Sales, fair value measurement, assets | (80) | (294) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (297) | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 100 | 43 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (66) | (48) | ||
Ending balance, financial assets | 163 | 489 | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | (20) | (10) | ||
Trading portfolio assets | Asset backed securities | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 389 | 151 | ||
Purchases, fair value measurement, assets | 90 | 305 | ||
Sales, fair value measurement, assets | (144) | (87) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (17) | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 43 | 40 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (11) | (11) | ||
Ending balance, financial assets | 404 | 423 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 54 | 25 | ||
Trading portfolio assets | Corporate debt | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 758 | 709 | ||
Purchases, fair value measurement, assets | 2,448 | 620 | ||
Sales, fair value measurement, assets | (459) | (131) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (84) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 50 | 124 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (113) | (106) | ||
Ending balance, financial assets | 2,695 | 1,145 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 11 | 13 | ||
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 303 | 214 | ||
Purchases, fair value measurement, assets | 21 | 13 | ||
Sales, fair value measurement, assets | (56) | (17) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 52 | 29 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (17) | (9) | ||
Ending balance, financial assets | 327 | 262 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 24 | 32 | ||
Trading portfolio assets | Equity cash products | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Trading portfolio assets | Other | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 377 | 103 | ||
Purchases, fair value measurement, assets | 326 | 21 | ||
Sales, fair value measurement, assets | (42) | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (5) | (51) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 39 | 162 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (84) | (1) | ||
Ending balance, financial assets | 667 | 233 | ||
Trading portfolio assets | Other | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 56 | (1) | ||
Trading portfolio assets | Other | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 9,712 | 8,506 | ||
Purchases, fair value measurement, assets | 6,763 | 3,255 | ||
Sales, fair value measurement, assets | (6,352) | (2,891) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (641) | (857) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 210 | 86 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (32) | (119) | ||
Ending balance, financial assets | 9,582 | 7,777 | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | (236) | (314) | ||
Financial assets at fair value through the income statement | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 158 | 111 | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 5,647 | 5,580 | ||
Purchases, fair value measurement, assets | 1,847 | 698 | ||
Sales, fair value measurement, assets | (757) | (299) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (484) | (687) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 52 | 69 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (9) | (48) | ||
Ending balance, financial assets | 5,962 | 5,194 | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | (334) | (119) | ||
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 90 | 326 | ||
Purchases, fair value measurement, assets | 0 | 160 | ||
Sales, fair value measurement, assets | 0 | (194) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 1 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 95 | 140 | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 3 | (171) | ||
Financial assets at fair value through the income statement | Equity cash products | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 2 | 18 | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 1,095 | 874 | ||
Purchases, fair value measurement, assets | 99 | 106 | ||
Sales, fair value measurement, assets | (16) | (9) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (1) | (8) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 59 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (4) | (71) | ||
Ending balance, financial assets | 1,290 | 979 | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 84 | (5) | ||
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | (26) | 92 | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 2,880 | 1,726 | ||
Purchases, fair value measurement, assets | 4,817 | 2,291 | ||
Sales, fair value measurement, assets | (5,579) | (2,389) | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | (156) | (162) | ||
Total gains or losses recognised in OCI, assets | 0 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 99 | 16 | ||
Transfers out of Level 3 of fair value hierarchy, assets | (19) | 0 | ||
Ending balance, financial assets | 2,235 | 1,464 | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 11 | (19) | ||
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 182 | 1 | ||
Assets at fair value through other comprehensive income | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 38 | 153 | ||
Purchases, fair value measurement, assets | 0 | 4 | ||
Sales, fair value measurement, assets | 0 | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (5) | ||
Total gains or losses recognised in OCI, assets | (1) | 2 | ||
Transfers into Level 3 of fair value hierarchy, assets | 6 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (106) | ||
Ending balance, financial assets | 43 | 48 | ||
Assets at fair value through other comprehensive income | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Assets at fair value through other comprehensive income | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 38 | 47 | ||
Purchases, fair value measurement, assets | 0 | 4 | ||
Sales, fair value measurement, assets | 0 | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | (5) | ||
Total gains or losses recognised in OCI, assets | (2) | 2 | ||
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | ||
Ending balance, financial assets | 36 | 48 | ||
Assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Assets at fair value through other comprehensive income | Asset backed securities | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | (Level 3) | ||||
Categories of financial assets [abstract] | ||||
Beginning balance, financial assets | 0 | 106 | ||
Purchases, fair value measurement, assets | 0 | 0 | ||
Sales, fair value measurement, assets | 0 | 0 | ||
Issues, fair value measurement, assets | 0 | 0 | ||
Settlements, fair value measurement, assets | 0 | 0 | ||
Total gains or losses recognised in OCI, assets | 1 | 0 | ||
Transfers into Level 3 of fair value hierarchy, assets | 6 | 0 | ||
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (106) | ||
Ending balance, financial assets | 7 | 0 | ||
Assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category trading | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | 0 | 0 | ||
Assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | (Level 3) | Financial assets at fair value through profit or loss, category other income | ||||
Categories of financial assets [abstract] | ||||
Total gains and losses in the period recognised in the income statement, assets | £ 0 | £ 0 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Fair value of financial instr_6
Fair value of financial instruments - Unrealised gains and losses recognised in the period on Level 3 assets and liabilities held at period end (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | ||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | £ 5,013 | £ 3,482 | [1] |
Other income | 120 | 72 | [1] |
Other compre hensive income | (929) | (1,600) | [2] |
(Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | 769 | (532) | |
Other income | (24) | 114 | |
Other compre hensive income | (1) | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | 744 | (418) | |
(Level 3) | Investment properties | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | 0 | 0 | |
Other income | (1) | 0 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | (1) | 0 | |
(Level 3) | Net derivative financial instruments | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | 862 | (367) | |
Other income | (1) | 0 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | 861 | (367) | |
Trading portfolio liabilities | (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | (35) | (6) | |
Other income | 0 | 0 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | (35) | (6) | |
Financial liabilities designated at fair value | (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | (14) | 7 | |
Other income | 0 | 0 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | (14) | 7 | |
Trading portfolio assets | (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | 121 | 35 | |
Other income | 0 | 0 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | 121 | 35 | |
Financial assets at fair value through the income statement | (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | (165) | (201) | |
Other income | (22) | 114 | |
Other compre hensive income | 0 | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | (187) | (87) | |
Assets at fair value through other comprehensive income | (Level 3) | |||
Disclosure of detailed information about financial instruments [line items] | |||
Trading income | 0 | 0 | |
Other income | 0 | 0 | |
Other compre hensive income | (1) | 0 | |
Total unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | £ (1) | £ 0 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Fair value of financial instr_7
Fair value of financial instruments - Sensitivity analysis of valuations using unobservable inputs (Details) - (Level 3) - Recurring fair value measurement - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 1,014 | £ 880 |
Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 1 | 0 |
Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1,177) | (1,005) |
Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1) | 0 |
Corporate debt | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 36 | 38 |
Corporate debt | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Corporate debt | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (35) | (28) |
Corporate debt | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Non-asset backed loans | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 298 | 165 |
Non-asset backed loans | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Non-asset backed loans | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (334) | (256) |
Non-asset backed loans | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity cash products | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 73 | 42 |
Equity cash products | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity cash products | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (129) | (61) |
Equity cash products | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Private equity investments | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 272 | 246 |
Private equity investments | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 1 | 0 |
Private equity investments | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (286) | (236) |
Private equity investments | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1) | 0 |
Other | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 27 | 20 |
Other | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Other | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (36) | (19) |
Other | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 75 | 51 |
Interest rate derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (108) | (79) |
Interest rate derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 15 | 20 |
Foreign exchange derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (22) | (28) |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 111 | 111 |
Credit derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (115) | (103) |
Credit derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 107 | 187 |
Equity derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (112) | (195) |
Equity derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 0 | £ 0 |
Fair value of financial instr_8
Fair value of financial instruments - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Dec. 31, 2021 | ||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | £ 568,670 | £ 519,433 | [1] |
Brokered certificates of deposit | |||
Disclosure of detailed information about financial instruments [line items] | |||
Deposits at amortised cost | 3,065 | 790 | |
(Level 3) | Recurring fair value measurement | Favourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Increase in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | 1,015 | 880 | |
(Level 3) | Recurring fair value measurement | Unfavourable changes | |||
Disclosure of detailed information about financial instruments [line items] | |||
Decrease in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | 1,178 | 1,005 | |
Exit price adjustments derived from market bid-offer spreads | |||
Disclosure of detailed information about financial instruments [line items] | |||
(Increase) decrease in fair value adjustments of derivatives | 33 | ||
Fair value adjustments | (539) | (506) | |
Uncollateralised derivative funding | |||
Disclosure of detailed information about financial instruments [line items] | |||
(Increase) decrease in fair value adjustments of derivatives | 45 | ||
Fair value adjustments | (82) | (127) | |
Derivative credit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
(Increase) decrease in fair value adjustments of derivatives | 176 | ||
Fair value adjustments | (388) | (212) | |
Derivative debit valuation adjustments | |||
Disclosure of detailed information about financial instruments [line items] | |||
(Increase) decrease in fair value adjustments of derivatives | 117 | ||
Fair value adjustments | 208 | 91 | |
Financial instruments at fair value, category | (Level 3) | Recurring fair value measurement | |||
Disclosure of detailed information about financial instruments [line items] | |||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 117 | 133 | |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 19 | 59 | |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 35 | 42 | |
Financial instruments at amortised cost, category | (Level 3) | Recurring fair value measurement | |||
Disclosure of detailed information about financial instruments [line items] | |||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 221 | 230 | |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 0 | 0 | |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | £ 9 | £ 17 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Fair value of financial instr_9
Fair value of financial instruments - Fair value adjustments (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Exit price adjustments derived from market bid-offer spreads | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ (539) | £ (506) |
Uncollateralised derivative funding | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (82) | (127) |
Derivative credit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (388) | (212) |
Derivative debit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ 208 | £ 91 |
Fair value of financial inst_10
Fair value of financial instruments - Comparison of carrying amounts and fair values for assets and liabilities not held at fair value (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Categories of financial assets [abstract] | ||||
Loans and advances at amortised cost | £ 395,824 | £ 361,451 | [1] | |
Reverse repurchase agreements and other similar secured lending | 1,639 | 3,227 | [1] | |
Categories of financial liabilities [abstract] | ||||
Deposits at amortised cost | (568,670) | (519,433) | [1] | |
Repurchase agreements and other similar secured borrowing | (28,566) | (28,352) | [1] | |
Debt securities in issue | (115,906) | (98,867) | [1] | |
Subordinated liabilities | (11,871) | (12,759) | [1] | £ (16,341) |
Fair value | ||||
Categories of financial assets [abstract] | ||||
Loans and advances at amortised cost | 396,475 | 362,424 | ||
Reverse repurchase agreements and other similar secured lending | 1,639 | 3,227 | ||
Categories of financial liabilities [abstract] | ||||
Deposits at amortised cost | (568,715) | (519,436) | ||
Repurchase agreements and other similar secured borrowing | (28,569) | (28,358) | ||
Debt securities in issue | (115,777) | (100,657) | ||
Subordinated liabilities | (11,799) | (13,334) | ||
Carrying amount | ||||
Categories of financial assets [abstract] | ||||
Loans and advances at amortised cost | 395,824 | 361,451 | ||
Reverse repurchase agreements and other similar secured lending | 1,639 | 3,227 | ||
Categories of financial liabilities [abstract] | ||||
Deposits at amortised cost | (568,670) | (519,433) | ||
Repurchase agreements and other similar secured borrowing | (28,566) | (28,352) | ||
Debt securities in issue | (115,906) | (98,867) | ||
Subordinated liabilities | £ (11,871) | £ (12,759) | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Loans and advances and deposi_3
Loans and advances and deposits at amortised cost (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | £ 568,670 | £ 519,433 |
Banks | Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 29,891 | 17,819 |
Customers | Deposits | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total deposits at amortised cost | 538,779 | 501,614 |
Total loans and advances at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 395,824 | 361,451 |
Total loans and advances at amortised cost | Banks | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 12,532 | 9,698 |
Total loans and advances at amortised cost | Customers | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | 337,220 | 319,922 |
Debt securities at amortised cost | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total loans and advances at amortised cost | £ 46,072 | £ 31,831 |
Goodwill and intangible asset_2
Goodwill and intangible assets (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | £ 3,912 | £ 3,893 | |
Intangibles | 4,333 | 4,168 | |
Total | 8,245 | 8,061 | [1] |
Head Office | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 44 | 42 | |
Intangibles | 7 | 5 | |
Total | 51 | 47 | |
Barclays UK | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 3,560 | 3,560 | |
Intangibles | 1,247 | 1,233 | |
Total | 4,807 | 4,793 | |
Barclays International | |||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | |||
Goodwill | 308 | 291 | |
Intangibles | 3,079 | 2,930 | |
Total | £ 3,387 | £ 3,221 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Subordinated liabilities (Detai
Subordinated liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Dec. 31, 2021 | |||
Subordinated liabilities [abstract] | ||||
Opening balance as at 1 January | £ 12,759 | [1] | £ 16,341 | |
Issuances | 259 | 1,890 | ||
Redemptions | (1,180) | (4,807) | ||
Other | 33 | (665) | ||
Closing balance | £ 11,871 | £ 12,759 | [1] | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Subordinated liabilities - Narr
Subordinated liabilities - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 259 | £ 1,890 |
Redemption of subordinated debt | 1,180 | £ 4,807 |
Barclays Plc | USD floating rate notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 128 | |
Barclays Plc | ZAR floating rate notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 89 | |
Other subsidiaries | USD floating rate notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | 74 | |
Other subsidiaries | EUR floating rate notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 42 | |
Other subsidiaries | GBP undated secured subordinated loan notes | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | 67 | |
Barclays Bank PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 1,039 | |
Barclays Bank PLC | Subordinated notes | ||
Disclosure of detailed information about borrowings [line items] | ||
Redemption of subordinated debt | 1,039 | |
Barclays Bank PLC | 6.625% fixed rate subordinated notes | Fixed interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 838 | |
Borrowings, interest rate | 6.625% | |
Barclays Bank PLC | 6.86% callable perpetual core T1 notes | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 147 | |
Borrowings, interest rate | 6.86% | |
Barclays Bank PLC | Subordinated floating rate notes | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 42 | |
Barclays Bank PLC | 6% callable perpetual ore T1 notes | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 12 | |
Borrowings, interest rate | 6% |
Provisions - Total Provisions (
Provisions - Total Provisions (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | |
Disclosure of other provisions [line items] | |||
Provisions | £ 3,426 | £ 1,908 | [1] |
Customer redress | |||
Disclosure of other provisions [line items] | |||
Provisions | 1,985 | 530 | |
Legal, competition and regulatory matters | |||
Disclosure of other provisions [line items] | |||
Provisions | 418 | 226 | |
Redundancy and restructuring | |||
Disclosure of other provisions [line items] | |||
Provisions | 216 | 326 | |
Undrawn contractually committed facilities and guarantees | |||
Disclosure of other provisions [line items] | |||
Provisions | 526 | 542 | |
Onerous contracts | |||
Disclosure of other provisions [line items] | |||
Provisions | 0 | 5 | |
Sundry provisions | |||
Disclosure of other provisions [line items] | |||
Provisions | £ 281 | £ 279 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Provisions - Narrative (Details
Provisions - Narrative (Details) £ in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 GBP (£) | Mar. 31, 2022 GBP (£) | Jun. 30, 2022 GBP (£) | Jun. 30, 2022 USD ($) | Dec. 31, 2021 GBP (£) | |
Disclosure of other provisions [line items] | |||||
Increase in existing provisions, other provisions | £ 1,372 | ||||
Over-issuance of securities | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | £ 1,757 | £ 1,757 | £ 220 | ||
Over-issuance of structured notes | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | 1,592 | 220 | |||
Accrued income including contract assets | 34 | £ 34 | |||
Securities issued in excess of limit | $ | $ 60 | ||||
Recission right | |||||
Disclosure of other provisions [line items] | |||||
Increase (decrease) in other provisions | £ 165 | £ 0 |
Retirement benefits (Narrative)
Retirement benefits (Narrative) (Details) - GBP (£) £ in Millions | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of fair value of plan assets [line items] | |||
Surplus (deficit) in plan | £ (4,900) | £ (3,600) | |
Future commitments | |||
Disclosure of fair value of plan assets [line items] | |||
Possible decrease in capital ratio | 0.30% | ||
United Kingdom | Financial assets at amortised cost | Senior notes | |||
Disclosure of fair value of plan assets [line items] | |||
Notional amount | 1,250 | ||
Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | Pension defined benefit plans | United Kingdom | |||
Disclosure of fair value of plan assets [line items] | |||
Surplus (deficit) in plan | £ (5,200) | £ (3,800) |
Retirement benefits - UKRF fund
Retirement benefits - UKRF funding valuations (Details) - GBP (£) £ in Millions | 1 Months Ended | 6 Months Ended | ||
Apr. 30, 2021 | Jun. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2020 | |
Disclosure of fair value of plan assets [line items] | ||||
Surplus (deficit) in plan | £ (4,900) | £ (3,600) | ||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | ||||
Disclosure of fair value of plan assets [line items] | ||||
Surplus (deficit) in plan | (5,200) | £ (3,800) | ||
Employer contributions | £ 147 | 700 | ||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Deficit contributions 30 September 2019 valuation | ||||
Disclosure of fair value of plan assets [line items] | ||||
Surplus (deficit) in plan | £ 900 | |||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Deficit contributions valuation recovery plan 2020 | ||||
Disclosure of fair value of plan assets [line items] | ||||
Surplus (deficit) in plan | 600 | |||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | 2022 | Barclays Bank PLC | ||||
Disclosure of fair value of plan assets [line items] | ||||
Employer contributions | 294 | |||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | 2023 | Barclays Bank PLC | ||||
Disclosure of fair value of plan assets [line items] | ||||
Employer contributions | 286 | |||
Pension defined benefit plans | Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | United Kingdom | Later than one month and not later than three months | ||||
Disclosure of fair value of plan assets [line items] | ||||
Estimate of contributions expected to be paid to plan for next annual reporting period | £ 147 |
Called up share capital (Detail
Called up share capital (Details) - GBP (£) | 6 Months Ended | ||||||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | |||||
Beginning Balance, equity | £ 70,041,000,000 | [1] | £ 68,056,000,000 | [2] | £ 66,882,000,000 | [2] | |
Issue of shares under employee share schemes | 450,000,000 | (19,000,000) | 314,000,000 | [2] | |||
Repurchase of shares | (432,000,000) | (500,000,000) | (700,000,000) | [2] | |||
Ending Balance, equity | 70,596,000,000 | 70,041,000,000 | [1] | 68,056,000,000 | [2] | ||
Share premium | |||||||
Beginning Balance, equity | 348,000,000 | ||||||
Issue of shares under employee share schemes | 27,000,000 | ||||||
Ending Balance, equity | 375,000,000 | 348,000,000 | |||||
Total share capital and share premium | |||||||
Beginning Balance, equity | 4,536,000,000 | [3] | 4,568,000,000 | [3],[4] | 4,637,000,000 | [4] | |
Issue of shares under employee share schemes | 33,000,000 | [3] | 35,000,000 | [3] | 25,000,000 | [4] | |
Repurchase of shares | (61,000,000) | [3] | (67,000,000) | [3] | (94,000,000) | [4] | |
Ending Balance, equity | [3] | 4,508,000,000 | 4,536,000,000 | £ 4,568,000,000 | [4] | ||
Ordinary share capital | |||||||
Beginning Balance, equity | 4,188,000,000 | ||||||
Issue of shares under employee share schemes | 6,000,000 | ||||||
Repurchase of shares | (61,000,000) | ||||||
Ending Balance, equity | £ 4,133,000,000 | £ 4,188,000,000 | |||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 89 90 89 91 |
Called up share capital (Narrat
Called up share capital (Narrative) (Details) - GBP (£) £ / shares in Units, £ in Millions, shares in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Repurchase of treasury shares (in shares) | 244 | |
Future commitments | ||
Payments to acquire or redeem entity's shares | £ 1,000 | |
Ordinary share capital | ||
Number of shares issued (in shares) | 16,531 | 16,752 |
Par value per share (in GBP per share) | £ 0.25 | £ 0.25 |
Other equity instruments (Detai
Other equity instruments (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended | ||||||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2021 | |||||
Opening balance as at 1 January | £ 12,259 | [1] | £ 11,172 | £ 11,172 | ||||
Securities held by the Group | (8) | £ 15 | (29) | [2] | ||||
Closing balance | 12,357 | 12,259 | [1] | 12,259 | [1] | |||
Other equity instruments | ||||||||
Issuances | 1,247 | 1,078 | ||||||
Redemptions | (1,132) | 0 | ||||||
Securities held by the Group | £ (17) | [3] | £ 14 | [3] | £ (5) | [4] | £ 9 | |
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 89 90 89 91 |
Other equity instruments (Narra
Other equity instruments (Narrative) (Details) £ in Millions | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) | Jun. 30, 2021 GBP (£) | Dec. 31, 2020 GBP (£) | ||||
Total equity | £ 70,596 | £ 70,041 | [1] | £ 68,056 | [2] | £ 66,882 | [2] | |
Barclays Plc | ||||||||
Total equity | 57,758 | 57,837 | ||||||
Other equity instruments | ||||||||
Total equity | £ 12,357 | [3] | £ 12,259 | [3] | £ 11,167 | [3],[4] | £ 11,172 | [4] |
AT1 Securities | Barclays Plc | ||||||||
Convertible instruments, conversion ratio minimum | 0.07 | |||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 89 90 89 91 |
Other reserves (Details)
Other reserves (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | |
Disclosure of reserves within equity [line items] | ||||
Other reserves | £ (218) | £ 1,770 | [1] | |
Currency translation reserve | ||||
Disclosure of reserves within equity [line items] | ||||
Other reserves | 4,443 | 2,740 | ||
Fair value through other comprehensive income reserve | ||||
Disclosure of reserves within equity [line items] | ||||
Other reserves | (1,081) | (283) | £ (1,081) | |
Cash flow hedging reserve | ||||
Disclosure of reserves within equity [line items] | ||||
Other reserves | (4,671) | (853) | ||
Own credit reserve | ||||
Disclosure of reserves within equity [line items] | ||||
Other reserves | (103) | (960) | £ (103) | |
Other reserves and treasury shares | ||||
Disclosure of reserves within equity [line items] | ||||
Other reserves | £ 1,194 | £ 1,126 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Other reserves - Narrative (Det
Other reserves - Narrative (Details) - GBP (£) £ in Millions, shares in Millions | 6 Months Ended | 12 Months Ended | |||||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2021 | ||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | £ 218 | £ (1,770) | [1] | £ (1,770) | [1] | ||
Securities held by the Group | £ (8) | 15 | £ (29) | [2] | |||
Repurchase of treasury shares (in shares) | 244 | ||||||
Future commitments | |||||||
Disclosure of reserves within equity [line items] | |||||||
Payments to acquire or redeem entity's shares | 1,000 | ||||||
Absa Group Limited | |||||||
Disclosure of reserves within equity [line items] | |||||||
Shares sold as percentage of total shares | 745% | ||||||
Currency translation reserve | |||||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | £ (4,443) | (2,740) | (2,740) | ||||
Movements | 1,703 | ||||||
Fair value through other comprehensive income reserve | |||||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | 1,081 | 283 | 1,081 | 283 | |||
Movements | (798) | ||||||
Gains (losses) on financial assets measured at fair value through other comprehensive income, before tax | (1,237) | ||||||
Reclassification adjustments on financial assets measured at fair value through other comprehensive income, before tax | 5 | ||||||
Tax | 326 | ||||||
Fair value through other comprehensive income reserve | Absa Group Limited | |||||||
Disclosure of reserves within equity [line items] | |||||||
Gains (losses) on financial assets measured at fair value through other comprehensive income, before tax | 153 | ||||||
Reclassification adjustments on financial assets measured at fair value through other comprehensive income, before tax | 39 | ||||||
Cash flow hedging reserve | |||||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | 4,671 | 853 | 853 | ||||
Movements | 3,818 | ||||||
Gains (losses) on financial assets measured at fair value through other comprehensive income, before tax | 4,747 | ||||||
Reclassification adjustments on financial assets measured at fair value through other comprehensive income, before tax | 429 | ||||||
Tax | 1,358 | ||||||
Own credit reserve | |||||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | 103 | 960 | £ 103 | 960 | |||
Movements | 857 | ||||||
Tax | 403 | ||||||
Gains (losses) on change in value of foreign currency basis spreads, before tax | 1,258 | ||||||
Other reserves and treasury shares | |||||||
Disclosure of reserves within equity [line items] | |||||||
Reserves | (1,194) | £ (1,126) | £ (1,126) | ||||
Movements | 61 | ||||||
Treasury shares | |||||||
Disclosure of reserves within equity [line items] | |||||||
Movements | £ 7 | ||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Contingent liabilities and co_3
Contingent liabilities and commitments (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 22,340 | £ 21,346 |
Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 397,926 | 345,711 |
Guarantees and letters of credit pledged as collateral security | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 16,463 | 15,549 |
Performance guarantees, acceptances and endorsements | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 5,877 | 5,797 |
Documentary credits and other short-term trade related transactions | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 1,888 | 1,584 |
Standby facilities, credit lines and other commitments | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 396,038 | £ 344,127 |
Legal, competition and regula_2
Legal, competition and regulatory matters (Narrative) (Details) $ in Thousands, € in Millions, £ in Millions, SFr in Millions | 1 Months Ended | 3 Months Ended | 5 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||
Jun. 30, 2022 GBP (£) | Jun. 30, 2022 lawsuits | Apr. 30, 2021 USD ($) | Jun. 30, 2019 CHF (SFr) settlement | May 31, 2019 EUR (€) settlement | Jan. 31, 2017 lawsuits | Mar. 31, 2022 GBP (£) | May 31, 2021 USD ($) | Jun. 30, 2022 GBP (£) lawsuits settlement plaintiff | Jun. 30, 2022 USD ($) lawsuits settlement plaintiff | Jun. 30, 2021 GBP (£) | [1] | Dec. 31, 2021 GBP (£) | Dec. 31, 2020 USD ($) pensionFund defendant | Dec. 31, 2018 GBP (£) | Dec. 31, 2016 USD ($) lawsuits | Dec. 31, 2015 USD ($) | Dec. 31, 2013 GBP (£) | Dec. 31, 2008 USD ($) agreement | |
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | £ | £ 1,857 | £ 176 | £ 397 | ||||||||||||||||
Over-issuance of securities | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Increase (decrease) in other provisions | £ | £ 1,757 | £ 1,757 | 220 | ||||||||||||||||
Over-issuance of structured notes | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Increase (decrease) in other provisions | £ | £ 1,592 | 220 | |||||||||||||||||
USD LIBOR Cases in MDL Court | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of settlements | settlement | 2 | 2 | |||||||||||||||||
Sterling LIBOR Case in SDNY | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 2 | ||||||||||||||||||
Non-US forex civil actions | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 2 | 2 | |||||||||||||||||
Foreign exchange investigations | Securities and Exchange Commission | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | SFr | SFr 27 | ||||||||||||||||||
Foreign exchange investigations | Fines settlement | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of settlements | settlement | 2 | 2 | |||||||||||||||||
Losses on litigation settlements | € 210 | 54 | |||||||||||||||||
Metals related civil actions | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | £ | £ 50 | ||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by acquired subsidiary | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 2 | 2 | |||||||||||||||||
Number of settlements | settlement | 2 | 2 | |||||||||||||||||
Number of lawsuits dismissed | 1 | ||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 32,500 | ||||||||||||||||||
Number of defendants | defendant | 6 | ||||||||||||||||||
Asset-backed debt instruments held | $ | $ 22,000 | ||||||||||||||||||
US residential and commercial mortgage-related activity and litigation | Legacy RMBS purchases | New Mexico | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of retirement benefit funds | pensionFund | 2 | ||||||||||||||||||
Supranational, sovereign and agency bonds civil actions | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits dismissed | 1 | 1 | |||||||||||||||||
Civil actions in respect of VRDO - private plaintiffs | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 2 | 2 | |||||||||||||||||
Civil actions in respect of VRDO - SNDY | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 3 | 3 | |||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - EDNY | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 6 | 6 | |||||||||||||||||
Number of lawsuits dismissed | 3 | 3 | |||||||||||||||||
Number of plaintiffs | plaintiff | 4,000 | 4,000 | |||||||||||||||||
Number of lawsuits subject to appeal | 1 | 1 | |||||||||||||||||
Civil actions in respect of the US Anti-Terrorism Act - SDNY | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 2 | 2 | |||||||||||||||||
Derivative transactions civil action | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 329 | ||||||||||||||||||
CFS remediation of ASL loans | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Expected reimbursement, other provisions | £ | £ 181 | ||||||||||||||||||
HMRC assessments concerning UK VAT | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 181 | ||||||||||||||||||
HMRC assessments concerning UK VAT | Barclays UK | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | 128 | ||||||||||||||||||
Investigation Into The Use Of Unapproved Communications Platforms | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Civil monetary penalty to SEC | £ | £ 125 | ||||||||||||||||||
Civil monetary penalty to CFTC | £ | £ 75 | ||||||||||||||||||
Barclays Bank PLC | FCA Proceedings and other investigations | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of advisory service agreements | agreement | 2 | ||||||||||||||||||
Loss contingency, financial penalty warning | £ | £ 50 | ||||||||||||||||||
Barclays Bank PLC | USD LIBOR Cases in MDL Court | Lawsuits with specified damages sought | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits with specified damages sought | 1 | 1 | |||||||||||||||||
Loss contingency, damages sought, claimed amounts, value | $ | $ 100,000 | ||||||||||||||||||
Barclays Bank PLC | USD LIBOR Cases in MDL Court | Exchange-based class claims | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 7,100 | 7,500 | |||||||||||||||||
Barclays Bank PLC | USD LIBOR Cases in MDL Court | Debt securities class claims | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 20,000 | 1,950 | |||||||||||||||||
Barclays Bank PLC | Japanese Yen LIBOR civil actions | Exchange-based class claims | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 17,750 | ||||||||||||||||||
Barclays Bank PLC | SIBOR/SOR cases in SDNY | Exchange-based class claims | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 91,000 | ||||||||||||||||||
Barclays Bank PLC | Non-US forex civil actions | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Number of lawsuits pending | 1 | ||||||||||||||||||
Barclays Bank PLC | Foreign exchange investigations | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 2,380,000 | ||||||||||||||||||
Barclays Bank PLC | Consolidated FX action | Securities and Exchange Commission | Barclays Capital Inc | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Losses on litigation settlements | $ | $ 384,000 | ||||||||||||||||||
Barclays Bank PLC | BDC Finance LLC | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Litigation settlements approved, value | $ | $ 3,300 | $ 298,000 | |||||||||||||||||
Barclays Bank PLC | HMRC assessments concerning UK VAT | |||||||||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 53 | ||||||||||||||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Barclays PLC parent company b_3
Barclays PLC parent company balance sheet (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | [2] | Dec. 31, 2020 | ||
Assets | ||||||||
Loans and advances to subsidiaries | £ 395,824 | £ 361,451 | [1] | |||||
Financial assets at fair value through the income statement | 212,723 | 191,972 | [1] | |||||
Derivative financial instruments | 344,855 | 262,572 | [1] | |||||
Other assets | 4,666 | 3,785 | [1] | |||||
Total assets | 1,589,230 | 1,384,285 | [1] | |||||
Liabilities | ||||||||
Deposits at amortised cost | 568,670 | 519,433 | [1] | |||||
Debt securities in issue | 115,906 | 98,867 | [1] | |||||
Subordinated liabilities | 11,871 | 12,759 | [1] | £ 16,341 | ||||
Financial liabilities designated at fair value | 255,136 | 250,960 | [1] | |||||
Derivative financial instruments | 321,396 | 256,883 | [1] | |||||
Other liabilities | 11,538 | 10,505 | [1] | |||||
Total liabilities | 1,518,634 | 1,314,244 | [1] | |||||
Equity | ||||||||
Other equity instruments | 12,357 | £ 11,119 | 12,259 | [1] | 11,172 | |||
Other reserves | (218) | 1,770 | [1] | |||||
Retained earnings | 52,980 | 50,487 | [1] | |||||
Total equity | 70,596 | 70,041 | [1] | £ 68,056 | £ 66,882 | [2] | ||
Total liabilities and equity | 1,589,230 | 1,384,285 | [1] | |||||
Barclays Plc | ||||||||
Assets | ||||||||
Investment in subsidiaries | 63,633 | 62,528 | ||||||
Loans and advances to subsidiaries | 20,369 | 22,072 | ||||||
Financial assets at fair value through the income statement | 24,052 | 25,091 | ||||||
Derivative financial instruments | 5 | 4 | ||||||
Other assets | 235 | 68 | ||||||
Total assets | 108,294 | 109,763 | ||||||
Liabilities | ||||||||
Deposits at amortised cost | 545 | 488 | ||||||
Debt securities in issue | 22,389 | 25,658 | ||||||
Subordinated liabilities | 10,070 | 9,301 | ||||||
Financial liabilities designated at fair value | 16,888 | 16,319 | ||||||
Derivative financial instruments | 540 | 43 | ||||||
Other liabilities | 104 | 117 | ||||||
Total liabilities | 50,536 | 51,926 | ||||||
Equity | ||||||||
Called up share capital | 4,133 | 4,188 | ||||||
Share premium account | 375 | 348 | ||||||
Other equity instruments | 12,347 | 12,241 | ||||||
Other reserves | 616 | 555 | ||||||
Retained earnings | 40,287 | 40,505 | ||||||
Total equity | 57,758 | 57,837 | ||||||
Total liabilities and equity | £ 108,294 | £ 109,763 | ||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Barclays PLC parent company b_4
Barclays PLC parent company balance sheet (Narrative) (Details) € in Millions, shares in Millions, $ in Millions | 6 Months Ended | 12 Months Ended | ||||||||||
Jun. 30, 2022 GBP (£) shares | Jun. 30, 2022 EUR (€) shares | Jun. 30, 2022 USD ($) shares | Dec. 31, 2021 GBP (£) | Jun. 30, 2021 GBP (£) | Dec. 31, 2021 GBP (£) | Dec. 31, 2020 GBP (£) | ||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Loans and advances to subsidiaries | £ 395,824,000,000 | £ 361,451,000,000 | [1] | £ 361,451,000,000 | [1] | |||||||
Increase (decrease) through treasury share transactions, equity | 432,000,000 | 500,000,000 | £ 700,000,000 | [2] | ||||||||
Financial liabilities designated at fair value | 255,136,000,000 | 250,960,000,000 | [1] | 250,960,000,000 | [1] | |||||||
Issuance of subordinated debt | 259,000,000 | 1,890,000,000 | ||||||||||
Financial assets at fair value through the income statement | 212,723,000,000 | 191,972,000,000 | [1] | 191,972,000,000 | [1] | |||||||
Subordinated liabilities | 11,871,000,000 | 12,759,000,000 | [1] | 12,759,000,000 | [1] | £ 16,341,000,000 | ||||||
Debt securities in issue | 115,906,000,000 | 98,867,000,000 | [1] | 98,867,000,000 | [1] | |||||||
Total equity | 70,596,000,000 | 70,041,000,000 | [1] | 68,056,000,000 | [2] | 70,041,000,000 | [1] | 66,882,000,000 | [2] | |||
Employee share schemes and hedging thereof | 450,000,000 | (19,000,000) | 314,000,000 | [2] | ||||||||
Other reserves | (218,000,000) | 1,770,000,000 | [1] | 1,770,000,000 | [1] | |||||||
Ordinary share capital | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Increase (decrease) through treasury share transactions, equity | 61,000,000 | |||||||||||
Total equity | 4,133,000,000 | 4,188,000,000 | 4,188,000,000 | |||||||||
Employee share schemes and hedging thereof | 6,000,000 | |||||||||||
Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Investment in subsidiaries | 63,633,000,000 | 62,528,000,000 | 62,528,000,000 | |||||||||
Decrease in loans and advances to related parties | (1,703,000,000) | |||||||||||
Loans and advances to subsidiaries | 20,369,000,000 | 22,072,000,000 | 22,072,000,000 | |||||||||
Foreign exchange gain (loss) | 1,326,000,000 | |||||||||||
Increase (decrease) through treasury share transactions, equity | 397,000,000 | |||||||||||
Financial liabilities designated at fair value | 16,888,000,000 | 16,319,000,000 | 16,319,000,000 | |||||||||
Financial assets at fair value through the income statement | 24,052,000,000 | 25,091,000,000 | 25,091,000,000 | |||||||||
Subordinated liabilities | 10,070,000,000 | 9,301,000,000 | 9,301,000,000 | |||||||||
Foreign exchange loss | 819,000,000 | |||||||||||
Debt securities in issue | 22,389,000,000 | 25,658,000,000 | 25,658,000,000 | |||||||||
Total equity | 57,758,000,000 | 57,837,000,000 | 57,837,000,000 | |||||||||
Other reserves | 616,000,000 | 555,000,000 | 555,000,000 | |||||||||
Financial liabilities designated at fair value | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Financial liabilities designated at fair value | 16,888,000,000 | 16,319,000,000 | 16,319,000,000 | |||||||||
Other equity instruments | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Total equity | 12,357,000,000 | [3] | 12,259,000,000 | [3] | 11,167,000,000 | [3],[4] | 12,259,000,000 | [3] | 11,172,000,000 | [4] | ||
Issuances | 1,247,000,000 | 1,078,000,000 | ||||||||||
Reduction of issued capital | 1,132,000,000 | 0 | ||||||||||
AT1 Securities | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Movements | 106,000,000 | |||||||||||
Issuances | 1,250,000,000 | |||||||||||
Reduction of issued capital | 1,500,000,000 | |||||||||||
Total share capital and share premium | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Increase (decrease) through treasury share transactions, equity | 61,000,000 | [3] | 67,000,000 | [3] | 94,000,000 | [4] | ||||||
Total equity | 4,508,000,000 | [3] | 4,536,000,000 | [3] | 4,568,000,000 | [3],[4] | 4,536,000,000 | [3] | £ 4,637,000,000 | [4] | ||
Employee share schemes and hedging thereof | 33,000,000 | [3] | 35,000,000 | [3] | £ 25,000,000 | [4] | ||||||
Total share capital and share premium | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Total equity | £ 4,508,000,000 | 4,536,000,000 | 4,536,000,000 | |||||||||
Number of shares repurchased | shares | 244 | 244 | 244 | |||||||||
Net purchase of treasury shares | £ 61,000,000 | |||||||||||
Employee share schemes and hedging thereof | 33,000,000 | |||||||||||
Barclays Bank PLC | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Dividends received | 1,010,000,000 | |||||||||||
Barclays Bank PLC | Barclays Plc | Ordinary share capital | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Investment in subsidiaries | 36,340,000,000 | 35,590,000,000 | 35,590,000,000 | |||||||||
Barclays Bank PLC | Barclays Plc | AT1 Securities | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Investment in subsidiaries | 9,849,000,000 | 9,493,000,000 | 9,493,000,000 | |||||||||
Barclays UK | Barclays Plc | Ordinary share capital | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Investment in subsidiaries | 14,245,000,000 | 14,245,000,000 | 14,245,000,000 | |||||||||
Barclays UK | Barclays Plc | AT1 Securities | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Investment in subsidiaries | 2,570,000,000 | £ 2,570,000,000 | £ 2,570,000,000 | |||||||||
Senior debt | Barclays Bank PLC | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Cash receipts from repayment of advances and loans made to related parties | 2,296,000,000 | |||||||||||
Senior debt | Barclays UK | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Cash receipts from repayment of advances and loans made to related parties | £ 836,000,000 | |||||||||||
Subordinated notes | Financial liabilities designated at fair value | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Issuance of subordinated debt | € | € 2,250 | |||||||||||
Senior notes | Fixed interest rate | Financial liabilities designated at fair value | Barclays Plc | ||||||||||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||||||||||
Issuance of subordinated debt | $ | $ 400 | |||||||||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 89 90 89 91 |
Credit Risk - Loans and advance
Credit Risk - Loans and advances at amortised cost by stage (Details) £ in Millions, $ in Billions | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 GBP (£) | Jun. 30, 2021 GBP (£) | Dec. 31, 2021 GBP (£) | Dec. 31, 2021 USD ($) | |||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 794,418 | £ 709,164 | ||||
Coverage ratio | 0.008 | 0.009 | 0.009 | |||
Loan impairment charge/(release) | £ 341 | £ (742) | [1] | £ (653) | ||
Loan loss rate | 0.0017 | |||||
Loans and advances to subsidiaries | £ 395,824 | 361,451 | [2] | |||
Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 800,441 | 715,448 | ||||
Loans and advances to subsidiaries | 395,824 | 361,451 | ||||
Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (6,023) | (6,284) | ||||
Financial assets at fair value, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Exposure to credit risk on loan commitments and financial guarantee contracts | £ 21,100 | £ 18,800 | ||||
Stage 1 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.002 | 0.002 | 0.002 | |||
Stage 1 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 726,130 | £ 631,007 | ||||
Stage 1 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (1,559) | £ (1,423) | ||||
Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.032 | 0.031 | 0.031 | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 65,884 | £ 75,908 | ||||
Lifetime expected credit losses | Stage 2 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (2,097) | £ (2,317) | ||||
Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.281 | 0.298 | 0.298 | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 8,427 | £ 8,533 | ||||
Lifetime expected credit losses | Stage 3 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (2,367) | (2,544) | ||||
Total Barclays Group wholesale | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 4.3 | 6,000 | ||||
Total Barclays Group wholesale | Financial assets at amortised cost, class | Government [member] | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Loans and advances to subsidiaries | 8,100 | 9,400 | ||||
Head Office | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Loan impairment charge/(release) | (17) | (6) | ||||
Barclays UK | Operating segments | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Loan impairment charge/(release) | 48 | (443) | ||||
Barclays International | Operating segments | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Loan impairment charge/(release) | 310 | £ (293) | ||||
Total loans and advances at amortised cost | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 395,824 | £ 361,451 | ||||
Coverage ratio | 0.014 | 0.016 | 0.016 | |||
Loan impairment charge/(release) | £ 360 | £ (121) | ||||
Loan loss rate | 0.0018 | 0 | ||||
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 401,322 | £ 367,193 | ||||
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (5,498) | (5,742) | ||||
Total loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 351,302 | £ 317,659 | ||||
Coverage ratio | 0.004 | 0.004 | 0.004 | |||
Total loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 352,586 | £ 318,865 | ||||
Total loans and advances at amortised cost | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (1,284) | (1,206) | ||||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 39,591 | £ 39,078 | ||||
Coverage ratio | 0.045 | 0.049 | 0.049 | |||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 41,455 | £ 41,093 | ||||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (1,864) | (2,015) | ||||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 4,931 | £ 4,714 | ||||
Coverage ratio | 0.323 | 0.348 | 0.348 | |||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 7,281 | £ 7,235 | ||||
Total loans and advances at amortised cost | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (2,350) | (2,521) | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 224,219 | £ 216,917 | ||||
Coverage ratio | 0.019 | 0.021 | 0.021 | |||
Loan impairment charge/(release) | £ 249 | £ (46) | ||||
Loan loss rate | 0.0022 | 0 | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 228,660 | £ 221,496 | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (4,441) | £ (4,579) | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.005 | 0.005 | 0.005 | |||
Total loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 196,015 | £ 190,411 | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (899) | £ (866) | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.059 | 0.069 | 0.069 | |||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 27,271 | £ 25,899 | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (1,617) | £ (1,780) | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.358 | 0.373 | 0.373 | |||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 5,374 | £ 5,186 | ||||
Total loans and advances at amortised cost | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (1,925) | (1,933) | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 171,605 | £ 144,534 | ||||
Coverage ratio | 0.006 | 0.008 | 0.008 | |||
Loan impairment charge/(release) | £ 111 | £ (75) | ||||
Loan loss rate | 0.0013 | 0 | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 172,662 | £ 145,697 | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (1,057) | £ (1,163) | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.002 | 0.003 | 0.003 | |||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 156,571 | £ 128,454 | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (385) | £ (340) | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.017 | 0.015 | 0.015 | |||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 14,184 | £ 15,194 | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (247) | £ (235) | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.223 | 0.287 | 0.287 | |||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 1,907 | £ 2,049 | ||||
Total loans and advances at amortised cost | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (425) | (588) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 4,391 | £ 4,484 | ||||
Coverage ratio | 0.077 | 0.079 | 0.079 | |||
Loan impairment charge/(release) | £ (18) | £ 0 | ||||
Loan loss rate | 0 | 0 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 4,755 | £ 4,869 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (364) | £ (385) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.001 | 0.001 | 0.001 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 3,852 | £ 3,735 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (2) | £ (2) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.074 | 0.084 | 0.084 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 215 | £ 429 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (16) | £ (36) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.503 | 0.492 | 0.492 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 688 | £ 705 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (346) | (347) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 189 | £ 546 | ||||
Coverage ratio | 0.100 | 0.034 | 0.034 | |||
Loan impairment charge/(release) | £ 0 | £ 0 | ||||
Loan loss rate | 0 | 0 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 210 | £ 565 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (21) | £ (19) | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0 | 0 | 0 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 186 | £ 542 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 0 | £ 0 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0 | 0 | 0 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 1 | £ 2 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 0 | £ 0 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.913 | 0.905 | 0.905 | |||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 23 | £ 21 | ||||
Total loans and advances at amortised cost | Head Office | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (21) | (19) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 185,176 | £ 184,451 | ||||
Coverage ratio | 0.009 | 0.010 | 0.010 | |||
Loan impairment charge/(release) | £ 14 | £ (227) | ||||
Loan loss rate | 0.0002 | 0 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 186,927 | £ 186,389 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (1,751) | £ (1,938) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.001 | 0.002 | 0.002 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 160,110 | £ 160,695 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (218) | £ (261) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.033 | 0.042 | 0.042 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 23,805 | £ 22,779 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (780) | £ (949) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.250 | 0.250 | 0.250 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 3,012 | £ 2,915 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (753) | (728) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 38,747 | £ 38,150 | ||||
Coverage ratio | 0.008 | 0.008 | 0.008 | |||
Loan impairment charge/(release) | £ 36 | £ 122 | ||||
Loan loss rate | 0.0019 | 0.0032 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 39,044 | £ 38,457 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (297) | £ (307) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.004 | 0.004 | 0.004 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 35,915 | £ 35,571 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (131) | £ (153) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.022 | 0.022 | 0.022 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 2,267 | £ 1,917 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (49) | £ (43) | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.136 | 0.115 | 0.115 | |||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 862 | £ 969 | ||||
Total loans and advances at amortised cost | Barclays UK | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (117) | (111) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 34,652 | £ 27,982 | ||||
Coverage ratio | 0.063 | 0.075 | 0.075 | |||
Loan impairment charge/(release) | £ 253 | £ 181 | ||||
Loan loss rate | 0.0138 | 0.0060 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 36,978 | £ 30,238 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (2,326) | £ (2,256) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.021 | 0.023 | 0.023 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 32,053 | £ 25,981 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (679) | £ (603) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.253 | 0.295 | 0.295 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 3,251 | £ 2,691 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (821) | £ (795) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.493 | 0.548 | 0.548 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 1,674 | £ 1,566 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group retail | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (826) | (858) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 132,669 | £ 105,838 | ||||
Coverage ratio | 0.006 | 0.008 | 0.008 | |||
Loan impairment charge/(release) | £ 75 | £ (197) | ||||
Loan loss rate | 0.0011 | 0 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 133,408 | £ 106,675 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (739) | £ (837) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.002 | 0.002 | 0.002 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 120,470 | £ 92,341 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Stage 1 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (254) | £ (187) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.017 | 0.014 | 0.014 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 11,916 | £ 13,275 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (198) | £ (192) | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.281 | 0.432 | 0.432 | |||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 1,022 | £ 1,059 | ||||
Total loans and advances at amortised cost | Barclays International | Operating segments | Total Barclays Group wholesale | Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (287) | (458) | ||||
Off balance sheet loan commitments and financial guarantee contracts | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 398,594 | £ 347,713 | ||||
Coverage ratio | 0.001 | 0.002 | 0.002 | |||
Loan impairment charge/(release) | £ (42) | £ (514) | ||||
Off balance sheet loan commitments and financial guarantee contracts | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 399,119 | 348,255 | ||||
Off balance sheet loan commitments and financial guarantee contracts | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (525) | £ (542) | ||||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.001 | 0.001 | 0.001 | |||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 373,544 | £ 312,142 | ||||
Off balance sheet loan commitments and financial guarantee contracts | Stage 1 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (275) | £ (217) | ||||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.010 | 0.009 | 0.009 | |||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 24,429 | £ 34,815 | ||||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 2 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (233) | £ (302) | ||||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Coverage ratio | 0.015 | 0.018 | 0.018 | |||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ 1,146 | £ 1,298 | ||||
Off balance sheet loan commitments and financial guarantee contracts | Lifetime expected credit losses | Stage 3 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (17) | (23) | ||||
Other financial assets subject to impairment | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Loan impairment charge/(release) | 23 | (18) | ||||
Other financial assets subject to impairment | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 197,300 | 155,200 | ||||
Other financial assets subject to impairment | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (149) | (114) | ||||
Other financial assets subject to impairment | Stage 1 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 195,000 | 154,900 | ||||
Other financial assets subject to impairment | Stage 1 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (11) | (6) | ||||
Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 2,100 | 157,000 | $ (0.2) | |||
Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | (2) | (1) | ||||
Other assets | Lifetime expected credit losses | Stage 3 | Gross exposure | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | 143 | 110 | ||||
Other assets | Lifetime expected credit losses | Stage 3 | Impairment allowance | ||||||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||||||
Total impairment allowance4 | £ (136) | £ (107) | ||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 73 |
Credit Risk - Loans and advan_2
Credit Risk - Loans and advances at amortised cost by product (Details) £ in Millions | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) |
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 794,418 | £ 709,164 |
Coverage ratio | 0.008 | 0.009 |
Gross exposure | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 800,441 | £ 715,448 |
Impairment allowance | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (6,023) | (6,284) |
Financial assets at amortised cost, class | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 395,824 | £ 361,451 |
Coverage ratio | 0.014 | 0.016 |
Financial assets at amortised cost, class | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 171,269 | £ 169,205 |
Coverage ratio | 0.003 | 0.003 |
Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 48,769 | £ 41,793 |
Coverage ratio | 0.073 | 0.088 |
Financial assets at amortised cost, class | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 175,786 | £ 150,453 |
Coverage ratio | 0.007 | 0.008 |
Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 401,322 | £ 367,193 |
Financial assets at amortised cost, class | Gross exposure | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 171,727 | 169,680 |
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 52,632 | 45,822 |
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 176,963 | 151,691 |
Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (5,498) | (5,742) |
Financial assets at amortised cost, class | Impairment allowance | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (458) | (475) |
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (3,863) | (4,029) |
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ (1,177) | £ (1,238) |
Stage 1 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Stage 1 | Gross exposure | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 726,130 | £ 631,007 |
Stage 1 | Impairment allowance | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,559) | (1,423) |
Stage 1 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 351,302 | £ 317,659 |
Coverage ratio | 0.004 | 0.004 |
Stage 1 | Financial assets at amortised cost, class | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 150,864 | £ 148,039 |
Coverage ratio | 0 | 0 |
Stage 1 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 42,768 | £ 37,016 |
Coverage ratio | 0.020 | 0.022 |
Stage 1 | Financial assets at amortised cost, class | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 157,670 | £ 132,604 |
Coverage ratio | 0.003 | 0.003 |
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 352,586 | £ 318,865 |
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 150,883 | 148,058 |
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 43,628 | 37,840 |
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 158,075 | 132,967 |
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,284) | (1,206) |
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (19) | (19) |
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (860) | (824) |
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ (405) | £ (363) |
Lifetime expected credit losses | Stage 2 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 0.032 | 0.031 |
Lifetime expected credit losses | Stage 2 | Gross exposure | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 65,884 | £ 75,908 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (2,097) | (2,317) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 39,591 | £ 39,078 |
Coverage ratio | 0.045 | 0.049 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 18,693 | £ 19,441 |
Coverage ratio | 0.002 | 0.003 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 4,939 | £ 3,949 |
Coverage ratio | 0.239 | 0.301 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 15,959 | £ 15,688 |
Coverage ratio | 0.017 | 0.016 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Not past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 36,379 | £ 35,694 |
Coverage ratio | 0.043 | 0.048 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Not past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 16,240 | £ 17,087 |
Coverage ratio | 0.002 | 0.003 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Not past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 4,589 | £ 3,609 |
Coverage ratio | 0.225 | 0.293 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Not past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 15,550 | £ 14,998 |
Coverage ratio | 0.017 | 0.016 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Less than or equal to 30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 1,979 | £ 2,171 |
Coverage ratio | 0.052 | 0.042 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Less than or equal to 30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 1,694 | £ 1,654 |
Coverage ratio | 0.004 | 0.004 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Less than or equal to 30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 203 | £ 215 |
Coverage ratio | 0.330 | 0.283 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Less than or equal to 30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 82 | £ 302 |
Coverage ratio | 0.024 | 0.013 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | >30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 1,233 | £ 1,213 |
Coverage ratio | 0.098 | 0.099 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | >30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 759 | £ 700 |
Coverage ratio | 0.008 | 0.010 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | >30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 147 | £ 125 |
Coverage ratio | 0.462 | 0.496 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | >30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 327 | £ 388 |
Coverage ratio | 0.006 | 0.008 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 41,455 | £ 41,093 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 18,734 | 19,500 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 6,494 | 5,650 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 16,227 | 15,943 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Not past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 38,001 | 37,481 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Not past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 16,269 | 17,133 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Not past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 5,918 | 5,102 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Not past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 15,814 | 15,246 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Less than or equal to 30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 2,087 | 2,266 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Less than or equal to 30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 1,700 | 1,660 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Less than or equal to 30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 303 | 300 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Less than or equal to 30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 84 | 306 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | >30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 1,367 | 1,346 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | >30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 765 | 707 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | >30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 273 | 248 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | >30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 329 | 391 |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,864) | (2,015) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (41) | (59) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,555) | (1,701) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (268) | (255) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Not past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,622) | (1,787) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Not past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (29) | (46) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Not past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,329) | (1,493) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Not past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (264) | (248) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Less than or equal to 30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (108) | (95) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Less than or equal to 30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (6) | (6) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Less than or equal to 30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (100) | (85) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Less than or equal to 30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (2) | (4) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | >30 days past due | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (134) | (133) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | >30 days past due | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (6) | (7) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | >30 days past due | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (126) | (123) |
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | >30 days past due | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ (2) | £ (3) |
Lifetime expected credit losses | Stage 3 | ||
Disclosure of financial assets [line items] | ||
Coverage ratio | 0.281 | 0.298 |
Lifetime expected credit losses | Stage 3 | Gross exposure | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 8,427 | £ 8,533 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (2,367) | (2,544) |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 4,931 | £ 4,714 |
Coverage ratio | 0.323 | 0.348 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 1,712 | £ 1,725 |
Coverage ratio | 0.189 | 0.187 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 1,062 | £ 828 |
Coverage ratio | 0.577 | 0.645 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 2,157 | £ 2,161 |
Coverage ratio | 0.189 | 0.223 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ 7,281 | £ 7,235 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 2,110 | 2,122 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 2,510 | 2,332 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | 2,661 | 2,781 |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (2,350) | (2,521) |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (398) | (397) |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | (1,448) | (1,504) |
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Total impairment allowance4 | £ (504) | £ (620) |
Credit Risk - Movement in gross
Credit Risk - Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees (Details) £ in Millions, $ in Billions | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 GBP (£) | Jun. 30, 2021 GBP (£) | Dec. 31, 2021 GBP (£) | Dec. 31, 2021 USD ($) | ||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Income statement charge for the period | £ 341 | £ (742) | [1] | £ (653) | |
Total impairment allowance4 | (794,418) | (709,164) | |||
Financial guarantee contracts | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Post write-off recoveries | 36 | 31 | |||
Net release in ECL | 11 | 216 | |||
Total loans and advances at amortised cost | |||||
Loans and advances at amortised cost | |||||
Opening balance | 6,284 | ||||
Closing balance | 6,023 | 6,284 | |||
Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 475 | ||||
Closing balance | 458 | 475 | |||
Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 4,160 | ||||
Closing balance | 4,014 | 4,160 | |||
Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 1,649 | ||||
Closing balance | 1,551 | 1,649 | |||
Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Income statement charge for the period | (42) | (514) | |||
Total impairment allowance4 | (398,594) | (347,713) | |||
Other financial assets subject to impairment | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Income statement charge for the period | 23 | (18) | |||
Gross exposure | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (800,441) | (715,448) | |||
Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (6,366) | ||||
Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 7,830 | ||||
Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 19,362 | ||||
Gross exposure | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (399,119) | (348,255) | |||
Gross exposure | Other financial assets subject to impairment | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (197,300) | (155,200) | |||
Impairment allowance | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 6,023 | 6,284 | |||
Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | ||||
Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 25 | ||||
Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (36) | ||||
Impairment allowance | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 525 | 542 | |||
Impairment allowance | Other financial assets subject to impairment | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 149 | 114 | |||
Financial assets at amortised cost, class | Total loans and advances at amortised cost | |||||
Loans and advances at amortised cost | |||||
Write-offs | 768 | 1,001 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Income statement charge for the period | 360 | (121) | |||
Post write-off recoveries | 36 | 31 | |||
Net write-offs | 732 | 970 | |||
Total impairment allowance4 | (395,824) | (361,451) | |||
Financial assets at amortised cost, class | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (171,269) | (169,205) | |||
Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (48,769) | (41,793) | |||
Financial assets at amortised cost, class | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (175,786) | (150,453) | |||
Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (401,322) | (367,193) | |||
Financial assets at amortised cost, class | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 169,680 | ||||
Business activity in the period | 15,063 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,726) | ||||
Final repayments | 8,277 | ||||
Disposals | 0 | ||||
Write-offs | 13 | ||||
Closing balance | 171,727 | 169,680 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (171,727) | (169,680) | |||
Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 45,822 | ||||
Business activity in the period | 8,545 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2,185 | ||||
Final repayments | 3,064 | ||||
Disposals | 301 | ||||
Write-offs | 555 | ||||
Closing balance | 52,632 | 45,822 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (52,632) | (45,822) | |||
Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period | 1,400 | 1,900 | |||
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 151,691 | ||||
Business activity in the period | 30,705 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 12,943 | ||||
Final repayments | 18,099 | ||||
Disposals | 77 | ||||
Write-offs | 200 | ||||
Closing balance | 176,963 | 151,691 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (176,963) | (151,691) | |||
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Gross exposure | US cards | |||||
Loans and advances at amortised cost | |||||
Disposals | 200 | ||||
Financial assets at amortised cost, class | Gross exposure | Debt sales | |||||
Loans and advances at amortised cost | |||||
Disposals | 100 | ||||
Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | 653 | ||||
Recoveries and reimbursements | (47) | ||||
Exchange and other adjustments | (246) | ||||
Total impairment allowance4 | 5,498 | 5,742 | |||
Financial assets at amortised cost, class | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 475 | ||||
Business activity in the period | 5 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | ||||
Final repayments | (5) | ||||
Disposals | 0 | ||||
Write-offs | (13) | ||||
Closing balance | 458 | 475 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | (4) | ||||
Total impairment allowance4 | 458 | 475 | |||
Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 4,029 | ||||
Business activity in the period | 391 | ||||
Refinements to models used for calculation | (326) | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (166) | ||||
Final repayments | (79) | ||||
Disposals | (83) | ||||
Write-offs | (555) | ||||
Closing balance | 3,863 | 4,029 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | 472 | ||||
Total impairment allowance4 | 3,863 | 4,029 | |||
Net release in ECL | 200 | £ 300 | |||
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 1,238 | ||||
Business activity in the period | 68 | ||||
Refinements to models used for calculation | 482 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 704 | ||||
Final repayments | (105) | ||||
Disposals | (46) | ||||
Write-offs | (200) | ||||
Closing balance | 1,177 | 1,238 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
ECL movement excluding assets derecognised due to disposals and write-offs | 185 | ||||
Total impairment allowance4 | 1,177 | 1,238 | |||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Loans to government | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 500 | ||||
Stage 1 | Gross exposure | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (726,130) | (631,007) | |||
Stage 1 | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (6,354) | ||||
Stage 1 | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 9,385 | ||||
Stage 1 | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 17,712 | ||||
Stage 1 | Gross exposure | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (373,544) | (312,142) | |||
Stage 1 | Gross exposure | Other financial assets subject to impairment | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (195,000) | (154,900) | |||
Stage 1 | Impairment allowance | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 1,559 | 1,423 | |||
Stage 1 | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | ||||
Stage 1 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3 | ||||
Stage 1 | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) | ||||
Stage 1 | Impairment allowance | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 275 | 217 | |||
Stage 1 | Impairment allowance | Other financial assets subject to impairment | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 11 | 6 | |||
Stage 1 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (351,302) | (317,659) | |||
Stage 1 | Financial assets at amortised cost, class | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (150,864) | (148,039) | |||
Stage 1 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (42,768) | (37,016) | |||
Stage 1 | Financial assets at amortised cost, class | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (157,670) | (132,604) | |||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (352,586) | (318,865) | |||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 148,058 | ||||
Business activity in the period | 14,723 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,151) | ||||
Final repayments | 6,975 | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 150,883 | 148,058 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (150,883) | (148,058) | |||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (5,725) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 5,131 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (197) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 19 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 37,840 | ||||
Business activity in the period | 8,231 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,678 | ||||
Final repayments | 2,673 | ||||
Disposals | 151 | ||||
Write-offs | 0 | ||||
Closing balance | 43,628 | 37,840 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (43,628) | (37,840) | |||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (2,572) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 1,689 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (444) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 30 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 132,967 | ||||
Business activity in the period | 28,927 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 12,529 | ||||
Final repayments | 16,201 | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 158,075 | 132,967 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (158,075) | (132,967) | |||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (5,129) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 5,544 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (676) | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 114 | ||||
Stage 1 | Financial assets at amortised cost, class | Gross exposure | US cards | |||||
Loans and advances at amortised cost | |||||
Business activity in the period | 2,700 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 1,284 | 1,206 | |||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 19 | ||||
Business activity in the period | 4 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (22) | ||||
Final repayments | 0 | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 19 | 19 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 19 | 19 | |||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (1) | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 18 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 1 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 824 | ||||
Business activity in the period | 354 | ||||
Refinements to models used for calculation | (43) | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (691) | ||||
Final repayments | (23) | ||||
Disposals | (4) | ||||
Write-offs | 0 | ||||
Closing balance | 860 | 824 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 860 | 824 | |||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (67) | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 422 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (11) | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 13 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 363 | ||||
Business activity in the period | 40 | ||||
Refinements to models used for calculation | 66 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 79 | ||||
Final repayments | (29) | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 405 | 363 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 405 | 363 | |||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (29) | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 41 | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (3) | ||||
Stage 1 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 9 | ||||
Lifetime expected credit losses | Stage 2 | Gross exposure | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (65,884) | (75,908) | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (12) | ||||
Lifetime expected credit losses | Stage 2 | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,267) | ||||
Lifetime expected credit losses | Stage 2 | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,510 | ||||
Lifetime expected credit losses | Stage 2 | Gross exposure | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (24,429) | (34,815) | |||
Lifetime expected credit losses | Stage 2 | Gross exposure | Financial assets at fair value through other comprehensive income | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (2,100) | (157,000) | $ 0.2 | ||
Lifetime expected credit losses | Stage 2 | Impairment allowance | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 2,097 | 2,317 | |||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | ||||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 20 | ||||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (22) | ||||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 233 | 302 | |||
Lifetime expected credit losses | Stage 2 | Impairment allowance | Financial assets at fair value through other comprehensive income | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 2 | 1 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (39,591) | (39,078) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (18,693) | (19,441) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (4,939) | (3,949) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (15,959) | (15,688) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (41,455) | (41,093) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 19,500 | ||||
Business activity in the period | 339 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (506) | ||||
Final repayments | 1,092 | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 18,734 | 19,500 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (18,734) | (19,500) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 5,725 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (5,131) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (234) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 133 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 5,650 | ||||
Business activity in the period | 294 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 413 | ||||
Final repayments | 251 | ||||
Disposals | 28 | ||||
Write-offs | 0 | ||||
Closing balance | 6,494 | 5,650 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (6,494) | (5,650) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 2,572 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (1,689) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (516) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 49 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 15,943 | ||||
Business activity in the period | 1,670 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,048 | ||||
Final repayments | 1,783 | ||||
Disposals | 31 | ||||
Write-offs | 0 | ||||
Closing balance | 16,227 | 15,943 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (16,227) | (15,943) | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 5,129 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (5,544) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (405) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 200 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 1,864 | 2,015 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 59 | ||||
Business activity in the period | 1 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | ||||
Final repayments | (2) | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 41 | 59 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 41 | 59 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 1 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (18) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (5) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 3 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 1,701 | ||||
Business activity in the period | 32 | ||||
Refinements to models used for calculation | (187) | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 240 | ||||
Final repayments | (27) | ||||
Disposals | (10) | ||||
Write-offs | 0 | ||||
Closing balance | 1,555 | 1,701 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 1,555 | 1,701 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 67 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (422) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (222) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 9 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 255 | ||||
Business activity in the period | 14 | ||||
Refinements to models used for calculation | 42 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 70 | ||||
Final repayments | (28) | ||||
Disposals | 0 | ||||
Write-offs | 0 | ||||
Closing balance | 268 | 255 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 268 | 255 | |||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 29 | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (41) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (6) | ||||
Lifetime expected credit losses | Stage 2 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 17 | ||||
Lifetime expected credit losses | Stage 3 | Gross exposure | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (8,427) | (8,533) | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | ||||
Lifetime expected credit losses | Stage 3 | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (288) | ||||
Lifetime expected credit losses | Stage 3 | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 140 | ||||
Lifetime expected credit losses | Stage 3 | Gross exposure | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (1,146) | (1,298) | |||
Lifetime expected credit losses | Stage 3 | Gross exposure | Other assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (143) | (110) | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 2,367 | 2,544 | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | ||||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | ||||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (5) | ||||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Impairment release on loan commitments and other financial guarantees | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 17 | 23 | |||
Lifetime expected credit losses | Stage 3 | Impairment allowance | Other assets | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 136 | 107 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (4,931) | (4,714) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Home loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (1,712) | (1,725) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Credit cards, unsecured loans and other retail lending | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (1,062) | (828) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Wholesale loans | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (2,157) | (2,161) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (7,281) | (7,235) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 2,122 | ||||
Business activity in the period | 1 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (69) | ||||
Final repayments | 210 | ||||
Disposals | 0 | ||||
Write-offs | 13 | ||||
Closing balance | 2,110 | 2,122 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (2,110) | (2,122) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 431 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (152) | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 2,332 | ||||
Business activity in the period | 20 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 94 | ||||
Final repayments | 140 | ||||
Disposals | 122 | ||||
Write-offs | 555 | ||||
Closing balance | 2,510 | 2,332 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (2,510) | (2,332) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 960 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (79) | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 2,781 | ||||
Business activity in the period | 108 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (634) | ||||
Final repayments | 115 | ||||
Disposals | 46 | ||||
Write-offs | 200 | ||||
Closing balance | 2,661 | 2,781 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | (2,661) | (2,781) | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 1,081 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Gross exposure | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (314) | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Total loans and advances at amortised cost | |||||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 2,350 | 2,521 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 397 | ||||
Business activity in the period | 0 | ||||
Refinements to models used for calculation | 0 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 16 | ||||
Final repayments | (3) | ||||
Disposals | 0 | ||||
Write-offs | (13) | ||||
Closing balance | 398 | 397 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 398 | 397 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 5 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Home loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (4) | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | |||||
Loans and advances at amortised cost | |||||
Opening balance | 1,504 | ||||
Business activity in the period | 5 | ||||
Refinements to models used for calculation | (96) | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 285 | ||||
Final repayments | (29) | ||||
Disposals | (69) | ||||
Write-offs | (555) | ||||
Closing balance | 1,448 | 1,504 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 1,448 | 1,504 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 233 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Credit cards, unsecured loans and other retail lending | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | (22) | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | |||||
Loans and advances at amortised cost | |||||
Opening balance | 620 | ||||
Business activity in the period | 14 | ||||
Refinements to models used for calculation | 374 | ||||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 555 | ||||
Final repayments | (48) | ||||
Disposals | (46) | ||||
Write-offs | (200) | ||||
Closing balance | 504 | 620 | |||
Reconciliation of ECL movement to impairment (charge)/release for the period, Loans and advances at amortised cost | |||||
Total impairment allowance4 | 504 | £ 620 | |||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 1 to Stage 2 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 2 to Stage 1 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 0 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers to Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | 9 | ||||
Lifetime expected credit losses | Stage 3 | Financial assets at amortised cost, class | Impairment allowance | Wholesale loans | Transfers from Stage 3 | |||||
Loans and advances at amortised cost | |||||
Increase (decrease) through transfers, financial assets | £ (26) | ||||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |
Credit Risk - Movement in gro_2
Credit Risk - Movement in gross exposure for loan commitment and financial guarantees (Details) £ in Millions | 6 Months Ended |
Jun. 30, 2022 GBP (£) | |
Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | £ 11,368 |
Net transfers between stages | 0 |
Business activity in the period | 8,146 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (6,366) |
Limit management and final repayments | (194) |
Ending balance | 12,954 |
Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 128,755 |
Net transfers between stages | 0 |
Business activity in the period | 27,104 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 7,830 |
Limit management and final repayments | (3,985) |
Ending balance | 159,704 |
Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 208,132 |
Net transfers between stages | 0 |
Business activity in the period | 40,223 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 19,362 |
Limit management and final repayments | (41,256) |
Ending balance | 226,461 |
Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 131 |
Net transfers between stages | 0 |
Business activity in the period | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 25 |
Limit management and final repayments | (4) |
Ending balance | 153 |
Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 411 |
Net transfers between stages | 0 |
Business activity in the period | 43 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (36) |
Limit management and final repayments | (46) |
Ending balance | 372 |
Stage 1 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 10,833 |
Net transfers between stages | 39 |
Business activity in the period | 8,146 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (6,354) |
Limit management and final repayments | (172) |
Ending balance | 12,492 |
Stage 1 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 122,819 |
Net transfers between stages | (1,277) |
Business activity in the period | 26,892 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 9,385 |
Limit management and final repayments | (3,740) |
Ending balance | 154,079 |
Stage 1 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 178,490 |
Net transfers between stages | 9,775 |
Business activity in the period | 37,358 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 17,712 |
Limit management and final repayments | (36,362) |
Ending balance | 206,973 |
Stage 1 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Stage 1 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 50 |
Net transfers between stages | 23 |
Business activity in the period | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3 |
Limit management and final repayments | (1) |
Ending balance | 76 |
Stage 1 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 167 |
Net transfers between stages | 36 |
Business activity in the period | 19 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) |
Limit management and final repayments | (14) |
Ending balance | 199 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 532 |
Net transfers between stages | (39) |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (12) |
Limit management and final repayments | (22) |
Ending balance | 459 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 5,718 |
Net transfers between stages | 935 |
Business activity in the period | 212 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,267) |
Limit management and final repayments | (209) |
Ending balance | 5,389 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 28,565 |
Net transfers between stages | (9,709) |
Business activity in the period | 2,864 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,510 |
Limit management and final repayments | (4,649) |
Ending balance | 18,581 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 61 |
Net transfers between stages | (18) |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 20 |
Limit management and final repayments | (3) |
Ending balance | 60 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 241 |
Net transfers between stages | (37) |
Business activity in the period | 24 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (22) |
Limit management and final repayments | (33) |
Ending balance | 173 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 3 |
Net transfers between stages | 0 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 3 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 218 |
Net transfers between stages | 342 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (288) |
Limit management and final repayments | (36) |
Ending balance | 236 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 1,077 |
Net transfers between stages | (66) |
Business activity in the period | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 140 |
Limit management and final repayments | (245) |
Ending balance | 907 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Home loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Credit cards, unsecured loans and other retail lending | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 20 |
Net transfers between stages | (5) |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 |
Limit management and final repayments | 0 |
Ending balance | 17 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Wholesale loans | |
Increase (decrease) in exposure to credit risk on loan commitments and financial guarantee contracts [abstract] | |
Opening balance | 3 |
Net transfers between stages | 1 |
Business activity in the period | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (5) |
Limit management and final repayments | 1 |
Ending balance | £ 0 |
Credit Risk - Management adjust
Credit Risk - Management adjustments to models for impairment (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Dec. 31, 2021 |
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 1,287 | £ 1,486 |
Proportion of total impairment allowances | 2,140% | 23.60% |
Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 1,287 | £ 1,486 |
Allowance account for credit losses of financial assets, Before adjustments | 4,736 | 4,798 |
Allowance account for credit losses of financial assets | 6,023 | 6,284 |
Total loans and advances at amortised cost | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 1,038 | 1,692 |
Total loans and advances at amortised cost | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 249 | (206) |
Total loans and advances at amortised cost | Modelled ECL | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets, Before adjustments | 4,100 | 4,100 |
Allowance account for credit losses of financial assets | 100 | |
Total loans and advances at amortised cost | ECL from individually assessed impairments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets, Before adjustments | 400 | 500 |
Total loans and advances at amortised cost | ECL from non-modelled and other management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets, Before adjustments | 200 | 200 |
Allowance account for credit losses of financial assets | (200) | (200) |
Home loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 76 | £ 103 |
Proportion of total impairment allowances | 1,660% | 21.70% |
Allowance account for credit losses of financial assets, Before adjustments | £ 382 | £ 372 |
Allowance account for credit losses of financial assets | 458 | 475 |
Home loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 43 | 72 |
Home loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 33 | 31 |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 785 | £ 1,362 |
Proportion of total impairment allowances | 1,960% | 32.70% |
Allowance account for credit losses of financial assets, Before adjustments | £ 3,229 | £ 2,798 |
Allowance account for credit losses of financial assets | 4,014 | 4,160 |
Credit cards, unsecured loans and other retail lending | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 578 | 1,217 |
Credit cards, unsecured loans and other retail lending | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 207 | 145 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 426 | £ 21 |
Proportion of total impairment allowances | 27.50% | 1.30% |
Allowance account for credit losses of financial assets, Before adjustments | £ 1,125 | £ 1,628 |
Allowance account for credit losses of financial assets | 1,551 | 1,649 |
Wholesale loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 417 | 403 |
Wholesale loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 9 | (382) |
Loans to government | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 400 | |
Loans to government | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ (400) |
Credit Risk - Economic uncertai
Credit Risk - Economic uncertainty adjustments, Narrative (Details) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 GBP (£) method | Dec. 31, 2021 GBP (£) | |
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 1,287 | £ 1,486 |
Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 6,023 | 6,284 |
Management adjustments to impairment allowances | 1,287 | 1,486 |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 4,014 | 4,160 |
Management adjustments to impairment allowances | 785 | 1,362 |
Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,551 | 1,649 |
Management adjustments to impairment allowances | £ 426 | 21 |
Covid-19 related uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Number of methods to determine uncertainty adjustments | method | 2 | |
Allowance account for credit losses of financial assets | £ 1,000 | 1,700 |
Covid-19 related uncertainty adjustments | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 800 | 1,500 |
Covid-19 related uncertainty adjustments | Credit cards, unsecured loans and other retail lending | US | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 500 | 800 |
Covid-19 related uncertainty adjustments | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 300 | 300 |
Covid-19 related uncertainty adjustments | Model uncertainty risk | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 200 | 200 |
Management adjustments to impairment allowances | 200 | 200 |
Covid-19 related uncertainty adjustments | Customers | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 800 | 1,500 |
Covid-19 related uncertainty adjustments | Customers | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 400 | |
Economic uncertainty adjustments | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 1,038 | 1,692 |
Economic uncertainty adjustments | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 578 | 1,217 |
Economic uncertainty adjustments | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 417 | 403 |
Economic uncertainty adjustments | Loans to government | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 400 | |
Other adjustments | Total loans and advances at amortised cost | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 249 | (206) |
Other adjustments | Credit cards, unsecured loans and other retail lending | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | 207 | 145 |
Other adjustments | Wholesale loans | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ 9 | (382) |
Other adjustments | Loans to government | ||
Disclosure of financial assets [line items] | ||
Management adjustments to impairment allowances | £ (400) |
Credit Risk - Measurement uncer
Credit Risk - Measurement uncertainty - Baseline average macroeconomic variables used in the calculation of ECL (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3,780% | 3,010% |
Baseline | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6.20% |
Baseline | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 4.90% |
Baseline | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.30% |
Baseline | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.90% |
Baseline | GDP | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.70% |
Baseline | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 5.50% |
Baseline | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 3.90% |
Baseline | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.60% |
Baseline | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.40% |
Baseline | GDP | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.40% |
Baseline | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.80% |
Baseline | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.70% |
Baseline | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.50% |
Baseline | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.30% |
Baseline | Unemployment | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.20% |
Baseline | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 5.50% |
Baseline | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.20% |
Baseline | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | Unemployment | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Baseline | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 4.70% |
Baseline | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1% | 1% |
Baseline | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 1.90% |
Baseline | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 1.90% |
Baseline | HPI | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.30% |
Baseline | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 11.80% |
Baseline | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.50% |
Baseline | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.20% |
Baseline | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 4.90% |
Baseline | HPI | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5% |
Baseline | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.10% |
Baseline | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 0.80% |
Baseline | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 1% |
Baseline | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 1% |
Baseline | UK bank rate | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 0.80% |
Baseline | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.20% |
Baseline | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 0.30% |
Baseline | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 0.90% |
Baseline | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 1.20% |
Baseline | US federal funds rate | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 1.30% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 740% | 700% |
Downside 2 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 6.20% |
Downside 2 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.80%) | 0.20% |
Downside 2 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.40%) | (4.00%) |
Downside 2 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 2.80% |
Downside 2 | GDP | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.30% |
Downside 2 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 5.50% |
Downside 2 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.10%) | (0.80%) |
Downside 2 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | (3.50%) |
Downside 2 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 2.50% |
Downside 2 | GDP | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 3.20% |
Downside 2 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 4.80% |
Downside 2 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.40% | 7.20% |
Downside 2 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.60% | 9% |
Downside 2 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.80% | 7.60% |
Downside 2 | Unemployment | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.90% | 6.30% |
Downside 2 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.50% |
Downside 2 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8% | 6.40% |
Downside 2 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9% | 9.10% |
Downside 2 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 8.10% |
Downside 2 | Unemployment | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.80% | 6.40% |
Downside 2 | HPI | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 30.80% | |
Downside 2 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.20% | 4.70% |
Downside 2 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (26.20%) | (14.30%) |
Downside 2 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.60%) | (21.80%) |
Downside 2 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 17.90% | 11.90% |
Downside 2 | HPI | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10.20% | 15.20% |
Downside 2 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | 11.80% |
Downside 2 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (11.70%) | (6.60%) |
Downside 2 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.20%) | (9.00%) |
Downside 2 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 5.90% |
Downside 2 | HPI | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.70% |
Downside 2 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.10% |
Downside 2 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 2.20% |
Downside 2 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 3.90% |
Downside 2 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 3.10% |
Downside 2 | UK bank rate | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.20% |
Downside 2 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 0.20% |
Downside 2 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 2.10% |
Downside 2 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 3.40% |
Downside 2 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 2.60% |
Downside 2 | US federal funds rate | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,480% |
Downside 1 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Downside 1 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.60%) | 2.80% |
Downside 1 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | (0.70%) |
Downside 1 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2.30% |
Downside 1 | GDP | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.90% |
Downside 1 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 5.50% |
Downside 1 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.00%) | 1.60% |
Downside 1 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | (0.40%) |
Downside 1 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.40% |
Downside 1 | GDP | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.70% |
Downside 1 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.80% |
Downside 1 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.20% |
Downside 1 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.80% |
Downside 1 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6% |
Downside 1 | Unemployment | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 5.30% |
Downside 1 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5.50% |
Downside 1 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 5.40% |
Downside 1 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.60% |
Downside 1 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6.10% |
Downside 1 | Unemployment | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.20% |
Downside 1 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 4.70% |
Downside 1 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.20%) | (6.80%) |
Downside 1 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | (10.50%) |
Downside 1 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10% | 6.90% |
Downside 1 | HPI | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 8.60% |
Downside 1 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 11.80% |
Downside 1 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.40%) | (1.20%) |
Downside 1 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | (2.10%) |
Downside 1 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 4.80% |
Downside 1 | HPI | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.20% |
Downside 1 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.10% |
Downside 1 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 1.60% |
Downside 1 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 2.70% |
Downside 1 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.30% |
Downside 1 | UK bank rate | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 1.60% |
Downside 1 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.20% |
Downside 1 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 1.30% |
Downside 1 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 2.30% |
Downside 1 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 2.10% |
Downside 1 | US federal funds rate | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 1.80% |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,400% | 2,090% |
Upside 2 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 6.20% |
Upside 2 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 7.20% |
Upside 2 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 4% |
Upside 2 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.70% |
Upside 2 | GDP | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.10% |
Upside 2 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 5.50% |
Upside 2 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 5.30% |
Upside 2 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.10% |
Upside 2 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.50% |
Upside 2 | GDP | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.40% |
Upside 2 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.80% |
Upside 2 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.50% |
Upside 2 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4.10% |
Upside 2 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 5.50% |
Upside 2 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.90% |
Upside 2 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.40% |
Upside 2 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.30% |
Upside 2 | Unemployment | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.30% |
Upside 2 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 4.70% |
Upside 2 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.20% | 8.50% |
Upside 2 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 9% |
Upside 2 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 5.20% |
Upside 2 | HPI | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.20% |
Upside 2 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 11.80% |
Upside 2 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 10.60% |
Upside 2 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 8.50% |
Upside 2 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 7.20% |
Upside 2 | HPI | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.60% |
Upside 2 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.20% | 0.10% |
Upside 2 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.20% |
Upside 2 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | 0.50% |
Upside 2 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.50% |
Upside 2 | UK bank rate | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Upside 2 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 0.20% |
Upside 2 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 0.30% |
Upside 2 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 0.40% |
Upside 2 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.70% |
Upside 2 | US federal funds rate | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 1% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,560% | 2,720% |
Upside 1 | GDP | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 6.20% |
Upside 1 | GDP | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6% |
Upside 1 | GDP | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.10% |
Upside 1 | GDP | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.30% |
Upside 1 | GDP | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 1.90% |
Upside 1 | GDP | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 5.50% |
Upside 1 | GDP | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.60% |
Upside 1 | GDP | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.40% |
Upside 1 | GDP | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.90% |
Upside 1 | GDP | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.90% |
Upside 1 | Unemployment | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.80% |
Upside 1 | Unemployment | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.60% |
Upside 1 | Unemployment | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.30% |
Upside 1 | Unemployment | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.20% |
Upside 1 | Unemployment | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.10% |
Upside 1 | Unemployment | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 5.50% |
Upside 1 | Unemployment | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 4% |
Upside 1 | Unemployment | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | Unemployment | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | Unemployment | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.50% |
Upside 1 | HPI | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.40% | 4.70% |
Upside 1 | HPI | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 5% |
Upside 1 | HPI | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 5% |
Upside 1 | HPI | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.90% |
Upside 1 | HPI | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.30% |
Upside 1 | HPI | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 11.80% |
Upside 1 | HPI | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 8.30% |
Upside 1 | HPI | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 7% |
Upside 1 | HPI | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 6% |
Upside 1 | HPI | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 5.70% |
Upside 1 | UK bank rate | UK | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.10% |
Upside 1 | UK bank rate | UK | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 0.60% |
Upside 1 | UK bank rate | UK | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.80% |
Upside 1 | UK bank rate | UK | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.80% |
Upside 1 | UK bank rate | UK | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.50% | 0.50% |
Upside 1 | US federal funds rate | US | 2022 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.20% |
Upside 1 | US federal funds rate | US | 2023 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 0.30% |
Upside 1 | US federal funds rate | US | 2024 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 0.60% |
Upside 1 | US federal funds rate | US | 2025 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 1% |
Upside 1 | US federal funds rate | US | 2026 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 1.10% |
Credit Risk - Measurement unc_2
Credit Risk - Measurement uncertainty - Scenario probability weighting (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,400% | 2,090% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,560% | 2,720% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3,780% | 3,010% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,480% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 740% | 700% |
Credit Risk - Measurement unc_3
Credit Risk - Measurement uncertainty - Macroeconomic variables (specific bases and 5-year averages) (Details) | Jun. 30, 2022 | Dec. 31, 2021 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,400% | 2,090% |
Upside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 16.80% | 21.40% |
Upside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.40% |
Upside 2 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 20.20% | 22.80% |
Upside 2 | GDP | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.40% |
Upside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 4% |
Upside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.30% |
Upside 2 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.30% |
Upside 2 | Unemployment | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.90% |
Upside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 36.70% | 35.70% |
Upside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 6.30% |
Upside 2 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 27% | 53.30% |
Upside 2 | HPI | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 8.90% |
Upside 2 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 2 | UK bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 0.30% |
Upside 2 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.10% |
Upside 2 | US federal funds rate | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.70% | 0.50% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,560% | 2,720% |
Upside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 12.80% | 18.30% |
Upside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 3.90% |
Upside 1 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 16.10% | 19.60% |
Upside 1 | GDP | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.90% |
Upside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.10% |
Upside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.40% |
Upside 1 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.50% |
Upside 1 | Unemployment | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 4% |
Upside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 24.80% | 23.80% |
Upside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 4.40% |
Upside 1 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 22.90% | 45.20% |
Upside 1 | HPI | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 7.70% |
Upside 1 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.10% |
Upside 1 | UK bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.50% |
Upside 1 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 0.10% |
Upside 1 | US federal funds rate | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 0.60% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3,780% | 3,010% |
Baseline | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.40% |
Baseline | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.40% |
Baseline | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.40% |
Baseline | GDP | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 3.40% |
Baseline | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.50% |
Baseline | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4.50% |
Baseline | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.10% |
Baseline | Unemployment | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 4.10% |
Baseline | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.40% |
Baseline | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.40% |
Baseline | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Baseline | HPI | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 6.20% |
Baseline | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.70% |
Baseline | UK bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 0.70% |
Baseline | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.80% |
Baseline | US federal funds rate | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 0.80% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,480% |
Downside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.10%) | (1.60%) |
Downside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.70% |
Downside 1 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.50%) | 1.50% |
Downside 1 | GDP | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 2.40% |
Downside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.60% | 7% |
Downside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 5.80% |
Downside 1 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 6.80% |
Downside 1 | Unemployment | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 5.70% |
Downside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.60%) | (12.70%) |
Downside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | 0.30% |
Downside 1 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.60%) | 2.20% |
Downside 1 | HPI | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.40% | 3.60% |
Downside 1 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 2.80% |
Downside 1 | UK bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 1.70% |
Downside 1 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 2.30% |
Downside 1 | US federal funds rate | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 1.50% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 740% | 700% |
Downside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.90%) | (1.60%) |
Downside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 1.80% |
Downside 2 | GDP | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.00%) | (1.30%) |
Downside 2 | GDP | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 1.30% |
Downside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.20% | 9.20% |
Downside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 7% |
Downside 2 | Unemployment | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.50% | 9.50% |
Downside 2 | Unemployment | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.90% | 7.10% |
Downside 2 | HPI | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 30.80% | |
Downside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (30.80%) | (29.90%) |
Downside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.50%) | (2.00%) |
Downside 2 | HPI | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (13.40%) | (5.00%) |
Downside 2 | HPI | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.80%) | 1.40% |
Downside 2 | UK bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 4% |
Downside 2 | UK bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 2.30% |
Downside 2 | US federal funds rate | US | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 3.50% |
Downside 2 | US federal funds rate | US | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 2.10% |
Credit Risk - Measurement unc_4
Credit Risk - Measurement uncertainty - ECL under 100% weighted scenarios for modelled portfolios, narrative (Details) £ in Millions | 6 Months Ended | |
Jun. 30, 2022 GBP (£) economic_scenario | Dec. 31, 2021 GBP (£) | |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 100% | |
Average EAD period | 12 months | |
Treasury assets ECL | £ 7.7 | |
Total impairment allowance4 | £ 794,418 | £ 709,164 |
Coverage ratio | 0.008 | 0.009 |
Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Transfers into Stage 2 | £ 22,100 | |
Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.032 | 0.031 |
Credit risk | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 2.40% | |
Scenario probability weighting | 3,780% | 3,010% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 740% | 700% |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 395,824 | £ 361,451 |
Coverage ratio | 0.014 | 0.016 |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 39,591 | £ 39,078 |
Coverage ratio | 0.045 | 0.049 |
Home loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 171,269 | £ 169,205 |
Coverage ratio | 0.003 | 0.003 |
Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 18,693 | £ 19,441 |
Coverage ratio | 0.002 | 0.003 |
Home loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Home loans | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 2.20% | |
Home loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Home loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 48,769 | £ 41,793 |
Coverage ratio | 0.073 | 0.088 |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 4,939 | £ 3,949 |
Coverage ratio | 0.239 | 0.301 |
Credit cards, unsecured loans and other retail lending | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.176 | 0.155 |
Credit cards, unsecured loans and other retail lending | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 1.70% | |
Credit cards, unsecured loans and other retail lending | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.174 | 0.156 |
Credit cards, unsecured loans and other retail lending | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.199 | 0.231 |
Wholesale loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 175,786 | £ 150,453 |
Coverage ratio | 0.007 | 0.008 |
Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 15,959 | £ 15,688 |
Coverage ratio | 0.017 | 0.016 |
Wholesale loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.020 | 0.018 |
Wholesale loans | Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Weighted expected credit loss, uplift percentage | 5.30% | |
Wholesale loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.019 | 0.017 |
Wholesale loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.027 | 0.034 |
UK | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.20% | |
UK | Downside 2 | HPI | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 30.80% | |
US | Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Unemployment rate | 9.50% | |
Impairment allowance | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (6,023) | £ (6,284) |
Impairment allowance | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,097) | (2,317) |
Impairment allowance | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (4,182) | (4,200) |
Impairment allowance | Total loans and advances at amortised cost | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (5,498) | (5,742) |
Increase (decrease) in financial assets | 653 | |
Impairment allowance | Total loans and advances at amortised cost | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,864) | (2,015) |
Impairment allowance | Total loans and advances at amortised cost | Credit risk | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (4,182) | (4,200) |
Impairment allowance | Total loans and advances at amortised cost | Baseline | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (4,085) | (4,043) |
Impairment allowance | Total loans and advances at amortised cost | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (5,802) | (7,609) |
Impairment allowance | Home loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (458) | (475) |
Increase (decrease) in financial assets | (4) | |
Impairment allowance | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (41) | (59) |
Impairment allowance | Home loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (329) | (322) |
Impairment allowance | Home loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (13) | (15) |
Impairment allowance | Home loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (322) | (314) |
Impairment allowance | Home loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (11) | (12) |
Impairment allowance | Home loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (407) | (407) |
Impairment allowance | Home loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (40) | (47) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,863) | (4,029) |
Increase (decrease) in financial assets | 472 | |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,555) | (1,701) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Credit risk | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,079) | (2,693) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,531) | (1,114) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Baseline | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,028) | (2,592) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,468) | (1,058) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,902) | (5,010) |
Impairment allowance | Credit cards, unsecured loans and other retail lending | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,318) | (3,295) |
Impairment allowance | Wholesale loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,177) | (1,238) |
Increase (decrease) in financial assets | 185 | |
Impairment allowance | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (268) | (255) |
Impairment allowance | Wholesale loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (774) | (1,185) |
Impairment allowance | Wholesale loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (463) | (572) |
Impairment allowance | Wholesale loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (735) | (1,137) |
Impairment allowance | Wholesale loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (438) | (528) |
Impairment allowance | Wholesale loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,493) | (2,192) |
Impairment allowance | Wholesale loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,091) | (1,510) |
Gross exposure | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 800,441 | 715,448 |
Gross exposure | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 65,884 | 75,908 |
Gross exposure | Total loans and advances at amortised cost | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 401,322 | 367,193 |
Gross exposure | Total loans and advances at amortised cost | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 41,455 | 41,093 |
Gross exposure | Home loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 171,727 | 169,680 |
Gross exposure | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,734 | 19,500 |
Gross exposure | Home loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,684 | 22,915 |
Gross exposure | Home loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,470 | 22,631 |
Gross exposure | Home loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 21,799 | 27,151 |
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 52,632 | 45,822 |
Gross exposure | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 6,494 | 5,650 |
Gross exposure | Credit cards, unsecured loans and other retail lending | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,699 | 7,200 |
Increase (decrease) in financial assets | 3,000 | |
Gross exposure | Credit cards, unsecured loans and other retail lending | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,448 | 6,795 |
Gross exposure | Credit cards, unsecured loans and other retail lending | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 11,658 | 14,290 |
Gross exposure | Wholesale loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 176,963 | 151,691 |
Gross exposure | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 16,227 | 15,943 |
Gross exposure | Wholesale loans | Credit risk | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 23,702 | 32,256 |
Gross exposure | Wholesale loans | Baseline | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 23,489 | 31,054 |
Gross exposure | Wholesale loans | Downside 2 | Financial assets at amortised cost, class | Modelled ECL | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 39,755 | £ 44,507 |
Credit Risk - Measurement unc_5
Credit Risk - Measurement uncertainty - ECL under 100% weighted scenarios for modelled portfolios (Details) £ in Millions | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) |
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 794,418 | £ 709,164 |
Coverage ratio | 0.008 | 0.009 |
Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.032 | 0.031 |
Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.281 | 0.298 |
Gross exposure | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 800,441 | £ 715,448 |
Gross exposure | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 726,130 | 631,007 |
Gross exposure | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 65,884 | 75,908 |
Gross exposure | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,427 | 8,533 |
Impairment allowance | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (6,023) | (6,284) |
Impairment allowance | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (4,182) | (4,200) |
Impairment allowance | ECL from individually assessed impairments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (376) | (524) |
Impairment allowance | ECL from non-modelled and other management adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,465) | (1,560) |
Impairment allowance | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,559) | (1,423) |
Impairment allowance | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,097) | (2,317) |
Impairment allowance | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,367) | (2,544) |
Total loans and advances at amortised cost | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | (6,023) | (6,284) |
Total loans and advances at amortised cost | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | (100) | |
Total loans and advances at amortised cost | ECL from post-model adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | 1,300 | 1,500 |
Total loans and advances at amortised cost | ECL from non-modelled and other management adjustments | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | 200 | 200 |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 395,824 | £ 361,451 |
Coverage ratio | 0.014 | 0.016 |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 351,302 | £ 317,659 |
Coverage ratio | 0.004 | 0.004 |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 39,591 | £ 39,078 |
Coverage ratio | 0.045 | 0.049 |
Total loans and advances at amortised cost | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 4,931 | £ 4,714 |
Coverage ratio | 0.323 | 0.348 |
Total loans and advances at amortised cost | Gross exposure | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 401,322 | £ 367,193 |
Total loans and advances at amortised cost | Gross exposure | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 352,586 | 318,865 |
Total loans and advances at amortised cost | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 41,455 | 41,093 |
Total loans and advances at amortised cost | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 7,281 | 7,235 |
Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (5,498) | (5,742) |
Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,284) | (1,206) |
Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,864) | (2,015) |
Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,350) | (2,521) |
Home loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | (458) | (475) |
Home loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 171,269 | £ 169,205 |
Coverage ratio | 0.003 | 0.003 |
Home loans | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 150,864 | £ 148,039 |
Coverage ratio | 0 | 0 |
Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 18,693 | £ 19,441 |
Coverage ratio | 0.002 | 0.003 |
Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 1,712 | £ 1,725 |
Coverage ratio | 0.189 | 0.187 |
Home loans | Gross exposure | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 171,727 | £ 169,680 |
Allowance account for credit losses of financial assets | (171,727) | (169,680) |
Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 150,883 | 148,058 |
Allowance account for credit losses of financial assets | (150,883) | (148,058) |
Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,734 | 19,500 |
Allowance account for credit losses of financial assets | (18,734) | (19,500) |
Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,110 | 2,122 |
Allowance account for credit losses of financial assets | (2,110) | (2,122) |
Home loans | Impairment allowance | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (458) | (475) |
Allowance account for credit losses of financial assets | (458) | (475) |
Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (19) | (19) |
Allowance account for credit losses of financial assets | (19) | (19) |
Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (41) | (59) |
Allowance account for credit losses of financial assets | (41) | (59) |
Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (398) | (397) |
Allowance account for credit losses of financial assets | (398) | (397) |
Credit cards, unsecured loans and other retail lending | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | (4,014) | (4,160) |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 48,769 | £ 41,793 |
Coverage ratio | 0.073 | 0.088 |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 42,768 | £ 37,016 |
Coverage ratio | 0.020 | 0.022 |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 4,939 | £ 3,949 |
Coverage ratio | 0.239 | 0.301 |
Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 1,062 | £ 828 |
Coverage ratio | 0.577 | 0.645 |
Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 52,632 | £ 45,822 |
Allowance account for credit losses of financial assets | (52,632) | (45,822) |
Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 43,628 | 37,840 |
Allowance account for credit losses of financial assets | (43,628) | (37,840) |
Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 6,494 | 5,650 |
Allowance account for credit losses of financial assets | (6,494) | (5,650) |
Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,510 | 2,332 |
Allowance account for credit losses of financial assets | (2,510) | (2,332) |
Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,863) | (4,029) |
Allowance account for credit losses of financial assets | (3,863) | (4,029) |
Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (860) | (824) |
Allowance account for credit losses of financial assets | (860) | (824) |
Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,555) | (1,701) |
Allowance account for credit losses of financial assets | (1,555) | (1,701) |
Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,448) | (1,504) |
Allowance account for credit losses of financial assets | (1,448) | (1,504) |
Wholesale loans | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Allowance account for credit losses of financial assets | (1,551) | (1,649) |
Wholesale loans | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 175,786 | £ 150,453 |
Coverage ratio | 0.007 | 0.008 |
Wholesale loans | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 157,670 | £ 132,604 |
Coverage ratio | 0.003 | 0.003 |
Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 15,959 | £ 15,688 |
Coverage ratio | 0.017 | 0.016 |
Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 2,157 | £ 2,161 |
Coverage ratio | 0.189 | 0.223 |
Wholesale loans | Gross exposure | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 176,963 | £ 151,691 |
Allowance account for credit losses of financial assets | (176,963) | (151,691) |
Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 158,075 | 132,967 |
Allowance account for credit losses of financial assets | (158,075) | (132,967) |
Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 16,227 | 15,943 |
Allowance account for credit losses of financial assets | (16,227) | (15,943) |
Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,661 | 2,781 |
Allowance account for credit losses of financial assets | (2,661) | (2,781) |
Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,177) | (1,238) |
Allowance account for credit losses of financial assets | (1,177) | (1,238) |
Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (405) | (363) |
Allowance account for credit losses of financial assets | (405) | (363) |
Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (268) | (255) |
Allowance account for credit losses of financial assets | (268) | (255) |
Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (504) | (620) |
Allowance account for credit losses of financial assets | (504) | (620) |
Credit risk | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (4,182) | £ (4,200) |
Credit risk | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Credit risk | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Credit risk | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.192 | 0.176 |
Credit risk | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 142,668 | £ 137,279 |
Credit risk | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,684 | 22,915 |
Credit risk | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Credit risk | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (329) | (322) |
Credit risk | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3) | (4) |
Credit risk | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (13) | (15) |
Credit risk | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (313) | £ (303) |
Credit risk | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.007 | 0.007 |
Credit risk | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.176 | 0.155 |
Credit risk | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.672 | 0.653 |
Credit risk | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 46,225 | £ 45,503 |
Credit risk | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,699 | 7,200 |
Credit risk | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Credit risk | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,079) | (2,693) |
Credit risk | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (341) | (324) |
Credit risk | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,531) | (1,114) |
Credit risk | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,207) | £ (1,255) |
Credit risk | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.002 |
Credit risk | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.020 | 0.018 |
Credit risk | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.025 | 0.178 |
Credit risk | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 183,356 | £ 174,249 |
Credit risk | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 23,702 | 32,256 |
Credit risk | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Credit risk | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (774) | (1,185) |
Credit risk | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (250) | (290) |
Credit risk | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (463) | (572) |
Credit risk | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (61) | (323) |
Upside 2 | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (3,743) | £ (3,723) |
Upside 2 | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Upside 2 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Upside 2 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.185 | 0.169 |
Upside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 144,569 | £ 139,117 |
Upside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 16,783 | 21,076 |
Upside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Upside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (311) | (304) |
Upside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2) | (2) |
Upside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (8) | (10) |
Upside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (301) | £ (292) |
Upside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.007 | 0.006 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.169 | 0.148 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.658 | 0.643 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 46,906 | £ 46,170 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 7,741 | 6,260 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Upside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,818) | (2,427) |
Upside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (329) | (266) |
Upside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,306) | (925) |
Upside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,183) | £ (1,236) |
Upside 2 | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Upside 2 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.020 | 0.015 |
Upside 2 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.023 | 0.177 |
Upside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 189,252 | £ 177,453 |
Upside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 17,806 | 29,052 |
Upside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Upside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (614) | (992) |
Upside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (210) | (240) |
Upside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (348) | (431) |
Upside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (56) | (321) |
Upside 1 | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (3,882) | £ (3,864) |
Upside 1 | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Upside 1 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Upside 1 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.187 | 0.171 |
Upside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 143,881 | £ 138,424 |
Upside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 17,471 | 21,769 |
Upside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Upside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (316) | (308) |
Upside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2) | (2) |
Upside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (9) | (11) |
Upside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (305) | £ (295) |
Upside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.007 | 0.006 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.171 | 0.152 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.663 | 0.648 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 46,692 | £ 45,963 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,048 | 6,521 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Upside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,902) | (2,505) |
Upside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (333) | (272) |
Upside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,378) | (988) |
Upside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,191) | £ (1,245) |
Upside 1 | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Upside 1 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.020 | 0.016 |
Upside 1 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.024 | 0.178 |
Upside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 187,709 | £ 176,774 |
Upside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 19,349 | 29,732 |
Upside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Upside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (664) | (1,051) |
Upside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (224) | (262) |
Upside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (382) | (467) |
Upside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (58) | (322) |
Baseline | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (4,085) | £ (4,043) |
Baseline | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Baseline | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Baseline | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.189 | 0.173 |
Baseline | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 142,882 | £ 137,563 |
Baseline | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 18,470 | 22,631 |
Baseline | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Baseline | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (322) | (314) |
Baseline | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2) | (3) |
Baseline | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (11) | (12) |
Baseline | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (309) | £ (299) |
Baseline | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.007 | 0.006 |
Baseline | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.174 | 0.156 |
Baseline | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.680 | 0.653 |
Baseline | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 46,446 | £ 45,751 |
Baseline | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 8,448 | 6,795 |
Baseline | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Baseline | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,028) | (2,592) |
Baseline | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (338) | (279) |
Baseline | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,468) | (1,058) |
Baseline | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,222) | £ (1,255) |
Baseline | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.002 |
Baseline | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.019 | 0.017 |
Baseline | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.025 | 0.178 |
Baseline | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 183,570 | £ 175,451 |
Baseline | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 23,489 | 31,054 |
Baseline | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Baseline | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (735) | (1,137) |
Baseline | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (237) | (286) |
Baseline | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (438) | (528) |
Baseline | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (60) | (323) |
Downside 1 | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (4,729) | £ (4,976) |
Downside 1 | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Downside 1 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.001 | 0.001 |
Downside 1 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.201 | 0.186 |
Downside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 141,536 | £ 135,544 |
Downside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 19,815 | 24,649 |
Downside 1 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Downside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (352) | (348) |
Downside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (4) | (6) |
Downside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (20) | (22) |
Downside 1 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (328) | £ (320) |
Downside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.008 | 0.008 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.185 | 0.154 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.678 | 0.664 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 45,324 | £ 43,131 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 9,932 | 9,708 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Downside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,411) | (3,124) |
Downside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (353) | (350) |
Downside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,840) | (1,497) |
Downside 1 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,218) | £ (1,277) |
Downside 1 | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Downside 1 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.021 | 0.023 |
Downside 1 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.027 | 0.180 |
Downside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 178,233 | £ 169,814 |
Downside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 28,825 | 36,692 |
Downside 1 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Downside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (966) | (1,504) |
Downside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (296) | (327) |
Downside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (604) | (851) |
Downside 1 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (66) | (326) |
Downside 2 | Total loans and advances at amortised cost | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (5,802) | £ (7,609) |
Downside 2 | Home loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0 | 0 |
Downside 2 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Downside 2 | Home loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.219 | 0.201 |
Downside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 139,553 | £ 133,042 |
Downside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 21,799 | 27,151 |
Downside 2 | Home loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,631 | 1,724 |
Downside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (407) | (407) |
Downside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (10) | (14) |
Downside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (40) | (47) |
Downside 2 | Home loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (357) | £ (346) |
Downside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.008 | 0.011 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.199 | 0.231 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.674 | 0.675 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 44,057 | £ 38,820 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 11,658 | 14,290 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 1,797 | 1,922 |
Downside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (3,902) | (5,010) |
Downside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (372) | (418) |
Downside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (2,318) | (3,295) |
Downside 2 | Credit cards, unsecured loans and other retail lending | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (1,212) | £ (1,297) |
Downside 2 | Wholesale loans | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.002 | 0.002 |
Downside 2 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.027 | 0.034 |
Downside 2 | Wholesale loans | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Coverage ratio | 0.030 | 0.183 |
Downside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ 167,303 | £ 161,998 |
Downside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 39,755 | 44,507 |
Downside 2 | Wholesale loans | Gross exposure | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | 2,431 | 1,811 |
Downside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,493) | (2,192) |
Downside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Stage 1 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (329) | (350) |
Downside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 2 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | (1,091) | (1,510) |
Downside 2 | Wholesale loans | Impairment allowance | Financial assets at amortised cost, class | Lifetime expected credit losses | Stage 3 | Modelled ECL | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Total impairment allowance4 | £ (73) | £ (332) |
Credit Risk - Management VaR (9
Credit Risk - Management VaR (95%) by asset class (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | |
Disclosure of financial assets [line items] | |||
VaR increase | 80% | ||
Average | |||
Disclosure of financial assets [line items] | |||
Value at risk | £ 27 | £ 15 | £ 22 |
Average | Credit risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 16 | 10 | 18 |
Average | Interest rate risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 10 | 5 | 8 |
Average | Equity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 10 | 8 | 10 |
Average | Basis risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 9 | 4 | 7 |
Average | Spread risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 5 | 4 | 4 |
Average | Foreign exchange risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 10 | 4 | 3 |
Average | Commodity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 0 | 0 | 0 |
Average | Inflation risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 6 | 3 | 2 |
Average | Diversification effect | |||
Disclosure of financial assets [line items] | |||
Value at risk | (39) | (23) | (30) |
Favourable changes | |||
Disclosure of financial assets [line items] | |||
Value at risk | 43 | 34 | 36 |
Favourable changes | Credit risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 24 | 13 | 30 |
Favourable changes | Interest rate risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 19 | 9 | 15 |
Favourable changes | Equity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 29 | 29 | 15 |
Favourable changes | Basis risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 24 | 7 | 10 |
Favourable changes | Spread risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 10 | 6 | 6 |
Favourable changes | Foreign exchange risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 25 | 16 | 6 |
Favourable changes | Commodity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 1 | 1 | 1 |
Favourable changes | Inflation risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 17 | 5 | 3 |
Unfavourable changes | |||
Disclosure of financial assets [line items] | |||
Value at risk | 13 | 6 | 13 |
Unfavourable changes | Credit risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 8 | 7 | 9 |
Unfavourable changes | Interest rate risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 4 | 4 | 4 |
Unfavourable changes | Equity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 4 | 4 | 6 |
Unfavourable changes | Basis risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 4 | 3 | 4 |
Unfavourable changes | Spread risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 3 | 3 | 3 |
Unfavourable changes | Foreign exchange risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 2 | 1 | 2 |
Unfavourable changes | Commodity risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | 0 | 0 | 0 |
Unfavourable changes | Inflation risk | |||
Disclosure of financial assets [line items] | |||
Value at risk | £ 3 | £ 2 | £ 2 |
Credit Risk - Capital Resources
Credit Risk - Capital Resources (Details) - GBP (£) £ in Millions | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disclosure of financial assets [line items] | |||||
Equity attributable to owners of parent | £ 69,627 | £ 68,465 | £ 69,052 | [1] | |
Less: other equity instruments (recognised as AT1 capital) | (12,357) | (11,119) | (12,259) | [1] | £ (11,172) |
Adjustment to retained earnings for foreseeable ordinary share dividends | (595) | (968) | (666) | ||
Adjustment to retained earnings for foreseeable repurchase of shares | (568) | (1,000) | 0 | ||
Adjustment to retained earnings for foreseeable other equity coupons | (32) | (39) | (32) | ||
Goodwill and intangible assets | (8,245) | (8,061) | [1] | ||
Defined benefit pension fund assets | (5,233) | (3,879) | [1] | ||
Total RWAs | 344,516 | 328,830 | 314,136 | ||
T1 capital | |||||
Disclosure of financial assets [line items] | |||||
PRA transitional regulatory capital | 58,988 | 56,328 | 60,143 | ||
CET1 capital | |||||
Disclosure of financial assets [line items] | |||||
Additional value adjustments (PVA) | (1,810) | (1,864) | (1,585) | ||
Goodwill and intangible assets | (8,232) | (8,035) | (6,804) | ||
Deferred tax assets that rely on future profitability excluding temporary differences | (1,010) | (938) | (1,028) | ||
Fair value reserves related to gains or losses on cash flow hedges | 4,673 | 3,343 | 852 | ||
Gains or losses on liabilities at fair value resulting from own credit | (62) | 4 | 892 | ||
Defined benefit pension fund assets | (3,785) | (3,225) | (2,619) | ||
Direct and indirect holdings by an institution of own CET1 instruments | (20) | (20) | (50) | ||
Adjustment under IFRS 9 transitional arrangements | 642 | 601 | 1,229 | ||
Other regulatory adjustments | 220 | 64 | 345 | ||
PRA transitional regulatory capital | 46,691 | 45,269 | 47,327 | ||
AT1 capital | |||||
Disclosure of financial assets [line items] | |||||
Equity attributable to owners of parent | 12,357 | 11,119 | 12,259 | ||
Other regulatory adjustments | (60) | (60) | (80) | ||
PRA transitional regulatory capital | 12,297 | 11,059 | 12,816 | ||
Qualifying T2 capital (including minority interests) issued by subsidiaries | 0 | 0 | 637 | ||
T2 capital | |||||
Disclosure of financial assets [line items] | |||||
Equity attributable to owners of parent | 8,442 | 8,334 | 8,713 | ||
Adjustment under IFRS 9 transitional arrangements | 73 | 98 | 73 | ||
Other regulatory adjustments | (160) | (160) | (160) | ||
PRA transitional regulatory capital | 68,620 | 66,140 | 69,882 | ||
Qualifying T2 capital (including minority interests) issued by subsidiaries | £ 1,277 | £ 1,540 | £ 1,113 | ||
[1]2021 financial metrics have been restated to reflect the impact of the Over-issuance of Securities. See Restatement of financial statements (Note 1) on page 73 |